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Abstract 
Many breast cancer diagnoses and second cancers are associated with BRCA gene 
mutations. Early detection of cancer is necessary to improve health outcomes, 
particularly with second cancers. Little is known about the influence of risk factors on 
time to diagnosis of second primary cancers after diagnosis with BRCA-related breast 
cancer. The purpose of this cohort study was to examine the risk of diagnosis of second 
primary cancers among women diagnosed with breast cancer after adjusting for BRCA 
status, age, and ethnicity. The study was guided by the empirical evidence supporting the 
mechanism of action in the mutation of BRCA leading to the development of cancer. 
Composite endpoint was used to define second primary cancer occurrences, and Kaplan-
Meier survival curves were used to compare the median time-to-event among comparison 
groups and BRCA gene mutation status. Cox proportional hazards was used to examine 
the relationships between age at diagnosis, ethnicity, BRCA gene mutation status, and 
diagnosis of a second primary cancer. The overall median time to event for diagnosis of 
second primary cancers was 14 years. The hazard ratios for BRCA2 = 1.47, 95% CI [1.03 
– 2.11], White = 1.511, 95% CI [1.18 – 1.94], and American Indian/Hawaiian = 1.424, 
95% CI [1.12 – 1.81] showed positive significant associations between BRCA2 mutation 
status and risk of diagnosis of second primary colorectal, endometrial, cervical, kidney, 
thyroid, and bladder cancers. Data on risk factors for development of second cancers 
would allow for identification of appropriate and timely screening procedures, 
determining the best course of action for prevention and treatment, and improving quality 
of life among breast cancer survivors.   
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Chapter 1: Introduction to the Study  
Breast cancer is a heterogeneous disease with multiple clinical presentations and 
tumor-specific features (Singletary, Robb, & Hortobagyi, 2004). Genetic mutations are 
implicated in breast cancer development and prognosis, as well as in the development of 
other types of cancers. Genetics are implicated in both sporadic and familial breast 
cancers (Nussbaum, McInnes, & Willard, 2007). Genes associated with triggering the 
process of cancer formation include those involved in encoding certain proteins 
responsible for cell proliferation in the signaling pathway, cytoskeletal components 
responsible for maintaining contact inhibition, the mitotic cycle regulators, components 
of apoptotic (cell death) machinery, and mutation detecting and repairing proteins 
(Nussbaum et al., 2007).  
Genetic mutations can trigger a gain-of-function in one allele of a proto-oncogene 
(Le, Bhushan, & Tolles, 2011), while other mutations may trigger a loss of function of 
both alleles or a dominant negative mutation of one allele of a tumor-suppressor gene 
(Nussbaum et al., 2007). BRCA1 and BRCA2 are known tumor suppressor genes 
(Venkitaraman, 2002). Genetic mutations are also involved in chromosomal 
translocations that give rise to misexpression of genes or create chimeric genes encoding 
proteins that have acquired new functional properties (Nussbaum et al., 2007). Once a 
gene mutation is initiated, cancer progresses by accumulating additional genetic 
destruction. This progression occurs through mutations or epigenetic silencing of the 
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genes that encode the cellular machinery that repairs damaged DNA and maintains 
cytogenetic integrity (Nussbaum et al., 2007).  
BRCA1 and BRCA2 mutations are associated with multiple primary cancers. 
There are limited data on the risk factors of BRCA1/BRCA2 gene mutations and time to 
diagnosis of second cancers after initial diagnosis with breast cancer in the United States. 
In addition, the roles of gender, ethnicity, and age in the time to development of second 
cancers have not been well defined. I examined the time to diagnosis of colorectal, 
endometrial, cervical, kidney, thyroid, and bladder cancers before and after stratification 
by, ethnicity, and age in a breast cancer population with BRCA mutations. 
Background 
BRCA1 and BRCA2 are known tumor suppressor genes (Venkitaraman, 2002). 
Deficiencies of BRCA1 (including protein loss expression, promoter hypermethylation, 
and gene copy deletion) have been implicated in the BRCA1 down-regulation that is 
directly related to breast tumor initiation, progression, and treatment (Ren et al., 2013). In 
most breast and ovarian cancers that have been investigated among BRCA mutation 
carriers, deletion of the normal allele gave rise to a loss of function, leading to the 
classification of BRCA1 and BRCA2 as tumor suppressor genes. 
BRCA1 and BRCA2 are used in multiple functions within cells, including 
homologous DNA repair, genomic stability, transcriptional regulation, protein 
ubiquitination, chromatin remodeling, and cell cycle control (Venkitaraman, 2002).    
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From a treatment perspective, BRCA1 expression level acts as a determinant of 
response to different classes of chemotherapy (Mullan, Gorski, & Harkin, 2006). Tumor 
cells without BRCA1 are usually hypersensitive to DNA damaging chemotherapeutic 
agents (e.g., mitomycin C and cisplatin) (Fedier et al., 2003). BRCA1 deficiency is an 
important therapeutic target, and the reactivation of BRCA1 by secondary mutations has 
been demonstrated to give rise to therapy resistance (Drost & Jonkers, 2014).  
Statement of the Problem 
BRCA gene mutation related to breast cancer has been reported in both male and 
female genders (Al-Mulla et al., 2009; Liede, Karla, & Narod, 2004). BRCA gene 
mutations have been reported to have an increased risk of developing second primary 
cancers (Le et al., 2008). One out of every four hereditary breast cancer diagnoses 
(Easton, 1999) and about 5-10% of all breast cancer diagnoses (Campeau, Foulkes, & 
Tischkowitz, 2008) are associated with BRCA1/BRCA2 gene mutations. There is also 
evidence of an increased risk of developing other cancers among individuals with BRCA 
gene mutations (Al-Mulla et al., 2009). While not all breast cancers are caused by BRCA 
gene mutations, it has been observed that those that are caused by the BRCA gene 
mutations may be sporadic and occur before 50 years of age (Al-Mulla et al. 2009).  
Scholars suggested a strong association between BRCA1/BRCA2 gene mutations 
and endometrial (Oh, Kim, Kim, & Kim, 2015), cervical (Rheim, Fisher, Bosse, 
Wappenschmidt, & Schmutzler, 2007), ovarian (Evans et al., 2009), prostate (Agalliu et 
al., 2007), bladder (Neveling et al., 2007), gallbladder (The Breast Cancer Linkage 
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Consortium, 1999), stomach (Bermejo & Hemminki, 2004), malignant melanoma (The 
Breast Cancer Linkage Consortium, 1999), uterus (Thomson, Easton, & the Breast 
Cancer Linkage Consortium, 2002), colon (Kadouri et al., 2007; Niell et al., 2004), and 
pancreatic cancers (Lubezky et al., 2012) cancers. 
There are limited data on the risk factors of BRCA1/BRCA2 gene mutations and 
time to diagnosis of second cancers after breast cancer diagnosis among varying age, 
gender, and racial and ethnic groups in the United States. The role of age and ethnicity in 
the diagnosis of BRCA-related cancers has been investigated, but needs further 
clarification. In this study, I addressed the gap in the literature by examining these 
variables. I intended to include males because both genders are at risk from BRCA-
related cancer (Al-Mulla et al., 2009; Giordano, Cohen, Buzdor, Perkins, & Hortobagyi, 
2004; Jemals et al., 2003; Liede et al., 2004); however, only female gender were 
observed in the dataset. Additionally, there is a reported correlation with a younger age of 
diagnosis of cancer (Bermejo & Hemminki, 2004; Lee et al., 2008; Papelard et al., 2000) 
and a high mortality rate for pancreatic and colon cancers (Leet al., 2011). The initial 
intent was to analyze only pancreatic and colon cancer. Because insufficient data for 
power were obtainable in the BCFR dataset when variables were limited to pancreatic 
and colorectal cancer, the study was expanded to include endometrial, cervical, kidney, 
thyroid, and bladder cancer. This enabled me to achieve a study power of 80% or greater 
using the composite endpoint technique. In this study, I explored ethnicity and age-
specific risk factors and their respective associations to time to event, defined as 
5 
 
 
 
diagnosis of colorectal, endometrial, cervical, kidney, thyroid, or bladder cancer, among 
patients with an initial diagnosis of BRCA1/BRCA2 breast cancer. 
Purpose of the Study 
The purpose of this quantitative study was to analyze the association of gender, 
ethnicity, and age of diagnosis of breast cancer with time to diagnosis for second primary 
cancers among subjects diagnosed with breast cancer. Specifically, I investigated the 
associations of exposures to outcomes within the framework of time-to-event analysis.  
Research Questions and Hypotheses 
The aim of the study was to answer the following questions and test the associated 
hypotheses: 
RQ1: Is there a relationship between BRCA mutation status and time to diagnosis 
of second primary cancers, pancreatic, colorectal, endometrial, or cervical, among 
women with breast cancer? 
H01: There is no relationship between BRCA mutation status and time to 
diagnosis of second primary cancers, pancreatic, colorectal, endometrial, or cervical, 
among women with breast cancer. 
Ha1: There is a relationship between BRCA mutation status and time to diagnosis 
of second primary cancers, pancreatic, colorectal, endometrial, or cervical, among 
women with breast cancer. 
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RQ2: Is there a relationship between ethnicity and age status and time to 
diagnosis of second primary cancers, pancreatic, colorectal, endometrial, or cervical, 
among women with BRCA-related breast cancer? 
H02: There is no relationship between ethnicity and age status and time to 
diagnosis of second primary cancers, pancreatic, colorectal, endometrial, or cervical, 
among women with BRCA-related breast cancer. 
HA2: There is a relationship between ethnicity and age status and time to diagnosis 
of second primary cancers, pancreatic, colorectal, endometrial, or cervical, among 
women with BRCA-related breast cancer. 
RQ2a: Is there a relationship between ethnicity and time to diagnosis of second 
primary cancers, pancreatic, colorectal, endometrial, or cervical, among women with 
BRCA-related breast cancer? 
RQ2b: Is there a relationship between age status and time to diagnosis of second 
primary cancers, pancreatic, colorectal, endometrial, or cervical, among women BRCA-
related breast cancer? 
RQ3: Is there a relationship between gender and time to diagnosis of second 
cancers, pancreatic, colorectal, endometrial, or cervical, among men and women 
diagnosed with BRCA-related breast cancer? 
H03: There is no relationship between gender and time to diagnosis of second 
primary cancers, pancreatic, colorectal, endometrial, or cervical, among men and women 
diagnosed with BRCA-related breast cancer. 
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Ha3: There is a relationship between gender and time to diagnosis of second 
primary cancers, pancreatic, colorectal, endometrial, or cervical, among men and women 
diagnosed with BRCA-related breast cancer. 
In each case, differences in median time distributions were examined using the 
Kaplan-Meier survival curves and tested using the log-rank test. 
Conceptual Framework 
The conceptual framework I used for this study was based on genetic fundamental 
principles and published empirical data that support a mechanism of action for BRCA in 
breast and other cancers. In 1990, the King laboratory localized the BRCA1 gene to 
chromosome 17q (Hall et al., 1990). Later, the BRCA2 gene was localized to 
chromosome 13q12-13 (Wooster et al., 1994). BRCA1 and BRCA2 are tumor suppressor 
genes, for which many different mutations have been identified (Petrucelli et al., 2011). 
Significant gene rearrangements and missense mutations (changes in amino acids 
sequence) give rise to mutant phenotypes (Meindl, 2002). Repeated episodes of DNA 
damage may occur after exposure to stressors, such as reactive oxygen species, cytotoxic 
chemotherapy, and ionizing radiation, triggering the mechanism of carcinogenesis 
(Bougie & Weberpals, 2011).  
These mutations may be specific to certain populations and ethnicities (Bougie & 
Weberpals, 2011). John et al. (2011) found that, among African Americans, 25% of 
BRCA1 mutations were frameshift, 38% were missense, 13% were nonsense, and 25% 
were splice mutations; differing percentages were found in other ethnic groups. Non-
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Hispanic White patients were found to show 36% frameshift, 14% missense, 29% 
nonsense, and 21% splice for BRCA1 mutations (John et al., 2011). Among the 
Ashkenazi Jewish population, three BRCA mutation types, including BRCA1 185delAG, 
BRCA1 5382insC, and BRCA2 6174delT have been well-documented (Moslehi et al., 
2000). Individuals with a positive diagnosis of BRCA gene mutations have been reported 
to be more susceptible to second malignancies, but the underlying mechanisms have not 
been fully elucidated (Bougie & Welberpals, 2011). Empirical data on the known 
mechanisms of tumor suppressor gene-related carcinogenesis and the published differing 
impacts of BRCA mutations on both genders, as well as various ethnicities provided the 
framework for the choice of variables and the research questions, were used in this study.  
Nature of the Study 
This study was a quantitative cohort design using secondary data. In cohort 
studies, sequences, patterns of change, growth, or trends over time are examined (Houser, 
2012). By describing the characteristics of groups of people at certain time periods, 
investigators attempt to identify risk factors for particular diseases and health conditions 
(Houser, 2012). I intended to use three cohorts to answer my research questions, but the 
design was changed to two cohorts because no male subjects were included in the study. 
Question 3 was intended to examine gender and relationship with second primary 
cancers. The first cohort consisted of women with and without a diagnosis of BRCA-
related breast cancer and a subsequent diagnosis of pancreatic, colorectal, endometrial, or 
cervical cancer. I compared time to diagnosis of colorectal, endometrial, cervical cancer, 
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kidney, thyroid, or bladder, among those women based on their BRCA status. The second 
cohort was women with a diagnosis of BRCA-related breast cancer. I analyzed the 
relationship of the three risk factors, BRCA status, age at initial diagnosis of breast 
cancer and ethnicity, to time to diagnosis of colorectal, endometrial, cervical, kidney, 
thyroid, and bladder cancer. The third cohort was intended to include men and women 
with a diagnosis of BRCA-related breast cancer, for whom I would compare time to 
diagnosis of colorectal, endometrial, cervical, kidney, thyroid, and bladder cancer based 
on gender. As noted previously, this cohort was not used. In the analysis of all research 
questions, the dependent variable was time to diagnosis of second primary cancers, 
specifically, colorectal, endometrial cervical, kidney, thyroid, and bladder. The 
independent variables were unique for each question and included the presence of BRCA 
mutation, ethnicity, and age. I assessed the statistical significance of the relationship 
between dependent and independent variables using Cox proportional hazards (CPH).  
Operational Definitions 
BRCA1: BRCA1 is a tumor suppressor gene on chromosome 17 that functions by 
helping to suppress cell growth. Some mutations in the BRCA1 gene are correlated with 
a higher risk of breast, ovarian, prostate, and other types of cancer (National Cancer 
Institute [NCI], 2014). For the purpose of this study, BRCA1 mutation diagnosis is 
retrievable from the dataset and is dichotomous. 
BRCA2: BRCA2 is a tumor suppressor gene on chromosome 13 that functions by 
helping to suppress cell growth. Certain mutations in the BRCA2 gene are associated 
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with higher risk of breast, ovarian, prostate, and other types of cancer (NCI, 2014). For 
the purpose of this study, BRCA2 mutation diagnosis is retrievable from the dataset and 
is dichotomous. 
BRCA both 1 and 2: BRCA both 1 and 2 refers to individuals diagnosed with both 
BRCA1 and BRCA2 gene mutations. BRCA both 1 and 2 is retrievable from the dataset 
and is dichotomous.  
Second cancers: For the purpose of this study, second cancer refers to any cancer 
that a patient experienced after initial diagnosis with BRCA1- or BRCA2-related breast 
cancer. Specifically, this study included pancreatic, colon, endometrial, and cervical 
cancer. 
Time to event: Time to event in this study was the time it takes for a patient with a 
BRCA1 or BRCA2 mutation related to breast cancer to be diagnosed with another form 
of cancer. Specifically, this study included only diagnosis with colorectal, endometrial, 
cervical, kidney, thyroid, or bladder cancer after diagnosis of breast cancer.     
Assumptions, Limitations, and Scope of the Study 
The source of the sample population in a secondary data analysis may lead to bias 
in the study. The sample population was drawn from the Breast Cancer Family Registries 
(BCFR), which contained clinical and population data on BRCA cancer-related incidence 
and time to diagnosis of a second primary cancer (NCI, 2014). The study was limited to 
the data available in the dataset. One limitation of this study was the nonavailability of 
data from all 50 states’ cancer registry in the BCFR databases. Another potential 
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limitation was related to the size of the dataset. The available data were limited due to 
rare screening of the disease and data availability. The ability of distinguishing secondary 
from second primary cancers in the data set did not pose a limitation. This study was 
originally intended to involve only pancreatic and colorectal cancer, unless there was an 
insufficient sample size. Finally, analyses of relationships among variables were limited 
by what information was collected originally. It was not possible for me to gain 
additional information about the subjects in the cohorts. An assumption was that the 
dataset contained correct diagnoses of BRCA mutations, cancers, age, gender, and 
ethnicity. It was also assumed that the BCFR dataset population was representative of the 
population, but results may not be generalizable to other populations.   
Significance of the Research 
Breast cancer is the most common cancer among women and the second most 
common cause of cancer-related death among women (NCI, 2013). The ratio of mortality 
to incidence is highest in developing countries (Groot et al., 2006). The 10-year period 
total cost of introducing Stage I treatment was estimated by Groot et al. (2006) to be $ 68 
million in Africa, $143 million in Asia, and $3,879 million in North America. Treatment 
of early stage cancer patients is more effective than treatment in the later stages, 
supporting the need to continually strive for better and more effective means of early 
detection.   
Those who carry BRCA mutations are also at risk of other types of cancer beyond 
breast cancer. I initially selected time to development of pancreatic and colon cancer in 
12 
 
 
 
patients with breast cancer and BRCA gene mutations as variables in this study because 
pancreatic and colon cancers are known to be associated with BRCA mutations and 
because of the relatively poor prognoses of these cancers (Al-Mulla et al., 2009; Kadouri 
et al., 2007; Le et al., 2011). Pancreatic adenocarcinoma is aggressive and is usually 
already metastasized at presentation; frequently patients have a prognosis of 6 months or 
less for survival time (Le et al., 2011). Colon cancer is the third most common and third 
most deadly cancer in the United States (Le et al., 2011), and BRCA gene mutations may 
be associated with early onset of colon cancer (Suchy et al., 2010). Endometrial and 
cervical cancer were added to the variables in order to have sufficient data to analyze, and 
because these cancers have also been associated with BRCA mutations. Endometrial 
cancer is the most common cancer of the female reproductive system, accounting for 6% 
of all the cancers among women in the United States (NCI, 2014). The association 
between germline mutations in BRCA genes and the risk of endometrial cancer remains 
unclear, but several case reports of endometrial carcinoma in women with 
a BRCA mutation exist (Oh, Kim, Kim, & Kim, 2015; Levine et al., 2001). In recent 
years, cervical cancer has become a growing concern in public health in the United 
States. According to the Surveillance, Epidemiology, and End Results Program (SEER, 
2015), the number of new cases of cervix uteri cancer was 7.7 per 100,000 women per 
year. The number of deaths was 2.3 per 100,000 women per year (author, year). These 
rates are age-adjusted and based on 2008-2012 cases and deaths (author, year). 
13 
 
 
 
There remains a gap in the literature regarding gender, ethnicity, and age of 
diagnosis as risk factors for the development of a second primary cancer in a BRCA 
positive, breast cancer population. To date, scholars have analyzed time to diagnosis of a 
second primary colon cancer in a BRCA positive, breast cancer population, and few 
researchers have investigated the time to diagnosis of a second primary pancreatic cancer 
in a population with BRCA-related breast cancer (Brose et al., 2002; Mocci et al., 2013). 
Mocci et al. (2013) did not analyze different ethnic groups or time to event of the 
pancreatic cancer. Other scholars have explored the risk for developing second primary 
cancers. Brose et al. (2002) estimated BRCA1-related cancer risks for individuals 
ascertained in a breast cancer risk evaluation clinic and that found by age 70, female 
breast cancer risk was 72.8%, the risk for developing a second primary breast cancer by 
age 70 was 40.5%, a two-fold increased risk of colon cancer, threefold risk of pancreatic 
cancer, fourfold risk of stomach cancer, and 120-fold increased risk of fallopian tube 
cancer among BRCA1 mutation carriers with breast cancer (Brose et al., 2003). An                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
increased risk for developing a second primary cancer has also been noted in a Taiwanese 
breast cancer population (Lee et al., 2008). Le et al. (2008) found that the peak incidence 
was among women in their 40s, with approximately 2% developing a nonbreast second 
primary cancer, with an average survival time of 2.87 years after the second cancer 
diagnosis. The risk of second primary colon cancer in patients following cancer of the 
breast has also been identified in a Connecticut, 1935-1982 population study (Harvey & 
Brinton, 1985). However, Harvey and Brinton (1985) failed to analyze BRCA status, 
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different ethnic groups, or time to event of the colon cancer. There has been a 
significantly increased risk of second primary rectal cancer (Observed/Expected = 1.97) 
in female breast cancer patients (Buiatti et al., 1997). This was observed in an Italian 
cohort population study that examined the incidence of second primary cancers in three 
cancer registries (Buiatti et al., 1997). Buiatti et al. (1997) also did not analyze different 
ethnic groups, BRCA status, or time to event of rectal cancer in the population. Certain 
subsets of breast cancer patients may demonstrate an elevated risk of developing second 
primary colorectal cancer (Kmet, Cook, Weiss, Schwartz, & White, 2003). Kmet et al. 
(2003) found that incidence of colorectal cancer was associated with a family history 
of breast cancer, high body mass index, and lobular breast cancer histology. Kmet et al. 
did not examine the BRCA status of the patients, ethnicity, and gender as specific risk 
factors. The risk of second primary contralateral breast cancer in BRCA1/BRCA2 
mutation carriers with a first breast cancer has been documented (Molina-Montes et al., 
2014). Molina-Montes et al. (2014) observed the risk of second primary contralateral 
breast cancer increases with length of time after the first breast cancer diagnosis in 
BRCA1/2 mutation carriers. The limitations of Molina-Montes et al.’s design included 
the exclusion of analysis of second primary cancer from other parts of the body system 
(e.g., pancreas, colon/rectum, endometrium, and cervix), ethnic groups, and time to 
diagnosis of second cancer. No studies were designed to analyze risk factors for time to 
diagnosis of a second cancer. These and other relevant studies are discussed further in 
Chapter 2.  
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My study fills this gap by examining the relationship between the risk factors age 
at diagnosis, ethnicity, and gender and time to diagnosis of a second primary cancer 
among women with breast cancer. Investigation of the risk factors and time to 
development of a second cancer after diagnosis with a BRCA germline mutation is 
needed to develop appropriate screening and treatment for breast cancer patients and 
survivors. Data on average time to diagnosis of second cancers for individuals with 
BRCA1/BRCA2 gene mutations would help clinicians to determine the best course of 
action for those newly diagnosed with a BRCA mutation and for breast cancer patients 
with BRCA mutations, thus supporting positive social change. Understanding the risk 
factors by the ethnicity, gender, and age of patients will assist clinicians in evaluating 
further screening options. In the study, application of the CPH model provided further 
insight based on time-to-event (diagnosis) in respect to the demographic variables gender, 
ethnicity, and age of diagnosis with BRCA1/BRCA2 mutation breast cancer for an 
association with time to diagnosis of second primary cancers, colorectal, endometrial,  
cervical, kidney, thyroid, and/or bladder. 
Summary 
Among women, breast cancer is the most common malignancy and the second 
leading cause of cancer mortality (Singletary et al., 2004). The discovery 
of BRCA1/BRCA2 gene mutations has resulted in more appropriate targeting of 
preventive and screening strategies, even within families previously assumed to be 
similar with respect to breast cancer risk (Breast Cancer Family Registry, 2014).   
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Only one scholar has specifically analyzed age for time to diagnosis of pancreatic 
among female subjects with BRCA-related breast cancer (Mocci et al., 2013). No 
researcher has examined time to event and ethnicity as a risk factor for developing a 
second primary pancreatic, colorectal, endometrial, cervical, kidney, thyroid, or bladder 
cancer in patients previously diagnosed with BRCA1/BRCA2-mutation-related breast 
cancer using the composite endpoint approach. In this study, I further explored various 
risk factors contributing to the development of a second primary cancer in a breast cancer 
population.   
Chapter 2 contains a review of the current literature on breast cancer 
epidemiology; BRCA1/BRCA2 mutations; and the pathology, diagnosis, and prognosis 
of breast, pancreatic, colorectal, endometrial, and cervical cancers. In Chapter 2, I present 
studies supporting the conceptual framework and study design. Modifiable risk factors 
such as hormone therapy radiation therapy, and oral contraceptives are outside the scope 
of the study and are covered only briefly, but the nonmodifiable risk factors of family 
history, age, ethnicity, and gender are addressed in more depth. 
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Chapter 2: Literature Review 
The purpose of this study was to analyze the association of gender, ethnicity, and 
age of diagnosis of BRCA1/BRCA2-associated breast cancer with time to diagnosis of a 
second primary cancer, specifically pancreatic, colorectal, endometrial, and cervical 
cancer. This chapter contains a systematic and comprehensive review of the literature to 
determine the extant knowledge of the different research problems addressed in this study 
and to identify relevant previous and current studies on BRCA-related breast cancer and 
time to diagnosis with second cancers. Chapter 2 begins with a discussion of breast 
cancer epidemiology, including BRCA-mutation-related cancers. The recent literature on 
the pathophysiology and prognoses of breast, pancreatic, colorectal, endometrial, and 
cervical cancer and published studies on the relationship of gender, age, and ethnicity to 
BRCA-related carcinogenesis are presented and analyzed. I briefly discuss the 
nonmodifiable risk factors, methods of BRCA detection, cancer detection, staging and 
grading, and treatment. Next, I provide an analysis of the literature supporting the 
conceptual framework. Finally, I discuss other relevant studies on this BCFR dataset and 
other studies supporting my chosen methodology.  
Literature Search Strategy 
I employed CINAHL, MEDLINE, National Cancer Institute Comprehensive 
Cancer Databases, PUBMED, GOOGLE SCHOLAR, and Walden University dissertation 
ProQuest to conduct this literature review. During the search, I used the following major 
terms: BRCA1, BRCA2, breast cancer, breast cancer epidemiology, diagnosis, second 
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cancers, colon cancer, pancreatic cancer, endometrial cancer, cervical cancer, survival 
analysis, breast cancer prognosis, age, gender, ethnicity, and Breast Cancer Family 
Registries (BCFR). The above search method generated numerous peer-reviewed 
published studies.  
There is a gap that needs to be addressed related to the nonmodifiable risk factors 
of BRCA1/BRCA2 gene mutations and time to diagnosis of second cancers after 
stratification by age, gender, and racial and ethnic groups. Non-peer-reviewed studies 
were excluded, as were studies older than 10 years (2003 and earlier) unless they seminal.   
Conceptual Framework 
The conceptual framework of this study was based on empirical data on the 
mechanisms of action for how BRCA mutations may cause breast and other cancers. The 
functions of BRCA1 and BRCA2 genes are not fully elucidated. However, it is evident 
that they act as tumor suppressor genes, which are implicated in the cellular response to 
double strand DNA breaks, such as occurs normally as a result of damage to DNA 
(Goldberg & Borgen, 2006). Tumor tissue from heterozygotes for BRCA1 and BRCA2 
mutations show a loss of heterozygosity, with the loss of the normal allele (Nussbaum et 
al., 2007). Many mutant alleles of BRCA1 and BRCA2 have now been catalogued. 
Several mutations have been found in the BRCA1 gene, distributed throughout the 
coding regions (Al-Mulla, Bland, Serrat, Miller, Chu, & Taylor, 2009).  
Hereditary linkage investigations in families showing early onset of breast cancer 
contributed to locating BRCA1 on chromosome 17q21 and BRCA2 on chromosome 
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13q12.3, and determining these as susceptibility genes for breast cancer (Le et al., 2011). 
Almost all known BRCA1 truncating mutations have demonstrated an association to 
disease, and a shortened BRCA1 protein leads to an increased risk for breast and ovarian 
cancer in women with a family hereditary susceptibility (Friedman et al., 1994). BRCA2 
germline mutation results in truncated protein, conferring an increased risk of breast 
cancer among both females and males (Friedman et al., 1994). About 80% of cases of 
hereditary breast neoplasms are as a result of gene mutations of either BRCA1 (40-45% 
of cases) or BRCA2 (35-40%; Collins et al., 1995). Some of the remaining 20% of 
hereditary cases are associated with mutations of non-BRCA genes, such as those of 
Cowden syndrome (the PTEN tumor, suppressor gene), the Li-Fraumeni syndrome 
(TP53), ataxia telangiectasia (ATM), and Peutz-Jeghers syndrome (STK1/LKB1). These 
known genes do not account for 100% of hereditary breast cancers, which suggests the 
likelihood of finding other susceptibility genes in the future (Nussbaum et al., 2007). 
Mutations occur continuously during cell division, and oncogenes and tumor 
suppressor genes are generally not inherently more prone to mutation than other genes. 
Strong positive selection for cell proliferation or increased cellular survival resulting 
from the mutation is what differentiates breast cancer gene mutations such as BRCA1 
and BRCA2 from other mutations (Nussbaum et al., 2007). The phenotype of a breast 
cancer cell is uncontrolled and excessive proliferation, which ultimately allows even one 
mutant cell to develop into a life threatening disease. Mutations that allow one cell 
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among many to lose function, or die, have no phenotypic effects and are masked by the 
greater number of healthy cells in an organ or tissue (Nussbaum et al., 2007).  
Although individuals with a strong hereditary susceptibility to cancer represent 
less than 5% of all patients with cancer, further elucidating the genetic basis of breast 
cancer has relevance for providing clinical management in affected families and for 
understanding breast cancer in general (Nussbaum et al., 2007).   
There are several observations of loss of BRCA2 heterozygosity in tumors of the 
prostate, cervix, ovary, colon, male breast, and ureter, indicating the association between 
and increased risk of secondary cancers (Lancaster et al., 1996; Phelan et al., 1997). 
These findings for how BRCA gene mutations may predispose affected individuals to 
secondary cancers provided the framework for exploring time to diagnosis of a secondary 
cancer among those with BRCA-mutation-related breast cancer.  
Breast Cancer 
Risk Factors and Incidence 
In the United States, breast cancer remains the most common type of neoplasm 
and is a cause of mortality among women (Le, Bhushan, & Tolles, 2011). The average 
age at diagnosis in the United States is 64 years (Nussbaum et al., 2007). Breast cancer 
risk varies from one population to another and is multifactorial (Satagopan et al., 2001). 
Modifiable risk factors include environmental exposure (Le et al., 2011), including 
radiation exposure at a young age such as in the treatment of Hodgkin disease 
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(Kleinerman, 2006), hormone therapy (Singletary et al., 2004), and obesity (Singletary et 
al., 2004).   
Nonmodifiable risk factors include gender (Ferrone et al., 2009), ethnicity (Suchy 
et al., 2010), age (Al-Mulla et al., 2009), geographic location (Althuis, Dozier, Anderson, 
Devesa, & Brinton, 2005), and family history of breast cancer (Niell et al., 2004). 
Carcinoma rarely develops before 25 years of age in nonhereditary cases. Breast cancer is 
more commonly observed in premenopausal women with a family history of breast 
cancer (Mitchell, Kumar, Abbas, Fausto, & Aster, 2012), with increased risk based on the 
number of first-degree relatives with cancer. Claus et al. (1994) determined that the risk 
of female breast cancer increased three fold if any close relative was affected and up to 
10 times if more than one first-degree relative was affected. The risks increased more 
when the disease onset is observed in first-degree relatives’ 40-years-old or younger 
(Claus et al., 1994).   
More than 2,000 mutations are associated with BRCA1 and BRCA2 (Thompson, 
& Easton, 2004). BRCA1 and BRCA2 mutations account for 3-10% of all hereditary 
breast cancers in susceptible population (Nussbaum et al., 2007). The BRCA1 gene 
mutation diagnosis is a risk factor for both breast and ovarian cancer, with an 
approximate risk of 80% of one or both types of cancer at 70 years (Nussbaum et al., 
2007). BRCA2 gene mutations are associated with an 80% risk of being diagnosed with 
breast cancer, but less than a 10 % risk of ovarian cancer (Evans et al., 2009; Lakhani et 
al., 2004; Le et al., 2011; Nussbaum et al., 2007).  
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BRCA1/BRCA2 gene mutations together are implicated in about 70- 80% of 
hereditary breast cancers and sometimes even in nonhereditary breast cancer (Nussbaum 
et al., 2007). As many as 19% of all breast cancer cases may show a polygenic or 
multifactorial mode of inheritance, while a small proportion appear to be a result of 
dominantly inherited Mendelian predisposition to breast cancer (Claus et al., 1994). 
These families have in common certain features of familial cancer not found in sporadic 
cancer, including multiple affected family members, earlier age of onset, and frequent 
bilateral disease (Nussbaum et al., 2007). Dite et al. (2010) determined that cancer risk 
increased among relatives of patients with early diagnosis with BRCA1 and BRCA2 
mutations. On the other hand, Loman, Bladstrom, Johanssonn, Borg, and Olsson (2003) 
demonstrated that the incidence of breast cancer among first-degree family members 
might increase as a result of other nongenetic risk factors.  
This relationship with family history is mostly observed for inherited genes, 
including BRCA1, BRCA2, p53 (Li Fraumeni syndrome), ATM (ataxia-telangiectasia), 
and the gene causing Cowden disease (Mitchell et al., 2012). Others at higher risk of 
breast cancer include women with history of proliferative breast disease, especially when 
changes are atypical, and women with carcinoma of the contralateral breast or 
endometrium (Le et al., 2011). Pedigree analysis remains critical to ascertain the 
estimated risk of a patient with BRCA1 or BRCA2 gene mutation. A three-generation 
pedigree involving the patient (the proband), all the siblings, and parental and 
grandparental generations is a minimum requirement.  
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Gender. Gender-based risk factors for breast cancer are often related to 
hormones. Hormone-related risk factors that have been identified include early menarche 
and late menopause, indicating long reproductive potential (Chang-Claude et al., 2007); 
nulliparous women as compared to multiparous women, suggesting unremitting exposure 
to ovarian cycles (Cullinane et al., 2005); having the first child after the age of 30 
(Cullinane et al., 2005); and obese postmenopausal women, which has been attributed to 
estrogen synthesis in fat depots (Mitchell et al., 2012). Obesity in younger women 
decreases the risk, due to an association with anovulatory cycles (Hernandez-Rey, 2014).  
There has been a noted increase in estrogen-receptor positive breast cancers, 
mainly among young White women (DeShantis, Ma, Bryan, & Jemal, 2014). This 
implies differential hormonal risk factors among various groups. Women with a 
deleterious BRCA1 mutation are more likely to be diagnosed with triple negative 
cancers, which generally have poorer prognosis than other breast cancers (Singletary et 
al., 2004). Further exploration is needed to determine the significant risk factors for 
breast cancer and prognosis. Based on the importance of these nonmodifiable factors in 
breast cancer epidemiology, I included gender, ethnicity, and age as variables in this 
study.  
Female gender is a well-known risk factor for breast cancer, but the risk for males 
is not negligible. My study included gender as a covariate, as it may influence the 
development of secondary cancers. Female breast cancer occurs 100 times more 
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frequently than male breast cancer, but male breast cancer has been associated with a 
higher mortality rate (Singletary et al., 2004).  
Data are somewhat conflicting on whether the incidence of male breast cancer has 
changed over time. La Vecchia, Levi, and Lucchini (1992) determined that rates were 
relatively stable over the past 40 years. However, in a more recent study, the incidence of 
male breast carcinoma increased significantly from 0.86 to 1.08 per 100,000 population 
(P < 0.001) during the period from 1973 to 1998 (Giordano, Cohen, Buzdar, Perkins, & 
Hortobagyi, 2004). About 1,300 new cases of male breast cancer were diagnosed in the 
United States in 2003, with approximately 400 deaths (Jemals et al., 2003). In 2014, 
2,360 males were diagnosed, including 430 deaths (NCI, 2014). Some male breast cancer 
cases have been identified among individuals without a family history (Csoka et al., 
1999). Males diagnosed at a later age and were more likely to have lymph node 
involvement, suggesting a more advanced stage at diagnosis (Giordano et al., 2004). 
Recognizing the risk factors for male breast cancer is imperative to early diagnosis and 
better health outcomes.  
There may be geographical differences for male breast cancer incidence 
(Contractor, Kaur, Rodrigues, Kulkarni, & Singhal, 2008). Male breast cancer accounts 
for only 1% of total breast cancer diagnoses in most Western countries (Contractor et al., 
2008). However, a higher proportion of cases in men were recorded in some countries 
(Amir, Moshiro, & Kwesigabo, 1996; Sasco, Lowenfels, & Pasker-de long, 1993). In 
Tanzania, 7% of breast cancers were reported in men (Amir et al., 1996). O;malley, 
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Prehn, Shema, and Glaser (2002) found higher incidence of male breast cancer in the 
United States and United Kingdom than Japan and Finland. There are limited data on 
male breast cancer from Africa. The incidence rate in the East African country of Uganda 
is rising (Contractor et al., 2008). In Zambia, male breast cancer accounts for about 15% 
of all breast cancer cases (Smigal et al., 2006), while it accounts for 6% in Tanzania 
(Ihekwaba, 1994). The World Cancer Research Fund International (2014) reported that 
the European incidence rate of breast cancer in 2012 had doubled that of Africa; North 
America presented the overall highest incidence rate of 92 per 100,000 population in the 
United States, closely followed by 80 per 100,000 population in Canada. 
Known male breast cancer risk factors include heritable mutations, including 
BRCA, and imbalances in hormonal levels (Ottini et al., 2003; Struewing et al., 1995). In 
an investigation of 76 men with a family history of breast cancer, Frank et al. (2002) 
found that 11% had BRCA1 mutations, but BRCA2 was not assessed in the study. Others 
have reported a much lower prevalence of BRCA1 mutations in males compared to 
BRCA2 (Basham et al., 2002; Ottini et al., 2003). Ottni et al. (2003) observed 16% of 
Italian men with breast cancer had either BRCA1 or BRCA2, with 75% of the cases 
having BRCA2 mutations (Ottini et al., 2003). Basham et al. (2002) determined that out 
of 19 cases of subjects with male breast cancer, none had BRCA1 mutations, and five 
cases had BRCA2 mutations. This suggests a possible stronger role for BRCA2 than 
BRCA1 in male breast cancer. The prevalence of BRCA2 mutations in men without a 
strong family history of breast cancer may range from 4% to up to 40% (Basham et al., 
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2002; Ottini et al., 2003). In families with a history of both female and male breast 
cancer, the presence of BRCA2 mutations has been reported to be as high as 60-76% 
(Osorio et al., 2000).  
Hormone status as a risk factor is not limited to females. There is a documented 
relationship between conditions that may be related to hormonal levels and risk of male 
breast cancer. In a case control study of 227 men, Thomas et al. (1992) reported an 
increased risk of male breast cancer with a history of undescended testes (relative risk 
[RR] =11.6), orchitis (RR = 2.0), infertility (RR = 2.3), and benign breast conditions (RR 
= 2.5). Thomas et al. also reported some probable nonhormonal risk factors, including 
Jewish ancestry (RR = 2.1), congenital inguinal hernia (RR=2.3), and amphetamine use 
(RR = 2.9). Similar results were obtained in a meta-analysis of risk factors for male 
breast cancer, with previous benign breast pathology, Jewish ancestry, and testicular 
pathology all predispositions to breast cancer (Sasco et al., 1993).     
Geographical location and ethnicity. There are data demonstrating geographical 
and ethnical disparities in overall breast cancer epidemiology (Nussbaum et al., 2007). 
Historically, in the United States, White women over the age of 40 have borne the highest 
risks of developing breast cancer. According to population-related epidemiological 
investigations, more than 9% of all women in North America are at risk of developing 
breast cancer (Claus, Risch, & Thompson, 1994). White women in the United States have 
incidence rates 20% to 40% higher than in non-White women (Claus et al., 1994). 
Incidence in some populations has not remained stable over time. In recent years, rates 
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for Black women have been approaching those for White women, while incidence among 
Hispanic women has decreased (DeShantis, Ma, Bryan, & Jemal, 2014). Black women 
less than 40 years of age have a higher incidence rate than their young White counterparts 
(Jemals et al., 2003).  
Mortality rates from breast cancer also differ by ethnicity and geography. In the 
United States, mortality rates are highest for Black women, followed by White, Hispanic, 
American Indian/Alaska Native, and Asian/Pacific Islanders (American Cancer Society, 
2003). Globally, most of the 300,000 deaths due to breast cancer in 1990 were in 
developed countries (Lacey, Devesa, & Brinton, 2002), with death rates lowest in Asia, 
moderate in South America and Eastern Europe, and highest in North America and 
Western Europe (Lacey et al., 2002). Overall, mortality from breast cancer has dropped 
in all ethnic groups except American Indians and Alaskan natives. These trends suggest 
some etiologic heterogeneity and the different effects of various risk factors that may 
differ among certain groups (DeSantis, 2014). 
Ethnicity is an important variable in studying hereditary mutations such as BRCA 
because the mutations may vary between populations. John et al. (2011) found differing 
percentages of frameshift, missense, nonsense, and splice mutations between ethnic 
groups. Tamboom et al. (2010) found three clinically important mutations in the BRCA1 
gene and two clinically important mutations associated with BRCA2 gene in an Estonian 
population. BRCA1 founder mutations are prevalent in certain populations (Kadouri, 
2007). Founder mutations are mainly observed among ethnic groups that live in relative 
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isolation, such as the people of Iceland or certain communities of Jewish people 
(Singletary, 2004). According to haplotype analysis, these mutations have the same 
ancestor. A higher prevalence of deleterious BRCA1 and BRCA2 gene mutations appear 
in the Ashkenazi Jewish population than in the general population (Singletary, 2004). 
Higher prevalence of specific deleterious BRCA1 and BRCA2 mutations have also been 
observed in other ethnic and geographical populations, such as the Icelandic people, the 
Norwegians, and the Dutch (NCI, 2014). Furthermore, the prevalence of harmful BRCA1 
and BRCA2 mutations may be different in individual ethnic and racial groups in the 
United States, including African Americans (Malone et al., 2006), Asian Americans, non-
Hispanics, and Hispanics (John et al., 2007). I stopped reviewing here due to time 
constraints.  
Among the Ashkenazi Jewish population, three mutation types (BRCA1 
185delAG, BRCA1 5382insC, and BRCA2 6174delT) are well documented (Moslehi et 
al., 2000). The 185delAG mutation is one of the most frequent BRCA1 mutations found 
among the Ashkenazi Jews (Neuhaussen et al., 1998). Two other founder mutations 
segregate in this ethnic group: the BRCA1 5382insC and the BRCA2 6174delT mutations 
(Roa, Boyd, Volcik, & Richards, 1996). At least one of the three founder mutations can 
be found in more than 2% of the Ashkenazi Jewish population and in about 12% of the 
Ashkenazi Jewish breast or ovarian cancer patients with no family history (Abeliovich et 
al., 1997). Subsequent screenings have shown other BRCA1 founder mutations in the 
Netherlands (Petrij-Bosch et al., 1997); Norway (Dorum, Hovig, Trope, Inganas, & 
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Moller, 1999) Sweden (Johannsson et al., 1999); and the Yorkshire/Humberside 
population in United Kingdom (Al-Mulla et al., 2009). Al-Mulla et al. (2009) also 
reported of identifying 14 new BRCA1/BRCA2 gene mutations among the 
Yorkshire/Humberside population. 
Papelard et al. (2000) investigated BRCA1 prevalence in 642 Dutch breast cancer 
patients in a hospital-based population. Four patients carried the Dutch founder deletion 
of exon 22. All mutation carriers were under 50 years-of-age at diagnosis of the first 
breast cancer, and five did not have any relative with breast cancer (Papelard et al., 
2000). The estimated prevalence of breast cancer in the general population in the 
Netherlands attributable to BRCA1 mutations is 2.1%, but specifically for less than 40 
years-of-age, the prevalence is 9.5% and under 50 years-of-age the prevalence is 6.4%. 
This supports a higher risk of younger breast cancer diagnosis for BRCA carriers in the 
Dutch population. 
Study design is an important consideration in determining ethnic differences in 
breast cancer incidence. Gathani et al. (2014) conducted a prospective cohort study on 
Black, White, and South Asian women using Cox regression models to calculate adjusted 
relative risks (RR). Initial findings indicated prevalence differed substantially by 
ethnicity (P<0.001), with South Asian (RR=0.82, 95% CI 0.72–0.94) and Black women 
(RR=0.85, 0.73–0.98) at a lower risk than White women (Gathani et al., 2014) after 
adjustment for age and region of residence. However, after additional adjustment for 
known breast cancer risk factors, incidence was similar to that of Whites, both in South 
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Asians and in Blacks. Different interpretations of findings for differences between 
ethnicities are possible and study design is an important factor. These data underscore the 
need for my study, which will further investigate the role of ethnicity in BRCA related 
cancer epidemiology.   
Time to diagnosis and tumor type may also differ by ethnicity and by mutation 
type. A cohort study among Japanese women determined the mean age at the time of 
diagnosis for BRCA1 and BRCA2 carriers to be 44 years compared to 54 years for the 
control group. The incidence of bilateral tumor was significantly higher in BRCA1 at 32 
percent and BRCA2 was associated with 29 percent compared to 6 percent observed in 
the control group (Noguchi et al., 1999). BRCA1-associated hereditary cancers in this 
study demonstrated an increase in the risk of solid-tubular type tumors and a significant 
increase in histologic grade 3 tumors (p<0.01) compared with the control group. BRCA1 
related familiar breast cancers in Japanese women demonstrated biologically aggressive 
phenotypes, while BRCA2 associated familiar breast cancer did not demonstrate 
distinguishable clinical or pathologic characteristics in comparison with the sporadic 
cancers. These findings suggest that recognizing differences in ethnicity and mutation 
status is essential to developing appropriate screening and follow up protocols.  
Age. Incidence of both female and male breast cancer increases with age (Ewertz, 
Holmberg, & Karjalainen, 1989). Early studies demonstrated that by seventy years of 
age, women have a more than eighty percent risk of developing breast cancer if 
heterozygous for BRCA1 or BRCA2 mutations (Nussbaum et al., 2007). However, age as 
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a risk factor is intertwined in some ways with ethnicity/geography and gender. Age older 
than 40 has been shown to be a risk factor for White women, but for  Black women, 
being younger than 40 years of age increases risk of breast cancer (Jemals et al., 2003). 
Heredity and family history are a major influence on the age at which risk is highest 
(Mitchell, Kumar, Abbas, Fausto, & Aster, 2012). Hormonal status is also difficult to 
separate from age. A younger woman who is obese will have a lower risk than an older 
woman who is obese (Hernandez-Rey, 2014), while a woman who put off childbearing to 
later years is at higher risk due to more ovulatory cycles (Cullinane et al., 2005).    
Increasing age remains the most vital and significant predictor of breast cancer 
risk. Most cancers of the breast occur after 50 years of age (Singletary et al., 2004). 
However, BRCA1 and BRCA2 mutation related breast cancer develops often before 50 
years of age (Papelard et al., 2000; Sing et al., 2000). Lifetime risk, as derived from 
incidence tables formulated through the NCI-SEER registry, is quoted as 1 in 9 when 
lifetime is considered up to 85 years of age or 1 in 8 when lifetime is considered beyond 
after 95 years of age. During clinical counseling sessions, lifetime and age specific rates 
for women at average risk are crucial parameters against which to compare quantitatively 
elevated risk figures (Singletary et al., 2004). 
Sing et al. (2000) determined that Chinese women are often diagnosed with 
BRCA1 and BRCA2 before 50 years of age. Sing et al. (2000) examined the prevalence 
of BRCA1 mutations in 92 Chinese breast cancer patients in Singapore with a history of 
cancer of the breast before the age of 40. All six disease-causing mutations occurred in 
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women less than 40 years (8.6%) with three occurring in patients under 35 years (13.6%). 
Missense mutations of unknown significance were found in three patients. Two of the ten 
women with affected relatives under 40 years had BRCA1 mutations. The prevalence of 
BRCA1 mutations in Chinese subjects with early-onset breast cancer is similar to that 
observed in Caucasian women (Sing et al., 2000). A limitation of the Singh et al. study is 
the lack of specific intent to analyze age as a risk factor. My study will further examine 
age of diagnosis of BRCA mutation related breast cancer and time to diagnosis of a 
second primary cancer. 
Second Primary Cancers and BRCA Genes 
Individuals with breast cancer have been reported to be more susceptible to 
developing additional malignancies, and these second cancers may adversely impact 
prognosis and survival time (Lee et al., 2008; Hemminki et al., 2005). A second cancer 
which develops after diagnosis with breast cancer may be either secondary or a second 
primary cancer. Secondary cancer occurs when the primary or initial cancer cells spread 
or metastasize to another part of the body (Singletary et al.., 2004) resulting in the 
formation of a new tumor with the same cell type as the original cancer. Breast cancer 
cells can metastasize from the primary cancer site through the lymphatic cells or the 
bloodstream (Singletary et al., 2004). Symptoms depend on the specific part of the body 
where metastasis has occurred (Cancer Research UK, 2014).  
The risk for developing second cancers may be significant for patients diagnosed 
with breast cancer before age 40 (Lee et al., 2008; Lee et al., 2006). Lee et al. (2008) 
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determined an increased risk for developing a second primary malignancy in a Taiwanese 
breast cancer population. Second cancers of the breast were excluded in order to rule out 
secondary cancer of the same cellular origin. Results indicated excess risk for cancer of 
the bone, uterus, ovary, non-melanoma skin, thyroid, esophagus, kidney, lung, leukemia, 
and lymphoma. Lee et al. found the peak incidence was among women in their 40s, with 
approximately 2% developing a non-breast second primary cancer, with an average 
survival time of 2.87 years after the second cancer diagnosis (Lee et al., 2008). This poor 
prognosis for individuals with a second cancer diagnosis highlights the significance of 
identifying those at risk as early as possible, in order to improve health outcomes for this 
population. A limitation of the Lee study is that it was not designed to determine any 
association with mutations such as BRCA. The Lee study did not report any association 
with pancreatic or colon cancer, which may be due to the specific focus on a Taiwanese 
population and differential risks. Although Lee did not analyze BRCA status, the finding 
for a higher risk with younger age is in line with the increased likelihood of those with a 
BRCA mutation to develop cancer at a younger age. Additional studies on other ethnic 
populations would be useful to characterize this risk.  
Several studies support an association between younger age and second cancers in 
a BRCA population (Mocci et al., 2013; Hemminki et al., 2005; Brose et al., 2002; 
Johannesdottir et al., 1996). Mocci et al. aimed to estimate pancreatic cancer risk in high-
risk breast cancer families according to the BRCA mutation status. The authors applied a 
retrospective cohort analysis in order to ascertain the standardized incidence ratios (SIR) 
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for pancreatic cancer. Eligibility was based on families with ≥1 breast cancer case tested 
for mutations in BRCA1 and/or BRCA2. They observed that the women diagnosed with a 
BRCA mutation related breast cancer before 50 years of age were at a higher risk for 
developing a second cancer (Mocci et al., 2013). Mocci and colleagues noted BRCA1 
mutation carriers were at increased risk of pancreatic cancer (SIR= 4.11; 95% confidence 
interval [CI], 2.94-5.76) as were BRCA2 mutation carriers (SIR=5.79; 95% CI, 4.28-
7.84) (Mocci et al., 2013). The study was limited in that it did not examine colorectal 
cancer and familial pancreatic cancer risk estimate based on many ethnic groups. My 
study will further examine certain risk factors, including age of diagnosis, gender, 
ethnicity, and time to event of second primary cancer, pancreatic, colorectal, endometrial 
and cervical, among patients with breast cancer. Further studies are needed to elucidate 
the correlation between BRCA mutations and pancreatic cancer.  
Hemminki et al. (2005) investigated the risks for second discordant tumors after 
male breast cancer in 3,409 male subjects. Data were obtained from 13 cancer registries 
using “standardized incidence ratios (SIR) adjusted for age, year and registry were 
calculated using indirect standardization methods. Exact confidence intervals (CI) around 
the SIR were calculated assuming a Poisson distribution for the observed number of 
neoplasms. Among the study cases, 12.5% were diagnosed with a second neoplasia other 
than breast cancer. There was a significant risk of a second primary neoplasia affecting 
either the small intestine, rectum, pancreas, skin (non-melanoma), prostate; and 
lymphohaematopoietic system. Hemminki and colleagues findings suggest that BRCA2 
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(and to some extent BRCA1) mutations may explain the findings for pancreatic and 
prostate cancers (Hemminki et al., 2005). Hemminki and colleagues did not examine the 
time to event of the various second cancers. My study will examine time to diagnosis of 
second cancer, pancreatic and colon and association with certain risk factors such as age 
of diagnosis, ethnicity and gender.  
In a study to estimate BRCA1-related cancer risks for individuals ascertained in a 
breast cancer risk evaluation clinic, Brose et al. (2002) used an observed and age-adjusted 
cancer risk estimates to determine and analyze 483 BRCA1 mutation carriers in 147 
families identified in two academic breast and ovarian cancer risk evaluation clinics. 
Brose et al. (2002) noted the mean “age at female breast cancer diagnosis in this study of 
BRCA1 mutation carriers, as in many others, was 42 years (95% CI = 40 to 44 years), 
and the average age at ovarian cancer diagnosis was 52 years (95% CI = 50 to 53 years). 
These ages are 20 and 10 years younger, respectively, than population averages. The 
average age at male breast cancer diagnosis was 53 years (95% CI = 45 to 60 years), 
compared with 69 years in the general population. The average age at colon cancer 
diagnosis was 65 years (95% CI = 59 to 71 years), compared with 72 years in the general 
population found that by 70 years of age, the risk among BRCA1 carriers of being 
diagnosed with ovarian cancer was 40.7%” (p. 1369). Brose et al. (2002) also observed a 
twofold increased risk of colon cancer, threefold risk of pancreatic cancer, fourfold risk 
of stomach cancer, and 120-fold increased risk of fallopian tube cancer among BRCA1 
mutation carriers with breast cancer in comparison with the SEER Program population-
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based estimates. A limitation is the study did not include BRCA2 carriers in the study 
design and analysis. Also, the Brose et al.’s study was not designed for patients with 
BRCA related breast cancer, but for families that had BRCA1 mutants identified. The 
above findings underscores the need for this study to investigate the role of age at 
diagnosis of BRCA mutation related breast cancer and time to event of diagnosing a 
second cancer in this susceptible population.  
In order to ascertain the prevalence of BRCA2 mutations in Icelandic breast and 
ovarian cancer patients and association with second cancer, Johannesdottir et al. used the 
biopsy data from breast tumor. All available DNA samples of patients collected from 
nuclear pellets of patients diagnosed in the years 1989-1994 were included in the study. 
DNA from patients diagnosed with cancer other than breast and prostate was obtained 
from the University Hospital Iceland tumor bank. The control group were randomly 
selected DNA samples from subjects in the Iceland National Diet Survey (Johannesdottir 
et al., 1996).  They determined the frequency of the 999del5 BRCA2 mutation in an 
Icelandic control population and four groups of patients diagnosed with breast 
cancer, ovarian cancer, prostate cancer, and any other cancer. The findings showed that 
BRCA2 conferred a very high risk of breast cancer and appears to be responsible for a 
substantial fraction of breast and ovarian cancer in Iceland, but only a small proportion of 
other cancers (endometrium, colon, stomach, rectum, testis and thyroid) (Johannesdottir 
et al., 1996). The study was limited by non-inclusion of BRCA1 patients in their study 
design and also was not designed to study the time to event of second cancers. My study 
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will further examine time to event of second cancer, pancreatic and colon and association 
the risk factors, age of diagnosis, ethnicity and gender. 
The literature demonstrates that aside from breast cancer, BRCA1 and BRCA2 
gene mutations are associated with multiple other types of cancer, including endometrial 
(Shu et al; 2014), cervical (Rheim, Fisher, Bosse, Wappenschmidt, & Schmutzler, 2007), 
ovarian (Evans et al., 2009), colon (Kadouri et al., 2007; Brose et al., 2002), pancreatic 
(Mocci et al., 2013; Al-Mulla et al., 2009), bladder (Neveling et al., 2007), prostate 
(Hemminki et al., 2005; Johannesdottir et al., 1996), uterine (Thompson, Easton & the 
Breast Cancer Linkage Consortium, 2002), stomach (Brose et al., 2002), fallopian tube 
(Brose et al., 2002), and endometrial (Johannesdottir et al., 1996). The following sections 
discuss the literature on pancreatic, colorectal, endometria, and cervical cancer, 
specifically.  
Pancreatic Cancer. Pancreatic cancer is the fifth leading cause of cancer 
mortality in the United States (Murphy et al., 2002). Each year about 40,000 pancreatic 
adenocarcinomas are diagnosed in the United States (Lowery et al., 2011). Pancreatitis 
usually occurs quickly while chronic pancreatitis occurs after several inflammatory 
insults to the pancreas over time leading to permanent damage (Schneider & Szanto, 
2006). Although patients with chronic pancreatitis are predisposed to having pancreatic 
cancer, pancreatic cancer is most likely the result of the common risk factors of smoking, 
alcohol consumption, and gene mutations (Le et al., 2011). The overall incidence in the 
United States has been stable among men since 1993, with a slight 0.6 % yearly increase 
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among women since 1994 (Cancer Facts and Figures, 2012). Globally, most countries 
have a recorded annual incidence rate of 8-10 cases per 100, 000 persons, while about 
two cases of pancreatic cancer per 100, 000 are recorded annually in India (Dragovich, 
2014). The average person has less than a 1% lifetime risk for this disease, but carcinoma 
of the pancreas accounts for 5 % of all cancer deaths in the United States (Dragovich, 
2014). Peak incidence is between 60 and 80 years of age, and the 5-year survival is less 
than 4 % (Mitchell et al., 2012).   
About 60% of the time, the carcinoma arises in the head of the pancreas, causing 
obstructive jaundice; somewhat less often it originates in the pancreatic body (15 %) or 
pancreatic tail (5 %), and 20% is diffuse or widely spread (Schneider & Szanto, 2006). 
Carcinoma involving the pancreatic tail can cause islet destruction and secondary 
diabetes mellitus (Schneider & Szanto, 2006). Tumors may be small and ill-defined or 
large (8-10 cm), with extensive local invasion and regional metastasis. Clinical 
characteristics show insidious growth over many years. About 85% of the carcinomas of 
the pancreas are unresectable, with poor prognosis. First year mortality exceeds 80%.  
Weight loss and pain are typical presenting symptoms; obstructing jaundice with 
palpable gallbladder develops with tumors in the Head of Periampullary region (Le et al., 
2011). Massive metastasis to the liver usually occurs through splenic vein invasion. It can 
also metastasize to the stomach, duodenum, colon, or any abdominal cavity surface 
during characteristic peritoneal spread (Dragovich, 2014). Migratory thrombophlebitis 
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may occur with pancreatic and pulmonary neoplasm or other visceral cancers (Mitchell et 
al., 2012).  
Although the risk for pancreatic cancer is small among the general population, 
several studies established an association between BRCA gene mutations and increased 
risk for pancreatic cancer (Ferrone et al; 2009; Mocci et al., 2013). Ferrone et al. (2009) 
found 1.3% of Jewish patients who had a resection for pancreatic cancer had BRCA1, 
and 4.1% had BRCA2 germline mutations. There was no age difference or other 
differences in clinicopathologic characteristics. The Ferrone et al.’s study was not 
designed to look at pancreatic cancer as a second primary cancer after diagnosis with 
breast cancer.  However, Ferrone reported previous breast cancer in 24% of the study 
subjects, suggesting that there is a correlation that needs further exploration.  
Several researchers have found higher risk of pancreatic cancer for BRCA2 
(Mocci et al., 2013; Goggins et al., 1996; Van Asperen et al., 2005).  Germ-line BRCA2 
mutations are the most common inherited genetic alteration known in hereditary 
pancreatic cancer, but BRCA is not the only gene related to pancreatic cancer. Greater 
than 90% of pancreatic cancers carry a K-ras mutation and 60 to 80% demonstrate 
mutations in p53 (Mitchell et al., 2012). However, these genes are outside the scope of 
my study, and remain a potential confounder for pancreatic cancer cases in my study.  
Some researchers have found significance for both BRCA1 and BRCA2 for risk 
of pancreatic cancer. Lowery et al. (2011) found that individuals who carried either 
BRCA1 or BRCA2 had increased risk of pancreatic cancer. Mocci et al. (2013) analyzed 
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the NCI- BCFR data of 5,799 families with at least one breast cancer case, testing for 
mutations in BRCA1 and BRCA2. Family members with at least one BRCA1 and/or 
BRCA2 case were at increased risk of pancreatic cancer, regardless of number of 
members with early-onset breast cancer adenocarcinoma.  
A National Familial Pancreas Tumor Registry (NFPTR) study sought to identify 
the germline mutations associated with increased risk for pancreatic cancer. Murphy et al. 
(2002) selected patients with pancreatic cancer from kindreds enrolled in the NFPTR 
containing three or more cases of pancreatic cancer, where at least two of the affected 
persons were first-degree relatives. Murphy et al. analyzed samples representing 29 
kindreds for four tumor suppressor genes, including BRCA2. Of the mutations studied, 
only BRCA2 was significantly associated with pancreatic cancer. However, Murphy et al. 
did not analyze other potential genes including BRCA1, K-ras, or p53 in this study. Two 
of the five BRCA2 mutation carriers also reported a family history of breast cancer 
(Murphy et al., 2002), further supporting the need for my study to analyze the 
relationship between breast cancer and pancreatic cancer in the BRCA carrier population.  
The above studies highlight the association that exists between BCRA mutations 
and increased susceptibility to both breast and pancreatic cancer. However, few if any 
studies have specifically examined the development of pancreatic cancer after diagnosis 
with breast cancer in a BRCA positive population. The proposed study fills a gap in the 
literature by reporting the time to event of pancreatic cancer among BRCA1/BRCA2 
cases after initial diagnosis with breast cancer.   
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Colorectal Cancer. Annually, there are approximately 1 million cases of 
colorectal cancer and about 500, 000 estimated deaths globally (Boyle & Leon, 2002). 
The Surveillance Epidemiology and End Results Program (SEER, 2014) estimated that in 
2011, approximately 1,162,426 individuals were living with colon and/or rectal cancer in 
the United States. Colorectal cancer affects more than 150,000 individuals every year in 
the United States alone and is responsible for 15 % of all cancers. Cancer of the colon is 
the third most common cancer, the third most deadly cancer in the United States, and the 
only cancer that occurs with equal frequency among men and women (Le et al., 2011; 
NCI, 2014). Most patients are greater than 50 years of age, and approximately 25 % have 
a family history (Le et al., 2011). About 4.8 percent of men and women living in the 
United States may be diagnosed with colon or rectal cancer at some point in life (SEER, 
2014).  
It can be difficult to differentiate cancers of colon and rectum in mortality 
statistics. According to NC1 (2014) there were 96,830 colon cancers and 40,000 rectal 
cancers, and colorectal cancer as a whole resulted in approximately 50,310 deaths. There 
are significant differences in incidence in multiracial/ethnic countries among ethnically or 
racially defined populations (Boyle, 1989). Boyle and Leon (2002) found the highest 
incidence in the United States, Canada, Japan, and New Zealand. These high rates were 
found in a variety of population groups including Blacks in Detroit (34.9 per 100,000), 
Los Angeles (34.8), San Francisco (33.8), Atlanta (32.4), and New Orleans (31.4), 
Hawaiian Japanese (34.4), Hawaiian Whites (32.7) and non-Maori in New Zealand 
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(31.2). Data from SEER (2014) incidence rates (per 100,000) reported as Blacks (47.5), 
Whites (37.3), Asian/Pacific Islanders (32), American Indian/Alaskan (35.5), and 
Hispanics (31.2).  
Colorectal cancer involves the epithelium of the colon or rectum and is one of the 
most common forms of cancer (Le et al., 2011). Invasive adenocarcinoma is a malignant 
lesion with metastatic potential because it has crossed into submucosa, which contains 
lymphatics (Le et al., 2011). Endoscopic removal of a malignant polyp is adequate if the 
invasive adenocarcinoma is superficial and there is no vascular or lymphatic invasion 
(Mitchell et al., 2012). There is substantial evidence to support a genetic factor for 
familial colon cancer (Nussbaum et al., 2007). 
A small proportion of colon cancer cases, with an annual incidence of 10,000 
cases, are due to Familial Adenomatous Polyposis (FAP). FAP is an autosomal dominant 
mutation of the APC gene on chromosome 5q. FAP (Nussbaum et al., 2007). In nearly 
70% of adenomatous polyps (precursors to colorectal cancer) in individuals without FAP, 
the two-hit model of tumorigenesis has been confirmed by the loss of both copies of APC 
in the adenoma, but not in the surrounding normal tissue (Nussbaum, et al., 2007). About 
90% of adenomas are found in the colon; they may also occur in the stomach and small 
intestine. Another proportion of familial colorectal cancer cases are observed in 
individuals with the hereditary non-polyposis colorectal cancer (HNPCC/Lynch 
syndrome), an autosomal-dominant mutation of DNA mismatch repair genes. 
Approximately 80% will progress to colorectal cancer (Le et al., 2011).   
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Most sporadic colorectal cancers are thought to arise in polyploid adenomas. Diet 
may be an important risk factor (Mitchell et al., 2012). Colorectal cancer risk is 
associated with excess energy intake relative to requirements, low vegetable fiber intake, 
high content of refined carbohydrates, and high intake of red meat and decreased intake 
of protective micronutrients (particularly vitamins A, C, and E). Such diets may cause 
increased exposure to bile acids and bacterial degradative by product. However, a causal 
relationship with diet has not been substantiated (Mitchell et al., 2012).  
Clinically, early onset of colon cancer and premalignant adenomatous polyps are 
usually asymptomatic, and this makes them difficult to discover until an advanced stage 
of colon cancer presenting with symptoms (Cappell, 2008). Symptoms of colorectal 
cancer include fatigue, weakness, iron deficiency anemia, abdominal discomfort, 
progressive bowel obstruction, and liver enlargement (Schneider & Szanto, 2006). 
Prognosis depends on the extent of invasion at diagnosis. Five-year survival depends on 
the depth of penetration and lymph node involvement and ranges from 100 % for lesions 
limited to the mucosa to 25 % for extensive invasive tumors. 
BRCA mutation status has been demonstrated to be a risk factor for colorectal 
cancer, particularly for younger women (Brose et al; 2002; Ford, Easton, Bishop, Narod, 
& Goldgar, 1994; Phelan et al., 2013; Suchy et al. 2010).  Brose et al. (2002) noted a 
twofold increased risk of colon cancer in BRCA1 mutation carriers’ families with breast 
cancer risk. Ford et al. demonstrated that carriers are at increased risk of colon and 
prostate cancer, which may be of clinical significance in certain families if the risk is 
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associated with specific mutation (Ford et al., 1994). However, few studies have 
specifically looked at the epidemiology of colon cancer as a second primary cancer after 
diagnosis with breast cancer.  
 Suchy et al. (2010) examined 2,398 Polish subjects with colorectal cancer for 
three known Polish BRCA1 founder mutations (C61G, 4153delA, and 5382insC). A 
BRCA1 mutation was present in 0.42% of unselected cases of colorectal cancer and in 
0.48% of controls. The mutation frequency was slightly higher (0.93%) in cases who 
reported a family history of colon cancer in a first- or second-degree relative. A BRCA1 
mutation was observed in 0.82% of cases who were diagnosed with colorectal cancer at 
age 60 or earlier. The mean age at onset in carriers was 7 years younger than in non-
carriers (57.0 years vs. 64.0) and the difference was significant (P = 0.05). Suchy et al. 
did not report on whether the subjects had breast cancer, but these findings support a 
higher risk for younger patients with BRCA mutations and potential for developing a 
second primary colon cancer in this susceptible population. My study examined the time 
to event of second primary colon cancer diagnosis in patients after initial diagnosis with 
BRCA mutation related breast cancer. 
Phelan et al. (2013), observed colorectal cancer cases in both BRCA1 and 
BRCA2 carriers. Findings demonstrated an increased risk of colorectal cancer among 
female carriers of BRCA1 gene mutation who were below 50 years of age, but not in 
older women or individuals with BRCA2 mutations. Phelan et al. (2013) did not 
specifically aim to examine the incidence of colorectal cancer as a second primary cancer 
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among women with BRCA1 or BRCA2 mutation related breast cancer. The above 
findings support an association between early onset of colorectal cancer and BRCA 
mutations. However, the association with the development of second primary colorectal 
cancer after diagnosis with BRCA related breast cancer needs more elucidation. In the 
proposed study, I will examine the time to event of colon cancer diagnosis in patients 
after initial diagnosis with BRCA mutation related breast cancer. 
Endometrial Cancer. Endometrial cancer is the most common cancer of the 
female reproductive system, accounting for 6% of all the cancers among women in the 
United States (National Cancer Institute (NCI), 2014). Endometrial cancer usually begins 
in the cells of the inner lining of the uterus (the endometrium) and can be divided into 
squamous cell carcinoma, adenocarcinoma and undifferentiated carcinoma, depending on 
the appearance of the cells under the microscope (American Cancer Society, 2015). Some 
risk factors associated with increased risk of endometrial cancer include genetics, 
postmenopausal estrogen therapy, obesity, tamoxifen use, early menarche and late 
menopause (NCI, 2014). Incidence rates have remained steady since 2002, whereas the 
mortality rates since 2001 have been rising gradually. In the United States, African 
American women have a slightly higher incidence rate compared to White women and 
twice the mortality rate compared to other ethnic/racial populations (NCI, 2014). 
However, Caucasian women have a 2.88% lifetime risk of developing uterine cancer 
compared to African American women, with lifetime risk of 1.69%. African American 
women are more likely to have non-endometrioid, high-grade tumors and a more 
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advanced stage of disease at the time of diagnosis compared to Caucasian women who 
have similar demographics (Oliver et al., 2001). Menopausal women account for the 
majority of individuals diagnosed with endometrial cancer, with an average age of 
diagnosis of 60. Endometrial cancer is rarely observed in women less than 40 years of 
age (5-10%) (OncoLink, 2015). According to the Surveillance, Epidemiology, and End 
Results Program (SEER, 2015) age-adjusted data based on 2008-2012 cases and deaths, 
there were 25.1 per 100,000 new cases of endometrial cancer in the United States per 
year; while the number of deaths was 4.4 per 100,000 women per year. 2012 prevalence 
data from SEER (2015) estimated that 621,612 women were living with endometrial 
cancer in the United States.  
Patients with an initial diagnosis of breast cancer may have an increased risk of 
developing a particular type of endometrial cancer later (Gehrig et al., 2004).  Gehrig et 
al. (2004) determined that women with breast cancer who were later diagnosed with 
endometrial cancer demonstrated a 2.6-fold increased risk of developing a uterine serous 
carcinoma as compared to an endometrioid carcinoma.  
The association between germline mutations in BRCA genes and the risk of 
endometrial cancer remains unclear, but several case reports of endometrial carcinoma in 
women with a BRCA mutation exist (Oh, Kim, Kim, & Kim, 2015; Levine et al., 2001). 
Inherited mutations in the BRCA1 or BRCA2 genes are associated with a greatly 
increased lifetime risk of breast and endometrial cancers (Shu et al., 2014) and cervical 
(Rheim et al., 2007). 
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Levine et al. (2001) conducted a retrospective cohort study with 199 consecutive 
Ashkenazi Jewish patients with endometrial carcinoma in in a New York City Cancer 
Center to examine the relationship between BRCA and endometrial carcinoma. All the 
study participants were genotyped for the three BRCA founder mutations (185delAG and 
5382insC in BRCA1 and 6174delT in BRCA2) that exist in this population, and the case 
frequency was compared to the known population frequency of these mutations. 
BRCA mutations were observed in 1.5% of the 199 patients; one in BRCA1 and two 
in BRCA2, compared to an expected frequency of 2.0%. Relative risk of endometrial 
carcinoma associated with BRCA mutation, as estimated by the odds ratio, was 
calculated as 0.75 (95% CI = 0.24–2.34). The above findings imply that despite the 
relationship between BRCA and endometrial carcinoma, for people with a germline 
BRCA mutation, the lifetime risk of endometrial cancer may be low.  
Shu et al. (2014) investigated 525 subjects to determine whether there was an 
increased risk of uterine cancer among patients with BRCA mutations. The prospective 
study aim was to determine whether the risk of uterine corpus cancer following risk-
reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations were 
greater than that seen in the general population. Subjects obtained from Memorial Sloan 
Kettering Cancer Center in New York were followed prospectively via annual 
questionnaires and medical record review for a median of 5.8 years. Shu and colleagues 
reported an aggressive form of uterine cancer, either serous carcinoma, carcinosarcoma, 
or leiomyosarcoma developed in 4 of the 296 women with a BRCA1 mutation, a 2.1% 
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risk over 10 years. This risk is approximately 26-fold higher than expected in the general 
population (Shu et al., 2014). None of the women with a BRCA2 mutation were 
diagnosed with uterine cancer. These data suggest that BRCA1 may be responsible for an 
increased risk of an aggressive form of uterine cancer, but there is insufficient data on the 
potential relationship to endometrial cancer. The study was not designed to look at time 
to diagnosis of second primary cancers in a population with breast cancer. My study  
further investigated  association of BRCA1 and BRCA2 with age, and ethnicity and the 
time to event of endometrial cancer among the study population. 
Cervical Cancer. Cervical cancer is strongly associated with the Human 
Papilloma Virus (HPV). In the United States, the incidence rates of cervical cancer have 
declined 45 percent and mortality rates have declined 49 percent since 1980. According 
to the National Vital Statistics System (2013), the age-adjusted cervical cancer death rate 
was 2.3 per 100,000 in 2013. The rate for non-Hispanic Black females was nearly double 
the rate for non-Hispanic White females (4.0 compared to 2.1) and 1.6 higher than the 
rate of 2.5 for Hispanic females. From 1999 to 2013, cervical cancer death rates have 
decreased 31% for Hispanic females, 26% for non-Hispanic Black females, and 16% for 
non-Hispanic White females. However, this disease remains a serious public health 
threat, and one that demonstrates racial disparities. Incidence rates in Hispanic women 
and American Indian/Alaska Native women are higher than in women from other 
racial/ethnic groups. Despite a recent overall decline, mortality rates among African 
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American women remain higher than for women of any other racial/ethnic group in the 
United States.  
Cervical cancer mortality and incidence rates also vary with socioeconomic status 
and geographic location, perhaps because cervical cancer screening rates vary across 
racial/ethnic, socioeconomic, and geographic groups (NCI, 2014). Although the overall 
rate of screening for cervical cancer in the United States has increased, many 
subpopulations are not being adequately screened. More than 60% of the women with a 
diagnosis of cervical carcinoma had never been screened or had not been screened within 
the previous 5 years of diagnosis (American College of Obstetricians and Gynecologists 
(2003). According to Centers for Disease Control (CDC, 2003), the report by National 
Breast and Cervical Cancer Early Detection Program (for 1991-2002) showed that 
racial/ethnic distribution of women receiving a pap smear for all years combined slightly 
less than half (47%) of the women were from racial/ethnic minority groups. For the most 
recent time period (2001–2002), the percentage from minority groups was slightly more 
than half (51%). Moreover, for both first and subsequent screening rounds, American 
Indian/Alaska Native women had the highest percentage of abnormal Pap test results 
(CDC, 2003). 
HPV types 16, 18, 31, 33, 45, and 51 are implicated in causing cervical cancer. 
Recent studies have examined the association between breast and cervical cancer. Fu, 
Wang, Shah, Wang, Zhang, and He (2015) investigated the association of human 
papilloma virus type 58 with breast cancer in Shaanxi province of China. 169 cases of 
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breast cancer samples and 83 benign breast lesions were analyzed. The presence of HPV 
58 in both normal duct epithelial cells and carcinoma in situ along with its presence in the 
cancer cells of the same specimen supports an association of HPV 58 with breast cancer 
(Fu et al., 2015). However, this study cannot provide information on the time to event 
and was not designed to analyze a correlation with BRCA gene mutations.  
There is some evidence of an association between BRCA1 and cancer of the 
uterine body and cervix. Thompson, Easton and the Breast Cancer Linkage Consortium 
(2002) carried out a cohort study of 11, 847 individuals from 699 families segregating a 
BRCA1 mutation that was ascertained in 30 centers across Europe and North America. 
The purpose of the study was to evaluate the risks of other cancers besides breast in 
BRCA1 mutation carriers. The findings demonstrated BRCA1 mutation carriers were at a 
statistically significantly increased risk for several non-breast cancers, including cancer 
of the uterine body (RR = 2.65, P<.001) and cervix (RR = 3.72, P<.001). The study does 
provide evidence of association with BRCA mutations, but was limited to BRCA1.  
The findings by Thompson et al. (2002) are supported by Rheim, Fisher, Bosse, 
Wappenschmidt and Schmutzler (2007). Rheim et al. (2007) analyzed cross sectional 
data from 4,405 German subjects from 409 families with BRCA1 (n=86) or BRCA2 
mutations (n=53) and 270. They also included high risk BRCA1/2 negative families 
ascertained by the Familial Breast and Ovarian Cancer Center Cologne. The study aim 
was to evaluate the risk of BRCA-associated cancers using proven mutation carriers, 
individuals affected by breast and ovarian cancer, and their first degree relatives. They 
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used 921 individuals with BRCA1 (604 female; 317 male), 571 with BRCA2 (365 
female; 206 male), and 2,913 who were BRCA1/2 negative (1938 female; 975 male) 
families that suffered from cancers other than breast and ovarian. Rheim and colleagues 
observed the risk for cervical cancer was significantly increased in BRCA1 and BRCA2 
positive females (RR=4.59, 95% CI=2.20 to 8.44, and RR=3.69, 95% CI=1.20 to 8.61; 
p=<0.001) and also increased among BRCA1/2 negative families (RR=2.97, 95% 
CI=1.88 to 4.45) Rheim et al; (2007). These findings suggests that cervical cancer is 
associated with breast cancer and BRCA genes. My study  further examined associations 
bewteen BRCA1 and BRCA2, age, ethnicity, and time to event of cervical cancer in a 
breast cancer population. 
Time to Diagnosis of a Second Cancer 
BRCA mutation status is clearly implicated in the formation of several cancers as 
noted in the prior sections, but there are limited data regarding time to event of these 
second cancers after initial diagnosis with breast cancer. In the proposed study, I 
examined the association between BRCA1 and BRCA2 mutation status in women with 
breast cancer and time to diagnosis of a second cancer, specifically pancreatic, colorectal, 
endometrial, or cervical cancer.  
Recognizing factors that influence  time to event of pancreatic cancer is crucial 
because symptoms of the disease may not be noted until late in the disease course (Le et 
al., 2011). Low survival rates are attributable to the fact that fewer than 20% of  tumors 
are confined to the pancreas at the time of diagnosis; in most cases, the malignancy has 
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already progressed to the point where surgical removal is impossible (American Cancer 
Society, 2014).  
Colorectal cancer diagnosis may also be influenced by several factors. The 
symptoms may present early or late in the course depending on the patient’s nutrition, 
race, age and genetic predisposition (American Cancer Society, 2014). Patients diagnosed 
with rare inherited conditions, such as inflammatory bowel disease (IBD), adenomatous 
polyps (adenomas) (Le et al., 2011) and personal history of BRCA1/BRCA2 (Kadouri et 
al., 2007) may be more severely impacted. The above findings underscore the need for 
further investigation of factors that impact the time to event of pancreatic, colorectal, 
endometrial, andcervical cancer. In the following sections, I discus the pertinent literature 
on the variables of age, ethnicity, and gender as they relate to time to diagnosis of second 
cancers.    
Age and Time to Diagnosis 
Typically, 60 to 80 years of age is the peak incidence for developing pancreatic 
cancer (Mitchell et al, 2012). Pancreatic cancer is not common in persons younger than 
45 years who have no predisposing risk factors, such as chronic pancreatitis and familial 
pancreatic cancer. After 50 years of age, the frequency of pancreatic cancers undergoes a 
linear increase (Dragovich, 2014). Dragovich (2014) found the average age at diagnosis 
was 69 years in Whites and 65 years in Blacks, while some single-institution data 
reported from large cancer centers (Dragovich, 2014) suggested that the average age at 
diagnosis in both sexes has fallen to 63 years of age. Bermejo and Hemminki (2004) 
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observed a twofold increased risk of pancreatic cancer in BRCA1 gene mutation carriers 
younger than 50 years of age. The above studies were not designed to analyze pancreatic 
cancer as a second cancer occurring after diagnosis of breast cancer, but do suggest that 
some portion of development of pancreatic cancer in a younger population could be 
attributable to predisposing factors such as BRCA mutations.  
Some studies have analyzed age as a risk factor in diagnosing pancreatic cancer as 
a second cancer occurring after breast cancer diagnosis. Mocci et al. (2013) in a 
retrospective cohort study analysis observed that the women diagnosed with a BRCA 
mutation related breast cancer before 50 years of age were at a higher risk for developing 
pancreatic cancer as second cancer. This finding is supported by an earlier study by Brose 
et al. (2002) that found observed threefold risk of pancreatic cancer among BRCA1 
mutation carriers with breast cancer in comparison with the SEER Program population-
based estimates. 
The risk of colon cancer has also been found to increase in individuals below 50 
years of age who have BRCA germline mutations (Phelan et al., 2014; Suchy et al., 2010; 
Ford et al., 1994). Phelan et al. found an increased risk of colorectal cancer among female 
carriers of BRCA1 gene mutation who were below 50 years of age, but not in older 
women or individuals with BRCA2 mutations (Phelan et al., 2014). Suchy et al. (2010) 
observed the mean age at onset of primary colon cancer in BRCA carriers was 7 years 
younger than in non-carriers (57.0 years vs. 64.0).  Ford et al. (1994) found primary 
ovarian cancers occurred in women with a previous breast cancer, with an estimated 
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cumulative risk of ovarian cancer of 44% by age 70. A higher risk of second cancers, 
including colon cancer, were also noted in individuals with breast or ovarian cancer and 
their first-degree relatives compared with expected national incidence rates. 
Although data is limited, the above findings imply that BRCA mutations have the 
potential to be a risk factor for development of second cancers after diagnosis with breast 
cancer, particularly for younger individuals.  
Beiner et al. (2007) conducted a prospective cohort study that examined the risk 
of endometrial cancer in women with BRCA1 and BRCA2 mutations. An international 
registry was used to identify women subjects with known BRCA1 or BRCA2 mutations, 
aged 45 to 70 and they were followed prospectively. The study involved 857 participants 
who completed a baseline questionnaire and one or more follow-up questionnaires. Study 
subjects were followed until diagnosis of endometrial cancer, ovarian cancer, death or the 
date of completion of the last questionnaire. The expected number of endometrial cancers 
was calculated using age and country-specific incidence rates (Beiner et al., 2007). The 
study findings indicated six women were diagnosed with endometrial cancer, compared 
to 1.13 cancers expected after follow-up (SIR = 5.3, p = 0.0011). Four of these six 
patients used tamoxifen in the past. The risk among women who were never exposed to 
tamoxifen treatment was not significantly elevated (SIR = 2.7, p = 0.17), but among the 
226 participants who had used tamoxifen (220 as treatment and six for the primary 
prevention of breast cancer) the relative risk for endometrial cancer was 11.6 (p = 0.0004) 
(Beiner et al., 2007). The above study demonstrated an increased risk of endometrial 
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cancer with age among BRCA carriers who had a previous breast cancer and were treated 
with tamoxifen. 
Little is known about the age at diagnosis of cervical cancer and association with 
BRCA mutation (Brose et al., 2002). Brose et al. (2002) evaluated cancer risk estimates 
by age 70 for BRCA1 mutation carriers and indicated several cancer risk estimates for 
BRCA1 mutation carriers. The cumulative age-adjusted lifetime second cervical cancer 
risk in BRCA1 mutation carriers for 95% CI was 0.3 (0.3 to 0.8) with a corresponding 
population risk of 0.8%.  
Ethnicity and Time to Diagnosis 
There are some data on ethnicity and risk of second cancers, but few have looked 
specifically at time to diagnosis of second cancers. Lee et al. (2008) found the peak 
incidence for a second cancer in Taiwanese women diagnosed with breast cancer at a 
young age was among women in their 40s. Approximately 2% developed a non-breast 
second primary cancer, with an average survival time of 2.87 years after the second 
cancer diagnosis.  
Other studies done in various populations have provided data correlating BRCA 
mutations with the risk of developing second cancers, but without analyzing the time to 
diagnosis. A study among breast cancer families in Iceland found that BRCA was 
responsible for a small proportion of second cancers, including endometrium, colon, 
lung, prostate, stomach and thyroid cancer (Johanannesdottir et al., 1996).  Al-Mulla et 
al. (2009) observed a significant association in United Kingdom families with breast 
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and/or ovarian cancer and BRCA1 or BRCA2 mutation and the occurrence of a second 
cancer including vaginal, colon, prostate, and pancreatic cancers (Al-Mulla et al., 2009).  
There is indication that Ashkenazi ethnicity could be neutral or perhaps even 
protective against the risk of developing colorectal cancer after diagnosis with a BRCA 
mutation, perhaps relating to the particular BRCA mutations present in this population 
(Niell et al., 2004). Niell et al. genotyped a northern Israeli population for the BRCA1 
187delAG, BRCA1 5385insC, and BRCA2 6174delT founder mutations. A family 
history of breast cancer in a female relative was not associated with an increased risk of 
colorectal cancer, even after adjustment for the presence of a BRCA founder mutation. 
Ashkenazi BRCA founder mutations may not confer a strong high risk of colorectal 
cancer and do not seem to be risk factor for colorectal cancer in that population (Niell et 
al., 2004). This study did not look at colon cancer as a second cancer after breast cancer, 
but provides some useful information about the role of ethnicity, which may relate to the 
type of BRCA mutation carried. These findings are consistent with other studies on 
Ashkenazi’s Jewish population finding no association between BRCA gene mutations 
and colon cancer (Kadouri et al., 2007; Drucker, Stackievitz, Shpitz, & Yarkoni, 2000). 
However, this suggests more data is necessary for other ethnic groups, which may be at a 
higher risk.  
There is some evidence for increased risk of pancreatic cancer in BRCA1 and 
BRCA2 mutation carriers in European and North American groups (Thompson & Easton, 
2002). Thompson and Easton found that BRCA1 mutations may confer small but 
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increased risks of other abdominal cancers in women and increased risks of pancreatic 
cancer in men and women (Thompson & Easton, 2002).  
Few studies have investigated ethnicity as a risk factor of endometrial cancer 
diagnosis among women with BRCA mutations (Setiawan, et al., 2006; Ofer et al., 2000; 
La Vecchia et al., 1984). Ofer et al. (2000) carried out a population study among the 
Jewish population with the study aim of determining the possible effects and incidence 
of BRCA1 and BRCA2 germline mutations in uterine serous papillary carcinoma (a 
subtype of endometrial carcinoma). Ofer et al. (2000) screened DNA from 12 women 
with uterine serous papillary carcinoma for BRCA1 and BRCA2 germline mutations 
common in the Jewish population (BRCA1–185delAG and 5382insC, BRCA2–
6174delT). In women subjects with germline mutations, tumor DNA was screened for 
loss of heterozygosity at the appropriate loci. They found nine women were of Jewish 
Ashkenazi origin and three were non-Ashkenazi. Two of nine Ashkenazi women were 
carriers of germline mutations: one 185delAG mutation and one 5382insC mutation. Five 
women had histories of breast carcinoma before diagnosis of uterine serous papillary 
carcinoma. Family histories of seven women had at least one first-degree relative with 
malignant disease. Of those, four had at least one first-degree relative with breast, 
ovarian, or colon carcinoma. Both carriers had strong family histories of breast-ovarian 
carcinoma. Loss of heterozygosity analysis found loss of the wild-type BRCA1 allele in 
the primary uterine tumors. BRCA1 germline mutations were observed in two of nine of 
the women in this series. The loss of heterozygosity in the tumor tissue of the carriers, 
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coupled with the high frequency of family and patient histories of breast or ovarian 
malignancies, suggest that uterine serous papillary carcinoma might be a manifestation of 
familial breast-ovarian cancer (Ofer et al., 2000). The above study supports other findings 
(Shu et al., 2014; Thompson et al., 2002; Levine et al., 2001) that ethnicity is a risk factor 
for endometrial cancer among populations with BRCA gene mutations. 
Thompson et al. (2002) found that BRCA1 mutation carriers were at a statistically 
significantly increased risk for several non-breast cancers, including cancer of the uterine 
body (RR = 2.65, P<.001) and cervix (RR = 3.72, P<.001). The study does provide 
evidence of association with BRCA mutations, but was limited to BRCA1 (Thompson et 
al., 2002). However, this study did not specifically aim to look at second primary cancers. 
My study will further examine the association between ethnicity as a risk factor for the 
time to diagnosis of second primary pancreatic, colorectal, endometrial, or cervical 
cancer in the study population 
Gender and Time to Diagnosis 
Male gender may be a risk factor for developing second cancers in those with 
BRCA1 and BRCA2 related breast cancer (Hemminki et al., 2005).  Some risks are 
necessarily gender specific. For example, the risk for prostate cancer is associated only 
with the male gender (Hemminki et al., 2005), while the risk for ovarian, endometrial, 
and cervical cancer found in other studies is associated only with females (Shu et al., 
2014; Evans et al., 2009; Rheim et al., 2007).  However, breast cancer is not limited to 
females and men with BRCA1 mutations are at increased risk of cancers of the breast 
59 
 
 
 
(Agalliu et al., 2007). Evidence supporting a gender difference for increased 
susceptibility to colon cancer is limited (Brose et al., 2013; Kadouri et al., 2007). 
There are some data that women have a greater lifetime risk of cancer with 
mutations of the BRCA1 gene, while BRCA2 conveys a greater risk for men. The 
spectrum of cancers is wider for BRCA2, and Liede et al. (2004) reported that the overall 
cancer risk for male BRCA2 carriers was higher than the risk for female carriers (Liede, 
Karlan, & Narod, 2004). Liede et al. (2004) found the relative risk to male BRCA2 
mutation carriers was highest before 65 years of age, mostly attributable to breast, 
prostate, and pancreatic cancers. BRCA2 mutation carriers are also at risk of stomach 
cancer and melanoma of the skin and eye (Liede et al., 2004). A limitation is that the 
Liede study was not designed to study second cancers after diagnosis of BRCA related 
cancer.   
Additional research into gender differences for BRCA mutation carriers is needed 
to ascertain the scope and magnitude of excess cancer risk in BRCA carriers. By 
critically examining the non-modifiable risk factors that may contribute to 
BRCA1/BRCA2 mutation related breast cancer and second cancers, I will provide data to 
help focus screening and risk reduction mechanisms. The following sections describe the 
methods of BRCA mutation detection, treatment options for breast, colorectal, and 
pancreatic cancer, and prognoses.  
Detection, Treatment, and Prognoses 
BRCA Mutation Detection 
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Currently, there are several available genetic detection methods used for detecting 
BRCA1 and BRCA2 gene mutation status. Tests can ascertain multiple mutations in both 
genes using a blood or saliva sample for DNA. Due to the relative rareness of the 
deleterious BRCA1 and BRCA2 gene mutations in the general population, it is generally 
recommended that mutation testing should be done only in patients with family history 
suggestive of the possible presence of a deleterious mutation in BRCA1 or BRCA2. The 
United States Preventive Services Task Force (2013) has provided a recommendation 
encouraging women whose close relatives are diagnosed with breast, ovarian, fallopian 
tube, or peritoneal cancer to be evaluated to ascertain if they have a family history that 
predispose them to an increased risk of a deleterious mutation in one of these genes.   
There are some screening tools to assess family history factors that are associated 
with an increased likelihood of having a harmful mutation in BRCA1 or BRCA2. These 
include breast cancer diagnosed before age 50 years, cancer in both breasts, having both 
breast and ovarian cancers, having multiple breast cancers, two or more primary types of 
BRCA1- or BRCA2-related cancers in a single family member, cases of male breast 
cancer, and Ashkenazi Jewish ethnicity (United States Preventive Services Task Force, 
2013). 
While screening can provide patients with some clarity regarding their risks, these 
individuals may then need to decide what to do with the information. The options at this 
time are fairly limited for patients diagnosed with BRCA1 or BRCA2 gene mutations to 
manage their risk of getting cancer, and include an enhanced screening method, the use of 
61 
 
 
 
prophylactic (risk-reducing) surgery, and the application of chemoprevention techniques 
(NCI, 2014). These options are discussed in further detail below.  
The enhanced screening option is recommended for women with a positive 
BRCA1 or BRCA2 test result at a young age. Women who carry the deleterious BRCA1 
or BRCA2 are encouraged to undergo clinical breast examination and a mammogram 
every year beginning at age 25 to 35 years (Burke et al., 1997). This option increases the 
chance of early detection of breast cancer and the likelihood of a better prognosis during 
treatment.  
MRI and mammography are widely used breast cancer detection tools. The use of 
MRI in breast cancer screening may be more sensitive than mammography (Kriege et al., 
2004), especially in high risk women who are BRCA1 or BRCA2 positive (Warner et al., 
2004). However, mammography can detect some breast cancers that are not detected by 
MRI (Obdeijn, et al., 2010), and MRI may be less specific (generating false positive 
outcomes) than mammography.  
It has not been fully elucidated if there is any benefit of screening for breast and 
other cancers in men that have positive BRCA1 or BRCA2 mutation diagnosis, but it has 
been suggested that men with positive BRCA1 and BRCA2 mutations should undergo 
prostate cancer testing and regular mammography (NCI, 2014). 
Breast Cancer Treatment and Prognosis 
 The array of breast cancer treatment options for some patients may involve 
aggressive surgery, chemotherapy, and radiotherapy, whereas others may receive only the 
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primary tumor surgical resection. To ascertain the best option for each patient, a risk 
prognostic, predictive data, as well as profile composing of clinical data is normally 
gathered (Singletary, 2004). Some prognostic markers such as lymph node status, tumor 
size, histologic subtype, proliferation rate, and hormone receptors are often used to 
ascertain a population-based estimate of the absolute risk of recurrence and/or death. Due 
to the relationship between prognostic factors and natural disease history, it is often 
suggested that these data are seen as treatment independent (Singletary et al., 2004). On 
the other hand, Singletary and Colleagues presented that predictive markers are usually 
utilized when identifying patients who will benefit, or not benefit, from a particular 
therapeutic regimen. Predictive markers are viewed as treatment associated. Some of 
these markers include the estrogen receptor (used to identify patients who will possibly 
benefit from hormonal therapy (Singletary et al., 2004).  
Due to the involvement of BRCA1 and BRCA2 genes in DNA repair, a 
deleterious mutation in either of these genes may be more sensitive to anticancer agents 
that act by damaging DNA, such as cisplatin (NCI, 2014). According NCI (2014), data 
from preclinical investigation on drugs associated with blocking repair of DNA damage 
have been found to inhibit the growth of cancer cells that have BRCA1 or BRCA2 
mutations. These drugs have likewise demonstrated some activity in cancer patients who 
carry BRCA1 or BRCA2 mutation breast cancer patients (NCI, 2014).  
Prophylactic surgery remains an option for women who carry BRCA1 and 
BRCA2 mutations. This is usually done by surgically removing as much “tissue at risk” 
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as possible with the option of bilateral mastectomy (removal of both breasts) (NCI, 
2012). Chemoprevention has been used extensively in delaying the recurrence and 
reducing risk of cancer. Chemoprevention therapy involves the use of drugs, vitamins and 
other agents in cancer treatment (NCI, 2014). Currently, the Food and Drug 
Administration (FDA) has approved two drugs with the aim of reducing the risk of breast 
cancer in women with increased predisposing risk factor, tamoxifen and raloxifen. The 
effect of these drugs in patients with the deleterious BRCA1 and BRCA2 mutations has 
not been well elucidated (NCI, 2014) and it remains unclear whether they could reduce 
the incidence of colon or pancreatic cancers among BRCA mutation carriers who have 
been diagnosed with breast cancer. Tamoxifen may have the potential to help in lowering 
the risk of cancer of the breast in BRCA1 and BRCA2 mutation carriers (King et al., 
2001) and has been associated with lowering risk of cancer in the opposite breast among 
women with a diagnosis of breast cancer (Phillips et al., 2013).  
Pancreatic Cancer Detection, Treatment, and Prognosis  
Pancreatic cancer onset is often very subtle. In most cases, it has metastasized 
prior to detection; resulting in poor prognosis (Le et al., 2011). Pancreatic carcinoma of 
the head of the pancreas is mostly characterized with painless obstructive jaundice. 
Patients with this sign may come to medical attention before their tumor grows large 
enough to cause abdominal pain. These patients usually notice a darkening of their urine 
and lightening of their stools before they or their families notice the change in skin 
pigmentation (Dragovich, 2014). Physicians can normally recognize clinical jaundice by 
64 
 
 
 
laboratory assay of total bilirubin, which patients and families may not notice until 
clinical jaundice is apparent.  Urine darkening, stool changes, and pruritus are often 
noticed by patients before clinical jaundice (Dragovich, 2014).  
Surgical therapy has always been the mainstay of the primary mode of treatment 
for pancreatic cancer. It has also been observed that the use of chemotherapy and/or 
radiation therapy plays an important role in an adjuvant or neoadjuvant environment, and 
in the treatment of patients with unresectable disease (Dragovich, 2014). 
There are several innovations for detection and pancreatic cancer treatment. NCI 
(2014) reported on the development of a laparoscopic technique that uses fluorescent 
light to improve pancreatic cancer staging and treatment, the Early Detection Research 
Network (EDRN) to enhance cancer detection and risk assessment, and investigation of 
stem cell biomarkers for early detection of pancreatic cancer. 
Cancer of the pancreas is very aggressive and often associated with poor 
prognosis (Le et al., 2011). The overall average survival time for patients range between 
2 months and 6 months (Dragovich, 2014). The American Cancer Society (American 
Cancer Society, 2014) recently suggested that the relative 1-year survival rate for patients 
with pancreatic cancer is only 24%, and the overall 5-year survival rate is 5%, having 
increased from the 3% rate calculated between 1975 and 1977. Notwithstanding, patients 
with neuroendocrine and cystic neoplasms of the pancreas, such as mucinous 
cystadenocarcinomas or intraductal papillary mucinous neoplasms [IPMN], have 
demonstrated better survival rates than do patients with pancreatic adenocarcinoma. 
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A 5-year survival in pancreatic cancer is no guarantee of cure; patients who 
survive for 5 years after successful surgery may still succumb to death due to recurrent 
disease years after the 5-year survival point. The occasional patient with metastatic 
disease or locally advanced disease who survives beyond 2-3 years may die of 
complications of local spread, such as bleeding esophageal varices (Dragovich, 2014). 
Colon Cancer Detection, Treatment, and Prognosis  
Due to the increased emphasis on screening practices, colon cancer is now often 
detected before it starts to cause symptoms. Currently, it is suggested patients 50 years 
and older undergo a screening test with stool occult blood test and colonoscopy (Le et al., 
2011), or a multimarker test for stool DNA (sDNA) (Mayo, 2014). The tumor may also 
be detected as a lesion seen on barium enema x-ray (Le et al., 2011). In advanced colon 
cancer cases, common clinical presentations include iron-deficiency anemia, rectal 
bleeding, abdominal pain, change in bowel habits, and intestinal obstruction or 
perforation. Right-sided lesions are more likely to bleed and cause diarrhea while left-
sided tumors are usually detected later and may present as bowel obstruction (Dragovich, 
2014).   
There are several treatment options for colon cancer. These include surgery, 
chemotherapy, and biologic agents (Dragovich, 2014). Surgery has been the major option 
for curative modality for localized colon cancer (stage I-III). Surgical resection 
potentially provides the only curative option for patients with limited metastatic disease 
in liver and/or lung (stage IV disease), but the proper use of elective colon resections in 
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non-obstructed patients with stage IV disease is a source of continuing debate 
(Dragovich, 2014). 
In the United States, the approximate 5-year survival rate for colorectal cancer 
patients (all stages included) is 65 % (Dragovich, 2014). Survival is noted to be inversely 
related to stage: approximate 5-year survival rates are 95% for patients with stage I 
disease, 60% for those with stage III disease, and 10% for those with stage IV 
(metastatic) disease (Dragovich, 2014). Chua Saxena, Chu, Zhao, & Morris (2011) in 
their investigation observed that approximately one in every three patients who undergo 
resection for colorectal liver metastases become actual 5-year survivors. Out of those, 
about half get to 10 years and are cured of colorectal liver metastases. Similarly, Fong, 
Fortner, Sun, Brennan, & Blumgart (1999) conducted a multivariate analysis that 
involved 1001 patients who underwent potentially curative resection of liver metastases. 
Fong and colleagues observed five factors as independent predictors of worse outcome. 
These include Size greater than 5 cm, disease-free interval of less than a year, more than 
one tumor Primary lymph node positivity, and Carcinoembryonic antigen (CEA) level 
greater than 200 ng/mL (Fong et al., 1999).  
Endometrial Cancer Detection, Treatment and Prognosis 
Predisposing risk factors for endometrial cancer include age (postmenopausal, 50 
to 70 years), estrogen therapy without progesterone, obesity, family history of uterine, 
colon, or ovarian cancer, difficulty getting pregnant, fewer than five periods in a year 
before starting menopause, and previous treatment of breast cancer with tamoxifen 
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(CDC, 2014). Signs and symptoms of endometrial cancer include abnormal vaginal 
bleeding not related to menstruation (observed in 80% of patients), difficulty or painful 
urination, pain during intercourse and pain in the pelvic area (NCI, 2015). Palpation of 
abdomen and pelvic region may detect endometrial cancer associated mass (Le et al., 
2006). No blood studies can confirm the diagnosis of endometrial carcinoma. Pap test is 
not often useful because endometrial cancer cells start inside the uterus and are not 
usually observed in the results. Confirmatory diagnosis may require that a sample of 
endometrial tissue be removed by endometrial biopsy and dilation curettage and checked 
under a microscope to look for cancer cells. A physical exam and history, transvaginal 
ultrasound exam, and CAT scan are also useful tools for endometrial cancer detection 
(NCI, 2015). 
Endometrial cancer is treatable if detected early before it spreads. Treatment of 
endometrial cancer depends on type and the extent of the spread and may involve surgical 
techniques to remove cancer tissue, lymph node dissection, progesterone therapy and 
radiotherapy. Chemotherapy is often used in treatment of advanced cases. 
Endometrial cancer is curable and usually has good prognosis. The overall 20-
year survival rate for all forms of endometrial carcinoma is about 80%, in comparison to 
62% for clear cell and 53% for papillary carcinomas (Colombo et al., 2013). The chance 
of patient recovery may depend on cancer stage (if located only in the endometrium, 
involves the whole uterus or has metastasized to other body regions), if the cancer cells 
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are affected by progesterone, and the appearance of the cancer cells under a microscope 
(NCI, 2015). 
Cervical Cancer Detection, Treatment and Prognosis 
A common early symptom of cervical cancer is abnormal vaginal bleeding. 
Patients may also have history of metrorrhagia, postcoital spotting, discharge (bloody or 
purulent, odorous, nonpruritic). In some cases, it may be asymptomatic (Le, Bhushan, & 
Skapik, 2006). Most cases are observed in premenopausal and women greater than 40 
years of age. Early stage diagnosis of cervical cancer increases the chance of a better 
prognosis. Detection of treatable pre-cancer in sexually active women can be enhanced 
by regular cervical screening tests, such as Pap smear (Le et al., 2006). Usually during 
each test, some cells are removed from the surface of the neck of the cervix. These cells 
are sent to the laboratory to be examined under a microscope. Normal cells are observed 
in most cells, while abnormal (dyskaryotic) cells are noticed in some cases. The test may 
also be helpful in detecting the human papillomavirus (HPV) which is a type of wart 
virus often implicated in the development of cervical cancer (National Cancer Institute, 
2014). Pelvic examination for lumps or abnormal areas during exam of the vagina, 
cervix, uterus, fallopian tubes, ovaries, and rectum is often used (NCI, 2014). 
Treatment options are often based on the stage of the cancer, type of cervical 
cancer, desire to have children, and age (NCI, 2014). Early treatment stage may involve 
chemo-radiation, radical hysterectomy, and lymphadenectomy. Advanced treatments of 
cervical cancer include irradiation and chemotherapy (Le et al., 2006). 
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Cervical cancer can be cured if detected early and the prognosis is best in patients 
who are diagnosed when cervical cancer is confined to the neck of the cervix and has not 
spread. According to the 1988 Bethesda System for reporting cervical/vaginal cytological 
diagnoses (1989), the prognosis for patients with cervical cancer is markedly affected by 
the extent of disease at the time of diagnosis. Greater than 90% of cervical cancer cases 
can be detected early through the use of the Pap test and HPV testing. Pap and HPV 
testing are not performed on approximately 33% of eligible women, which results in a 
higher-than-expected death rate. 
Grading and Staging 
According to Mitchell et al. (2012), the grade and stage of malignant neoplasms 
provide a semi-quantitative estimate of the clinical gravity of a tumor: Grading is based 
on the degree of differentiation and the number of mitoses within the tumor. Cancers are 
classified as grades I to IV with increasing anaplasia. In general, higher-grade tumors are 
more aggressive than lower grade tumors. Grading is assumed imperfect because 
different parts of the same tumor may display different degrees of differentiation and the 
grade of the tumor may change as the tumor grows (Mitchell et al., 2012). 
Staging is founded on the anatomic extent of the tumor. Relevant to staging are 
the size of the primary tumor and the extent of local and distant spread. Two methods of 
staging are currently in use: The TNM (tumor, node, metastases) and the AJC (American 
Joint Committee) systems. Both systems assign to a higher stage those tumors that are 
larger, locally invasive, and metastatic (Mitchell et al., 2012). Histologic grading and 
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clinical staging are valuable for prognostication and for planning therapy, although 
staging has proved to be of greater clinical value (Le et al., 2011). This underscores the 
need for further study on the various risk factors that could play significant role in 
diagnosis and prognosis of various cancers that may have the potential to be malignant. 
Therefore, my study will examine the time to diagnosis of second primary pancreatic, 
colorectal, endometrial, and cervical and cancer among women with breast cancer as well 
as associations with patient age, gender, race, and ethnicity. The following section 
explores other relevant studies that have used similar methodologies and provides support 
for my chosen methodology.  
Studies Using BCFR 
The BCFR database is recognized as a standard data set for conducting quality 
research. Quality assurance remains one of the top priorities of all the six participating 
sites (BCFR, 2013). Since the inception of BCFR in 1996, several studies have been 
conducted with the data sets collected from different BCFR database sites across the 
United States (Gaudet et al., 2010), Canada and Australia (Dite et al., 2010). These 
studies included both population-based genetic investigations using focus groups and 
telephone interviews to ascertain knowledge levels about screening options (Lewis, Frost, 
& Venne, 2009) as well as clinic-based studies (Mclure et al., 2010). The following 
sections describe the most relevant studies that have used this data set and how the 
proposed study will add to this knowledge.  
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Dite et al. (2010) carried out a cohort study with BCFR data set that involved 
2,208 parents and siblings of 504 unselected population-based Caucasian women with 
breast cancer who were diagnosed before 35 years of age. The women were from 
Australia, Canada, and United States, carrying mutations in BRCA1, BRCA2, or both 
genes. Dite and colleagues employed cancer-specific standardized incidence ratios (SIRs) 
which were estimated by comparing the number of affected relatives (50% verified 
overall) with that expected based on incidences specific for country, sex, age and year of 
birth (Dite et al., 2010). The investigators found that first-degree relatives of women that 
had very early-onset breast cancer were at increased risk of other cancers, such as lung, 
ovarian, urinary and prostate cancer. The observed increased risks were mostly evident in 
younger women and women with at least one affected relative with early age diagnosis 
(Dite et al., 2010). There are several limitations to this study. Dite and colleagues only 
studied women from one ethnic group (Caucasian). They also did not explore other 
cancers such as pancreatic and colorectal that have been found in other studies to have 
association with BRCA1 and BRCA2 (Mocci et al., 2013; Brose et al., 2002). The study 
was not designed to study time to diagnosis of second cancers. My study will go beyond 
this study to examine ethnicity, gender, and age, and time to diagnosis of pancreatic 
and/or colon cancer among women with breast cancer.    
Several other epidemiologic investigations on breast, pancreatic, and colon 
cancers have been done using BCFR data (Mocci, et al., 2013; Kadouri et al., 2009; Niell 
et al., 2004). Mocci et al. (2013) analyzed high-risk breast cancer families from six BCFR 
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sites in the United States, Canada, and Australia for the risk of pancreatic cancer in 
families with germline BRCA1 or BRCA2 mutation related breast cancer. They used 
one-way ANOVA to determine the age mean difference in individuals diagnosed with 
pancreatic cancer. They also employed the survival analysis technique to ascertain the 
time in years from birth to diagnosis of pancreatic cancer, death, or last contact (Mocci et 
al., 2013). Mocci et al. found germ-line BRCA1 carriers were at increased risk of 
pancreatic cancer. However, the study was not designed to look at second cancers in 
breast cancer patients and was limited to BRCA1 carriers and associated risk of 
pancreatic cancer in breast cancer families. My study will go further to use Cox 
Proportional Hazards to model the relationships between the independent and dependent 
variables among three cohorts and survival analysis will ascertain the probability of the 
incidence proportion. 
My study will use BCFR data to explore age at diagnosis with breast cancer, 
ethnicity, and gender and the relationship with time to diagnosis of a second pancreatic 
colorectal, endometrial and cervical cancer. To date, no other study has been published 
that has used BCFR data to specifically determine all of these variables. The literature 
reviewed for this chapter supports the use of the BCFR data set and Cox Proportional 
Hazard to model the relationships between the independent and dependent variable 
among three cohorts and survival analysis to ascertain the probability of the incidence 
proportion (Mocci et al., 2013). There are other genes besides BRCA that increase the 
risk of colon cancer in susceptible individuals (Meijer-Heijboer et al., 2003) which are 
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outside the scope of this study. Any limitations to interpretations resulting from this 
scope will be discussed further in Chapter 5.   
Summary 
BRCA1 and BRCA2 related breast cancer is a genetic disorder in which the 
control of cell proliferation is lost (Nussbaum et al., 2007). The fundamental mechanism 
pertaining to all cancers is a genetic mutation, either in the germline or more frequently, 
in the somatic cells (Nussbaum et al., 2007). There is much yet to be learned about the 
genetic process of the origin of cancer and the factors that may trigger a malignancy. This 
chapter reviewed the current state of knowledge for the variables that will be used in the 
proposed study, including age, ethnicity, gender as risk factors for second cancers among 
a BRCA-related breast cancer population.  
Age is a risk factor for both primary breast cancer (Mitchell et al., 2012) and 
second primary cancers (Lee et al., 2008). Several studies reported that women with 
BRCA1 and BRCA2 germ-line mutations were at a higher risk for being diagnosed with 
second cancer before 50 years of age (Mocci et al., 2013: Brose et al., 2002). Mocci et al. 
(2013) found that the women diagnosed with a BRCA mutation related breast cancer 
before 50 years of age were at increased risk of pancreatic cancer. Brose et al. (2002) 
observed that by 70 years of age, the risk among BRCA1 carriers of being diagnosed with 
ovarian cancer was 40.7%.    
Data on ethnicity as a risk factor for BRCA gene mutations and second primary 
cancers were documented for several ethnic groups, including Ashkenazi Jews (Niell et 
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al., 2004), United States Caucasians (Mocci et al., 2013), Australians and Canadians 
(Dite et al., 2010). Taiwanese (Lee et al., 2008), and Europeans (Thompson & Easton, 
2002). Niell et al. (2004) found Ashkenazi ethnicity may be protective against risk of 
developing colorectal cancer after diagnosis with a BRCA gene mutation, suggesting the 
type of mutation is relevant. However, Mocci et al. (2013) observed families of 
Caucasian breast cancer BRCA1 gene mutation carriers were at increased risk of 
pancreatic cancer. Dite and colleagues also noted that first-degree relatives of Australian 
and Canadian women that had very early-onset breast cancer were at increased risk of 
other cancers, such as lung, ovarian, urinary and prostate cancer (Dite et al., 2010). Lee et 
al. (2010) found the peak incidence for age at diagnosis of second cancer among 
Taiwanese women was in their 40s, with poor prognosis after the second cancer diagnosis 
(Lee et al., 2008). Thompson and Easton found that BRCA1 gene mutations conferred 
small but increased risks of other abdominal cancers in European women and increased 
risks of pancreatic cancer in men and women (Thompson & Easton, 2002).  There is a 
need for additional studies in various ethnic and racial groups, as varying founder 
mutations may confer different risks.  
Gender as a risk factor has been well studied in both primary breast cancer 
(Mitchell et al., 2012) and second primary cancer (Phelan et al., 2014; Lee et al., 2008; 
Hemminki et al., 2005). There are some data suggesting that women may have a greater 
life time risk of cancer with BRCA1 gene mutations, while BRCA2 gene mutations 
conveys greater risk for men (Liede, Karla, & Narod, 2004). Liede et al. (2004) found the 
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relative risk to male BRCA2 gene mutation carriers was highest before 65 years of age, 
mostly attributable to breast, prostate, and pancreatic cancers. The increased risks for 
pancreatic or colon cancer in patients with BRCA1 or BRCA2 gene mutations have been 
observed in both female (Kadouri et al., 2007) and male (Hemminki et al., 2005) 
subjects, while BRCA1 conveys a higher risk of ovarian cancer in women (Le et al; 
2011). More data is needed on the interplay between gender and other study variables 
with time to event of second primary, pancreatic and colon cancers.  
The option of early detection of breast cancer provides the likelihood of a better 
prognosis during treatment. Women who carry the deleterious BRCA1 or BRCA2 gene 
mutations are encouraged to undergo clinical breast examination and a mammogram 
every year beginning at age 25 to 35 years (Burke et al., 1997). The prognosis of second 
primary cancers, such as pancreatic, colorectal, endometrial, and cervical cancers may 
vary depending on age of diagnosis, ethnicity and gender. Pancreatic cancer onset is often 
very subtle. In most cases, it has metastasized prior to detection; resulting in poor 
prognosis (Le et al., 2011). The overall average survival time for patients range between 
2 months and 6 months (Dragovich, 2014). In the United States, the approximate 5-year 
survival rate for colorectal cancer patients (all stages included) is 65 % (Dragovich, 
2014). Survival is noted to be inversely related to stage: approximate 5-year survival rates 
are 95% for patients with stage I disease, 60% for those with stage III disease, and 10% 
for those with stage IV (metastatic) disease (Dragovich, 2014). Predictive markers have 
been useful in treatment options (Singletary et al., 2004). The association between 
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germline mutations in BRCA genes and the risk of endometrial cancer remains unclear, 
but several case reports of endometrial carcinoma in women with a BRCA gene mutation 
exist (Oh et al., 2015; Levine et al., 2001). Age-adjusted data based on 2008-2012 cases 
and deaths, there were 25.1 per 100,000 new cases of endometrial cancer in the United 
States per year; while the number of deaths was 4.4 per 100,000 women per year. 2012 
prevalence data from SEER (2015) estimated that 621,612 women were living with 
endometrial cancer in the United States. Since, 1999 to 2013, cervical cancer death rates 
have decreased 31% for Hispanic females, 26% for non-Hispanic Black females, and 
16% for non-Hispanic White females. However, this disease remains a serious public 
health threat, and one that demonstrates racial disparities 
Due to the cancer risks associated with BRCA gene mutations, and the poorer 
prognosis for individuals with second cancers, particularly for pancreatic,  colorectal, 
endometrial, cervical, kidney, thyroid, and bladder cancer, understanding the risk factors 
associated with time to diagnosis of second cancers after breast cancer in this population 
is crucial. The results of this study will aid clinicians in determining appropriate 
screening and timely treatment and interventions to reduce mortality and improve health 
outcomes.  
Chapter 3 discussed the research design and rationale, population, sampling and 
sampling procedures, and a power analysis and sample size estimate. Instrumentation and 
materials, data collection and analysis, and examined the independent variables, 
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dependent variables, as well as study questions were also included. Quality assurance and 
protection of human subjects concludes the chapter. 
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Chapter 3: Research Method 
The purpose of this study was to test the relationship of gender, ethnicity, and age 
of diagnosis of breast cancer to time to diagnosis for two second primary cancers, 
pancreatic and colon cancer. Specifically, I investigated these associations within the 
framework of time-to-event analysis. In this chapter, I present the research design and 
rationale in which I discuss the study research questions and examine study research 
designs in relationship to the research questions. I also address constraints related to 
research choice and consistency of research choice with the state of knowledge in the 
field. In the study population section, I describe the population under study and target 
population size estimates. I also include information on the sample and sampling 
procedures that I applied to this study. This study was a secondary data analysis, and no 
treatment of any kind was used during this study. In the instrumentation section, I detail 
the data collection methods, and I discuss the reliability, validity, and the type of data that 
were assessed using the BCFR data set. In the data analysis section, I explain the use of 
SPSS software and statistical tests such as the CPH and logistic regression for analysis of 
both the independent and dependent study variables. The last session includes the 
protection of study participants and information regarding how BCFR sites ensured that 
all study subjects’ data are kept confidential and the role of Walden University IRB to 
ensure that ethical standards are not violated. 
Research Design and Rationale 
The research questions for this study were as follows:  
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RQ1: Is there a relationship between BRCA mutation status and time to diagnosis 
of second primary cancers, pancreatic, colorectal, endometrial, or cervical, among 
women with breast cancer? 
RQ2: Is there a relationship between ethnicity and age status and time to 
diagnosis of second primary cancers, pancreatic, colorectal, endometrial, or cervical, 
among women with BRCA-related breast cancer? 
RQ2a: Is there a relationship between ethnicity and time to diagnosis of second 
primary cancers, pancreatic, colorectal, endometrial, or cervical, among women with 
BRCA-related breast cancer? 
RQ2b: Is there a relationship between age status and time to diagnosis of second 
primary cancers, pancreatic, colorectal, endometrial, or cervical, among women with 
BRCA-related breast cancer? 
RQ3: Is there a relationship between gender and time to diagnosis of second 
primary cancers, pancreatic, colorectal, endometrial, or cervical, among men and women 
diagnosed with BRCA-related breast cancer? 
H0: There is no relationship between gender and time to diagnosis of second 
primary cancers, pancreatic, colorectal, endometrial, or cervical, among men and women 
diagnosed with BRCA-related breast cancer. 
Ha: There is a relationship between gender and time to diagnosis of second 
cancers, pancreatic, colorectal, endometrial, or cervical, among men and women 
diagnosed with BRCA-related breast cancer. 
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The study was a quantitative cohort design using secondary data. I used three 
cohorts to answer the research questions. These are presented in Table 1. 
Table 1  
Research Questions, Independent Variables, and Cohort 
Research Question Independent Variable Cohort 
RQ 1  
 
BRCA mutation status 
among women with 
breast cancer 
Women with a diagnosis of 
Breast Cancer with and 
without BRCA gene 
mutations 
RQ 2 Ethnicity and Age Women with BRCA related 
Breast Cancer 
RQ 3 Gender Men and Women with 
BRCA related Breast 
Cancer 
Note. In each case, the dependent variable is the diagnosis of second primary cancer, 
pancreatic, colorectal, endometrial, and cervical cancer 
 
The first cohort consisted of women with a diagnosis of breast cancer, with and 
without BRCA gene mutations. In this cohort, I compared time to diagnosis of second 
cancers of the, colon/rectum, endometrium, cervix, kidney, thyroid, and bladder. The 
second cohort contained only women with a diagnosis of BRCA-related breast cancer. I 
analyzed the relationship of the risk factors of ethnicity and age at initial diagnosis of 
breast cancer as the independent variables, to time to diagnosis of second colorectal, 
endometrial, cervical, kidney, thyroid, or bladder cancers as the dependent variables. The 
third cohort included men and women with a diagnosis of BRCA-related breast cancer, 
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with gender as the independent variable. In the third cohort, I planned initially to compare 
time to diagnosis of second cancers of the colorectal, endometrial, cervical, kidney, 
thyroid, and bladder for women.  
As a result of inclusion of endometrial, cervical, kidney, thyroid, and bladder 
cancer with the intention of increasing the study power, the composite endpoint-based 
analysis was employed. This was done using the CPH model. The hazard ratio generated 
was measured in the association in this case. The known BRCA mutation status of all 
breast cancer cases served as a strata variable. Event was defined = 1 if there was 
pancreatic or colorectal or endometrial, or cervical cancer after diagnosis with breast 
cancer; else event = 0. A composite endpoint (outcome) consists of two or more 
component outcomes (in the above case, pancreatic, colorectal, endometrial and cervical 
cancer). Patients who have experienced any one of the events specified by the 
components are considered to have experienced the composite outcome (Ferreira-
Gonzalez et al., 2007). The benefits of the application of a composite endpoint are that it 
increases statistical efficiency and power due to higher event rates, which reduces sample 
size need; it helps researchers avoid an arbitrary choice between several important 
outcomes that refer to the same disease process; and it is a means of evaluating the 
effectiveness of a patient-reported outcome that addresses more than one aspect of the 
patient’s health status (Ferreira-Gonzalez et al., 2007; Ross, 2007). 
I anticipated no time or resource constraints for this study design choice. 
However, I did experience some delay in getting approvals processed by the NCI - 
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Columbia University Breast Cancer Family Registry (BCFR) Data Center. The study was 
a quantitative cohort design that used a secondary dataset collected over many years by 
various BCFR sites. These data are free and easily accessible to researchers in 
collaboration with the BCFR. After I submitted a collaboration agreement application 
form, the application was assessed, and the research was approved. A BCFR liaison 
contact (a preceptor and expert in the area of interest) was assigned to work with me 
during the data collection and analysis phases of the study. It takes approximately 1 
month to receive a BCFR approval, from the time of application to the assigning of a 
BCFR liaison contact (BCFR, 2013). 
I chose a quantitative cohort study design due to its use in similar studies (Houser, 
2012). The quantitative cohort study design is useful in determining relationships 
between a risk and an outcome, with causality inferred based on varying criteria. The 
relationship between breast cancer risk factors and disease cannot be tested with a true 
experimental design because it is not ethical to expose individuals to risk factors they 
would otherwise not experience. These variables must be studied as they naturally occur. 
This quantitative study design does not allow me to control many extraneous, modifiable 
variables; this was a limitation to this study 
Study Population 
I used secondary data from the BCFR. The BCFR contains data on the general 
population as well as clinic-based data. The BCFR collects health data and biospecimens 
from families across a wide spectrum of breast cancer risk. The six BCFR sites have 
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recruited breast cancer families through population-based cancer registries, clinical 
settings, and community outreach from four areas of the United States: (a) the Greater 
San Francisco Bay area, California; (b) New York City, New York; (c) Philadelphia, 
Pennsylvania; (d) Salt Lake City, Utah; (e) the Province of Ontario, Canada; and (f) the 
metropolitan areas of Melbourne and Sydney, Australia (BCFR, 2013). The BCFR 
reported recruiting a total of 55,595 individuals for population-based families from 1996-
2013, while for the clinic-based families, a total of 14,010 individuals were recruited 
(BCFR, 2013).  
The study population I extracted from the dataset included female patients 
diagnosed with breast cancer from 1997-2014. The dataset included information on 
BRCA1 or BRCA2 mutations, ethnicity, gender, and age status, and any diagnosis of 
pancreatic, colorectal, endometria, and cervical cancer after an initial diagnosis of breast 
cancer with and without the BRCA1 or BRCA2 mutations. Therefore, this dataset 
contained the information needed to answer the research questions.   
Sampling Procedures 
The minimum number within an event was ascertained using a nested case-
control approach to assure enough cases as demonstrated below. This nested case-control 
approach was based on a sampling technique known as incidence density sampling 
(Checkoway, Pearce, & Crawford-Brown, 1989) or risk sampling (Breslow & Day, 
1987). Cases were compared with a subset (a sample) of the “risk set,” that is, the cohort 
members who are at risk who could become a case at the time when each case occurs. By 
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using this strategy, cases occurring later during the follow-up are eligible to be controls 
for earlier cases (Szklo & Nieto, 2014). For this study, all cases were drawn from the 
same cohort, and then the correct number of subjects with second primary cancers was 
selected and then matched with those without second primary cancers. In RQ1, cases 
must have had one of the BRCA mutations. For RQ2 with women and RQ3 with women 
and men, I confirmed that the participating subjects have a BRCA1 or BRCA2 mutation.  
The sample consisted of female study participants diagnosed with breast cancer 
based on certain inclusion criteria. For all research questions, subjects must have been 
diagnosed with a breast cancer-related second primary cancer, pancreatic, colorectal, 
endometrium, or cervical during the period from 1997 to 2014. In Table 2, I presented 
additional criteria stratified by the research questions. 
Table 2 
Study Sample Inclusion Criteria Stratified by Research Question  
Research Question Inclusion Criteria 
RQ 1 Females, with and without BRCA 
mutations  
RQ 2 Females, with BRCA mutations, with data 
on age at diagnosis of breast cancer and 
ethnicity  
RQ 3 Males and Females, BRCA mutations  
 
Sample Size and Power  
The sample sizes for the secondary analyses of BRCA1- and BRCA2-related 
breast cancer and second primary cancers (pancreatic, colorectal, endometrial, and 
cervical cancer) were restricted by the size of the BCFR data set; BCFR included only 
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those with current consent during the follow-up period. For both the population-based 
families and clinic-based families, the total affected population (exposed males (57) and 
females (4,136) was 4,193. For the unaffected population, there was a total population of 
36,410 (males (13, 343) and females (23, 067) for both the population-based families and 
clinic-based families (BCFR, 2013). 
The OpenEpi Version 3 and XLSTAT software were used to calculate the study 
statistical power a priori as shown in Table 1. Statistical power of a test may be referred 
to as the ability of the test to generate an effect or the likelihood that the test will not 
accept the null hypothesis (no effect; Park, 2008). Houser (2012) noted that in 
quantitative studies, the standard for determining sample size adequacy is power. 
Adequate power signifies that there are sufficient study participants to observe a 
difference in the outcome variable if one exists. Therefore, the calculation of power is a 
mathematical process and may be calculated prospectively (to determine how many study 
participants are needed) or retrospectively (to ascertain how much power a sample 
possessed; Houser, 2012). In Table 3, I present the null and alternate hypotheses 
associated with each research question. 
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Table 3 
Null and Alternative Hypotheses per Research Question 
Research 
Question 
Null Hypothesis Alternative Hypothesis 
RQ 1 There is no relationship 
between BRCA mutation status 
and time to diagnosis of 
second primary cancers, 
pancreatic, colorectal, 
endometrial, or cervical, 
among women with breast 
cancer. 
There is a relationship between BRCA 
mutation status and time to diagnosis 
of second primary cancers, pancreatic, 
colorectal, endometrial, or cervical, 
among women with breast cancer. 
RQ 2 There is no relationship 
between ethnicity and age 
status and time to diagnosis of 
second primary cancers, 
pancreatic, colorectal, 
endometrial, or cervical, 
among women with BRCA 
related breast cancer. 
There is a relationship between 
ethnicity and age status and time to 
diagnosis of second primary cancers, 
pancreatic, colorectal, endometrial, or 
cervical, among women with BRCA 
related breast cancer. 
RQ 3 There is no relationship 
between gender and time to 
diagnosis of second primary 
cancers, pancreatic, colorectal, 
endometrial, or cervical, 
among men and women 
diagnosed with BRCA related 
breast cancer. 
 
There is a relationship between gender 
and time to diagnosis of second 
primary cancers, pancreatic, 
colorectal, endometrial, or cervical, 
among men and women diagnosed 
with BRCA related breast cancer. 
 
I used CPH for the statistical analyses of time to event given the nested case-
control study design. While the effect size is unknown, I estimated it based on previous 
studies. Also unknown was the time to diagnosis or event. Upon receipt of permission to 
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access the BCFR data set, I used SPSS version 21 and conducted a posthoc evaluation of 
the power of the study to identify significant associations should they exist.  
I performed an a priori power analysis using the estimated sample size and the 
proposed analysis using CPH. The minimum number within an event was ascertained 
using a nested case-control approach to assure enough cases as demonstrated below. This 
nested case-control approach was based on a sampling technique known as incidence 
density sampling (Checkoway et al., 1989) or risk sampling (Breslow & Day, 1987). 
Cases are compared with a subset (a sample) of the risk set; therefore, the cohort 
members who remain at risk at the time when each case occurs can serve as a control 
(Szklo & Nieto, 2014). For this study, all cases were drawn from the same cohort; 
subjects with second cancers and subjects not yet been diagnosed with a second cancer 
were included. For the RQ1 with only females and in the RQ3 with women with BRCA, I 
confirmed that the participating subjects have a BRCA1 or BRCA2 mutation. Therefore, 
I estimated a total sample size of 335 after adjusting for the minimum number of subjects 
with an event. The OpenEpi Version 3 software was used for sample size analysis, and it 
was confirmed using the XLSTAT software.  
The odds ratio from the number of subjects with an event using the nested case-
control approach was 0.026. I used this information to establish the power (1- β) expected 
with an α (Type 1 error) of 0.05, and an expected minimum sample size of 335. The 
OpenEpi (2010) “power for cohort studies” calculator provided the adjusted power 
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presented in Table 4. The XLSTAT calculations of power for the CPH model are 
presented in Table 5 and Figure 1. 
Table 4 
Minimum Sample Sizes to Achieve 80% Power 
Parameters Inputs and Results 
Two-sided significance level (1- α) 95 
Ratio of sample size, 
Unexposed/Exposed 
1:1 
Percent of Unexposed with 
Outcome 
5 
Percent of Exposed with Outcome: 0.14 
Odds Ratio .026 
Risk/Prevalence Ratio .03 
Risk/Prevalence difference -4.9 
 Kelsey Fleiss Fleiss with CC* 
Sample Size, exposed** 167 165 205 
Sample Size, non-exposed** 167 165 205 
Total sample size** 334 330 410 
Adapted from “Observational Epidemiology (2nd ed) by Kelsey, J. L; Whittemore, A. S; 
Evans, A. S; & Thompson, W. D. 1996. Oxford University Press. Table 15:12. 
Fleiss, Statistical Methods for Rates and Proportions, formulas 3.18 &3.19 
*CC = continuity correction.  
**Sample sizes are rounded to the nearest integer. 
 
Table 5 
Power for CPH using XLSTAT 
Parameters Inputs and Results 
Event rate (P): 0.026 
B(Log(Hazard ratio)): 1 
Std dev of X1: 1 
R² of X1 with other X's: 0.1 
Power 0.8 
Alpha 0.05 
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Sample size 335 
 
 
Figure 1. Sample size/power simulation plot I stopped reviewing here due to time 
constraints.  
Instrumentation and Materials 
This study used archival data from the NCI- BCFR. BCFR was established in 
1995 as pan international research infrastructure for interdisciplinary and translational 
studies of the genetic epidemiology of breast cancer (John et al., 2004). It is the 
fundamental objective of BCRF to: “address unanswered research questions regarding the 
etiology of breast cancer and to expedite the translation of research results to affected and 
at-risk populations” (John et al., 2004, p.75). The BCFR contains epidemiologic risk 
factors, clinical, and follow-up data; population-based and clinic-based ascertainment; a 
combined informatics center; systematic collection of validated family history; and 
ongoing molecular characterization of the participating families (BCFR, 2013).  
 
300
350
400
450
500
550
600
0.78 0.83 0.88 0.93
Sa
m
p
le
 s
iz
e
Power
Simulation plot
90 
 
 
 
Reliability of Data 
Quantitative researchers are concerned with reliability and validity to allow them 
to generalize their findings to other populations. (Houser, 2012). BCFR assures the 
reliability of data collected in six sites by providing detailed description of research 
methods, researcher journal, peer examination of procedures and results, and measures of 
instrument reliability (accuracy and consistency  of test instrument and results) (BCFR, 
2013). BCFR also uses triangulation, by cross-checking information and conclusions, 
multiple data sources, and the multiple research methods used by researchers to study the 
phenomenon in order to ensure the reliability of data collected from study participants 
(BCFR, 2012).  
Validity of Data 
Validity helps researchers to ensure that the study measures that which it was 
intended to measure, or the truthfulness of the result generated (Golafshani, 2003). BCFR 
has in place several methods of ensuring the validity of data collected from study 
participants in all six locations across United States, Canada, and Australia. In order to 
ascertain internal validity, the BCFR employs prolonged engagement (investment of 
sufficient time in the data collection process to allow the researcher an in-depth 
understanding of the population under study) (BCFR, 2012), member checking (a method 
of ensuring validity by having participants review and comment on the accuracy of 
transcripts, interpretations or conclusions) and triangulation (BCFR, 2013). External 
validity is sustained by application of inclusion/exclusion criteria and the description of 
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the setting (BCFR, 2013). All study subjects with complete data will be included, while 
those with incomplete data will be excluded. Criterion-related predictive validity and 
content validity have also been used as a test to ascertain the validity in BCFR population 
and clinical studies (BCFR, 2012). The BCFR procedures used in collecting data is 
presented in Table 6. 
Table 6 
BCFR Procedures used to collect Data  
Populations Procedure 
Individuals and Families with Breast 
Cancer Risk 
Recruited from a wide spectrum of breast 
cancer risk 
Early-onset Breast Cancer Families with a history of early-onset 
breast cancer 
Racial and Ethnic Minority Families Inclusion of all racial and ethnic groups 
not replicated elsewhere 
  
All included participants were screened based on extensive molecular 
characterizations active follow-up of both probands and family members. Thus, the 
BCFR comprises a unique cohort of probands and family members at familial/genetic 
risk of breast cancer that will continue to facilitate a wide range of research studies, such 
as gene discovery, examination of cancer-related outcomes and risk factors in high-risk 
subjects, investigation of novel behavioral interventions, and cancer prevention trials 
among at-risk family members. (BCFR, 2013).  
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Data Collection 
I conducted this study using data obtained from the National Cancer Institute- 
Breast Cancer Family Registry (NCI-BCFR) for the years 1997-2014.  Data abstraction 
began after formal approvals from the NCI-BCFR and Walden Institutional Review 
Boards. The BCFR is a cohort study of families who are at elevated risk of breast and 
ovarian cancer based on family history or genetic mutations and it contains epidemiologic 
data on risk factors, clinical and nonclinical variables over time, and family history of 
participants. It consists of a unique cohort of probands and family members at increased 
risk of breast cancer. The BCFR population included six participating sites located in the 
United States, Canada and Australia (John et al.; 2004). United States residing 
population-based participants were recruited from the Greater San Francisco Bay area, 
California, United States, by the Northern California Cancer Center. Additionally, 
population-based families were recruited from the province of Ontario, Canada, by 
Cancer Care Ontario, and from Melbourne and Sydney, Australia, by the University of 
Melbourne and the New South Wales Cancer Council. The data used in this study 
consists of 7,302 breast cancer cases extracted from the six BCFR sites. 
Three additional cancer sites were identified and added as mentioned above in 
order to increase the study power. These included kidney, thyroid, and bladder. Several 
researchers have investigated the relationship between breast cancer diagnosis and 
diagnosis of kidney cancer (Dite et al., 2003), thyroid cancer (Dite et al, 2003), and 
bladder cancer (Neveling et al., 2007; Dite et al., 2010; Dite et al., 2003; Johannesdottir 
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et al., 1996). BRCA mutations in women diagnosed with breast cancer have also been 
associated with diagnosis of kidney, thyroid, and bladder cancer (Johanannesdottir et al., 
1996). 
The study participants were recruited from the six BCFR sites located in the 
United States, Canada, and Australia (John et al., 2004). United States residing 
population-based participants were recruited from the Greater San Francisco Bay area, 
California, United States, by the Northern California Cancer Center. Additionally, 
population-based families were recruited from the province of Ontario, Canada, by 
Cancer Care Ontario, and from Melbourne and Sydney, Australia, by the University of 
Melbourne and the New South Wales Cancer Council.  
Clinic-based families were recruited by Columbia University in New York City,  
the Fox Chase Cancer Center in Philadelphia,  and Huntsman Cancer Institute at the 
University of Utah in Salt Lake City. Clinic based participants in Australia were recruited 
by the University of Melbourne and New South Wales Cancer Council in Melbourne and 
Sydney. In Ontario, Canada, recruitment of clinic-based families was limited to those of 
Ashkenazi Jewish ancestry. 
The BCFR data dictionary provided the listing of the various variables in the data 
set and the explanation of the codes used for case definitions. The study variables 
available in the BCFR data set were confirmed with their corresponding case definitions 
in the data dictionary. The BCFR data dictionary consists of over 18 case definitions. 
These include, AUSTRALIAN DIETARY QUESTIONS, BREAST CANCER 
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CONFIRMATION, BREAST EPIDEMIOLOGY, BREAST EPIDEMIOLOGY 
PROCEDURE, BREAST EPIDEMIOLOGY STATUS, BREAST INVASIVE, BREAST 
MUTATION, BREAST NON-MUTATION, BREAST RX, BREAST SURGERY, 
CANCER (second cancers), FAMILY PRIMARY, FAMILY MEMBERSHIP, 
HAWAIIAN DIETARY QUESTION, INDIVIDUAL, NUTRIENT, OVARIAN 
CONFIRMATION, OVARIAN PATHOLOGY, and PREGNANCY. The data set 
selection tab was used to select the cases of interest for this study, which included 
females diagnosed with breast cancer, BRCA1, or/and BRCA2 mutations, and second 
primary cancers between 1997 and 2014, from the six BCFR sites. This initial selection 
resulted in 7,302 cases from the data set, which were later merged. Output data files and 
logs were saved on the home computer.  
After the initial selection of cases and merging of data, subjects and records that 
did not have breast cancer dates were excluded from the list. Second primary cancer 
cases were identified using the International Classification of Diseases (ICD) for 
Oncology 2nd edition and filtered for second primary case studies. Subjects who had a 
second primary cancer after initial diagnosis with breast cancer were considered; 
whereas, subjects who had second primary cancer diagnosis before diagnosis with breast 
cancer were excluded. The above inclusion and exclusion criteria resulted in 702 eligible 
cases for this study. The close date was defined by the event date for subjects who had a 
second primary cancer. But for the censored events, the close date was arbitrarily taken to 
be one week after the latest event date in the data set for second primary cancer event 
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date. The DateDIF function in Microsoft Excel was used to compute the follow up date 
and event =1 if the subject had second primary cancer after diagnosis with breast cancer 
and event = 0 otherwise.  
Age at diagnosis of breast cancer (AGEDX) was converted from continuous to 
ordinal variable (Age groups): Less than 46 years = 1,  47-56 = 2, and 57 and older = 3 
The rationale was to ascertain the relationship of developing second primary cancers, 
colorectal, endometrial, cervical, renal, thyroid, or bladder, among women with breast 
cancer, at different range of age at diagnosis. Breast cancer variable (not mutated) was 
selected from the data set under Breast RX. It has 4 variants, 0, 1, 2, and 3. Variant 0 
stands for the breast cancer not confirmed, but relies on family history provided by 
relative, variant 1 stands for breast cancer confirmation from death certificate noting 
cancer of specific site, variant 2 stands for breast cancer confirmation from medical 
records indicating treatment for cancer of specific site, variant 3 stands for breast cancer 
confirmation from pathology report indicating tumor site and histology, and variant 4 
stands for breast cancer confirmation from histology. Only variants 1 and 2 associated 
with subjects in the selected case definition for breast cancer diagnosis (Breast_ RX) 
were used in this study for analyses. BRCA1_PERSON_STATUS and 
BRCA2_PERSON_STATUS for mutations were coded with 1 for positive diagnosis and 
0 for negative diagnosis and used for BRCA1 and BRCA2 variables related analyses. A 
categorical variable, BRCA both 1 and 2 was created and coded to examine subjects with 
both BRCA1 and BRCA2 and subjects without both mutations (0). SITE (second 
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cancers) was selected from the data set under the CANCER case definition. The selected 
study second cancers ICD codes included C18-C20, for colorectal cancer, C53, for 
cervical cancer, C54-C55 for endometrial cancer, C64, for renal (kidney) cancer, C73, for 
cancer of the thyroid gland, and C67, for bladder cancer. 
For the race/ethnicity variable, the BCFR data set has 4 variants: RACE_BR1 
(obtained from epidemiology question and takes precedence if available), RACE_BR2 
(second precedent from other self-reported information), RACE-BR3 (third precedence 
from questionnaire), and RACE_BR4 (fourth precedence from other sources). 
RACE_BR1 from the INDIVIDUAL case definition of the data set was selected based on 
the above criteria. The various ethnicities and races were presented using these codes: 01 
for White, 02 for Black, 03 for American Indian and Hawaiian, and 4 for Asian. Other 
codes such as 10, 99, 70, and 88 were removed due to incomplete or missing data. Three 
covariates were also included for the analyses: SMOKING (smoking status), 
BRCA1_FAMILY HISTORY, and BRCA2_FAMILY HISTORY.  The dichotomous 
smoking status variable was coded with 1 for subjects who indicated smoking at least 1 
cigarette per day for 3 months or longer and 0 was used for subjects who indicated no 
smoking history. The dichotomous BRCA1 and BRCA2 family history status were coded 
with 1 for subjects with positive family history of either BRCA1 or BRCA2 respectively. 
Subjects without family history of BRCA1 or BRCA2 were assigned 0.  
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Data Analysis Plan 
Only secondary data was used for this study. Data from cancer patients are 
confidential, and permission is needed before accessing BCFR data. Access is normally 
limited by the registry’s procedure for research approval and assurance that HIPPA 
standards are met (BCFR, 2013). A collaboration agreement was submitted and approved 
before information was released to me (BCFR, 2013). I received data that was free of 
identifying patient information. The secondary data I proposed to use for this study was 
extracted electronically and analyzed using SPSS (PASW version 21). SPSS was chosen 
because of its ability to handle large data sets and its capacity to provide adequate 
analysis of relevant statistical tests. I cleaned the data after collection of the dataset and 
prior to my proposed analyses. This data cleaning was necessary to address potential 
issues such as unreasonable, miscoded, and missing data (Frankfort-Nachmias & 
Nachmias, 2008). Summary statistics involving frequency and distributions are usually 
reviewed by BCFR principal investigators at each BCFR site. Set upper and lower and 
upper parameters was used to query age as the only interval data.  
I would have queried and brought unreasonable, missing, or miscoded data to the 
attention of the BCFR site manager and informatics staff for appropriate validation. Any 
issue of missing or miscoded data that could not have been settled would have been 
addressed, depending on the research question and relationship with my study. I included 
only study subjects with complete data to provide accurate information (yes or no) for 
those with the dichotomous BRCA variable. All breast cancers was dichotomized to 
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BRCA1 or BRCA2 mutation breast cancers or non-BRCA1 or BRCA2 mutation breast 
cancers.  
Study Variables 
The independent variables that I proposed to use in this study are presented in 
Table 7. 
Table 7 
Study Variables 
Variable Name Research 
Question(s) 
Role Potential 
Responses 
Level of 
Measurement 
Time to Diagnosis of 
Pancreatic,  
colorectal, 
endometrial, and 
cervical cancer 
1, 2, 3 Dependent Time 
expressed in 
Months 
Continuous 
BRCA Status 1 Independent  BRCA1  
BRCA2 
Dichotomous 
   BRCA both 1 
and 2 
 
Ethnicity 
 
2a Independent Asian 
Ashkenazi 
Jews 
Black  
Native- 
American 
White            
Categorical 
Age 2b Independent Age in Years Continuous 
Gender 3 Independent Male             
Female 
Dichotomous 
Family History 1,2,3 Covariate Yes/No 
family 
Dichotomous 
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history of 
BRCA  
Smoking 1,2,3 Covariate Yes/No 
history of 
smoking 
Dichotomous 
     
Data Analysis 
Statistical analyses was carried out using SPSS® 21 statistical software (IBM, 
2012). The description was divided by the primary research questions.  I also used:  
Descriptive statistics. I calculated the descriptive statistics for each of the study 
variables in table 7.  Frequencies were used to describe the dichotomous and categorical 
variables, while mean and standard deviation were used for the continuous variables age 
and time to event. 
Survival Analysis and Cox Proportional-Hazards (CPH). I used survival 
analysis techniques, including CPH, to model relationships between dependent and 
independent variables in the three cohorts. Survival analysis is used to ascertain the 
probability of the event, also known as incidence proportion (Szklo & Nieto, 2014). 
Survival analysis mainly explores the relationship of the survival distribution to 
covariates. The specification of a linear-like model for the log hazard or hazard function 
is often involved in this analysis (Fox, 2002). According to Fox (2002), the hazard 
function [this relation demonstrates h(t)] formula: 
h(t) = lim∆t0  Pr{t ≤ T < t + ∆t ǀ T ≥ t} 
                                 ∆t 
Where t represents the time when observation starts, T shows an outcome event 
occurrence time and t + ∆t represents the observation end time. The implication of the 
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above equation is based on the premise of assumption that the outcome T took place after 
observation time started (ǀ T ≥ t). Survival analysis targets predictions of the 
instantaneous risk that a particular outcome will take place at time t. By the reason of the 
continuous nature of time, the probability (Pr) that an outcome will take place exactly at 
time t is necessarily 0. Thus, survival analysis takes into cognizance the likelihood that an 
event will take place between t and t + ∆t in a short time interval. Therefore, the 
denominator presented as a change in t (∆t) assumes the role of divisor that brings 
together the amount of time within that interval to increase precision. A fundamental 
disadvantage to the above hazard function is that the hazards in both the exposed and the 
reference groups may be approximately constant (Szklo & Nieto, 2014). This is the 
appropriate test because the research questions include time to diagnosis. Logistic 
regression can only examine the relationship of the independent variables to whether 
there was a diagnosis of second cancer, and not to how long after the diagnosis of breast 
cancer that it occurred. CPH provides hazard ratios, which are defined as an estimate of 
the ratio of the hazard rate in patients with BRCA and non-BRCA breast cancer. The 
hazard rate represents the likelihood that if the event in question has not already occurred, 
it is expected to occur in the next time interval, divided by the length of the interval 
(Spruance, Reid, & Samore, 2004).   
Bivariate Tests. The log-rank test was used to identify significant differences in 
the median time to event between BRCA status, ethnicity, family, and smoking histories 
and time to diagnosis of second primary cancers, colorectal, endometrial, cervical, 
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kidney, thyroid, and bladder among women with breast cancer. Spearman correlation was 
used to test the relationship between time to event and age.  
Test of Proportionality. Survival analysis was used to test the assumption of 
proportional risks required to use CPH. I graphed survival times for those with and 
without risks to test proportionality. Risks are not proportionate if the survival times cross 
each other within the period graphed. If this happens, I may need to perform separate 
tests, before and after the cross, to generate valid hazard ratios (Szklo & Nieto, 2014). An 
example of the test of proportionality is presented in Figure 2. 
 
Figure 2. Kaplan-Maier Curves  
Curves used for analysis of the assumption of proportionality in two arms of a 
clinical trials protocol. The green curve shows the hazards or failure in the placebo arm 
and the red curve shows the hazards or failure in the experimental of the above clinical 
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process. Adapted from “Association between Diabetes Incidence and Metabolic 
Syndrome in Western Alaska Native People”, by K. R. Koller (2013), ProQuest, p.132. 
Adapted with permission. 
Time to event. The time to event for all research questions was the time between 
the diagnosis of breast cancer and the diagnosis of either of the following second primary 
cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder. The time was 
expressed using months. Because not only those participants who developed the second 
primary cancers were included in the dataset, there was need for censoring. Entry was 
based on the diagnosis of breast cancer and exit on the diagnosis of second primary 
cancers. For each of the following three research questions, I examined the associations 
between time to event and the independent variables listed in table 7. These associations 
was addressed using the cohorts presented in Table 1. 
Research Question 1 
 Is there a relationship between BRCA mutation status and time to diagnosis of 
second primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, 
among women with breast cancer? The objective was to ascertain the relationship and 
time to event of developing second primary cancers, specified as, colorectal, endometrial,  
cervical, kidney, thyroid, or bladder, among women with BRCA related breast cancer and 
those with non BRCA related breast cancer. Second cancers are cancers that develop after 
initial diagnosis with BRCA1 or BRCA2 related breast cancer. A single hypothesis was 
tested to ascertain this relationship. 
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H0: There is no relationship between BRCA mutation status and time to diagnosis 
of second primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, 
among women with breast cancer. 
Ha: There is a relationship between BRCA mutation status and time to diagnosis 
of second primary cancers, colorectal, endometrial,  cervical, kidney, thyroid, or bladder, 
among women with breast cancer. 
Research Question 2  
Is there a relationship between ethnicity and age status and time to diagnosis of 
second primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, 
among women with BRCA related breast cancer? The objective was to ascertain the 
relationship of developing second primary cancers, colorectal, endometrial, cervical, 
kidney, thyroid, or bladder, among women with BRCA related breast cancer, their 
ethnicity and age at diagnosis. This research question required two hypothesis statements. 
Is there a relationship between ethnicity and time to diagnosis of second primary 
cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, among women 
with BRCA related breast cancer?  
Is there a relationship between age status and time to diagnosis of second primary 
cancers, colorectal, endometrial,  cervical, kidney, thyroid, or bladder, among women 
BRCA related breast cancer?  
One hypothesis was tested to ascertain this relationship: 
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H0: There is no relationship between ethnicity and age status and time to 
diagnosis of second primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or 
bladder, among women with BRCA related breast cancer. 
Ha: There is a relationship between ethnicity and age status and time to diagnosis 
of second primary cancers,  colorectal, endometrial,  cervical, kidney, thyroid, or bladder, 
among women with BRCA related breast cancer. 
Research Question 3 
Is there a relationship between gender and time to diagnosis of second primary 
cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, among men and 
women diagnosed with BRCA related breast cancer? The objective was to ascertain the 
relationship of developing second primary cancer, pancreatic, colorectal, endometrial, or 
cervical, among men and women with BRCA related breast cancer and gender. Because 
of no availability of male gender data in the data set, the relationship between gender and 
time to diagnosis of second primary cancers was not analyzed. A single hypothesis was 
intended to be tested to ascertain this relationship. 
H0: There is no relationship between gender and time to diagnosis of second 
primary cancers, colorectal, endometrial,  cervical, kidney, thyroid, or bladder, among 
men and women diagnosed with BRCA related breast cancer. 
Ha: There is a relationship between gender and time to diagnosis of second 
primary cancers, , colorectal, endometrial, cervical, kidney, thyroid, or bladder, among 
men and women diagnosed with BRCA related breast cancer. 
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Threats to Internal and External Validity 
It is important to balance control of threats to internal validity with the need to 
maximize external validity. Generalization remains a major issue for research that is to be 
used as evidence (Houser, 2012). When a research study becomes too highly controlled, 
its artificial nature limits applicability to real-world populations. The research must 
balance each element that strengthens internal validity with a concern to maintain as 
broad of external validity as possible (Houser, 2012).  
 BCFR database is recognized as a standard for quality research. Quality 
assurance remains the mainstay of all the six participating sites (BCFR, 2013). BCFR 
minimizes threats to internal validity by encouraging studies that create logical and 
evidence-based research, collecting data to support such research, using appropriate 
design, and controlling bias (BCFR, 2013). Threats to external validity are minimized by 
maintaining the generalizability of the findings of their various studies to other 
populations or settings (BCFR, 2013). 
Ethical Considerations 
According to BCFR (2013), each of the six participating research sites has an 
Institutional Review Board (IRB) that reviews the study protocol and questionnaires, 
identifying issues and concerns, and works with the investigators as needed to improve 
the study. The IRB at each site is diverse and includes ethicists, lawyers, physicians, 
scientists, and community members. The researchers and staff who are conducting the 
study are provided with regular monitoring and education to ensure that these 
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requirements are met (BCFR, 2013). BCFR has provided several protections for the 
privacy of study participants and their respective data (BCFR, 2013). When study 
participants data are collected, they are usually assigned a unique identification (ID) 
number. After data collection, the bio-specimen samples, questionnaires, and interview 
data are stored separately from any personal identifiers, such as patient’s name, address, 
and phone number. Personal contact information of the study subjects are kept in separate 
files available only to the research staff at the specific site where they participate. When 
data are used for analytical purpose, the randomly assigned numeric ID is the only 
identifier available to investigators (BCFR, 2013). 
A Certificate of Confidentiality is normally provided to each of the six BCFR 
sites to protect the confidentiality of data against compulsory legal demands (e.g., court 
orders and subpoenas) that may seek the name or other identifying characteristics of a 
research subject. With a Certificate of Confidentiality, researchers cannot be mandated by 
anyone to provide information that could identify the study participants (BCFR, 2013). 
BCRF also requires researchers interested in using its data to submit an application for a 
short-term data agreement/collaboration. This is to ensure quality research procedures are 
followed as well as to maintain confidentiality of study data. Collaborating researchers 
are encouraged to work closely with the BCFR liaison, throughout the design phase of 
their studies (BCFR, 2013). Additionally, a Walden University IRB application was 
submitted for this study and an approval was also received. The IRB approval number for 
this study was 02-23-15-0085556.  
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Summary 
In this chapter, I presented the methodology for the proposed study. I conducted 
secondary data analyses using a nested case-control study design. The study population 
included female patients diagnosed with breast cancer from 1997-2014. The population 
also included females diagnosed with BRCA1 or BRCA2 mutations, with data on 
ethnicity, and age status. Three other covariates were included and analyzed: Smoking 
status, and BRCA1/BRCA2 family history. The BCFR data set also included only female 
patients diagnosed with second cancers (including pancreatic, colorectal, endometrial, 
and cervical cancer) after initial diagnosis with BRCA1 or BRCA2 mutation. Three other 
cancer sites were included in order to increase the sample size: Kidney, thyroid, and 
bladder. The study was intended to involve the application of survival analysis to look for 
associations at the bivariate level and to test the associations between the time to 
diagnosis with second primary cancers including colorectal, endometrial, cervical, 
kidney, thyroid, and bladder cancer and risk factors specified in this chapter using Cox 
proportional hazards regression. This was the appropriate test because the research 
questions were about time to diagnosis of second primary cancers such as colorectal, 
endometrial, cervical, kidney, thyroid, and bladder cancer among subjects diagnosed with 
breast cancer. The results of this study are presented in Chapter 4. 
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Chapter 4: Results 
Introduction 
The purpose of this quantitative study was to investigate the association of 
gender, ethnicity, and age of diagnosis of breast cancer with risk of diagnosis of second 
primary cancers, including pancreatic cancer, colorectal cancer, endometrial cancer, and 
cervical cancer, among subjects diagnosed with breast cancer. A composite endpoints 
approach was used in defining events and testing the stated associations. It was necessary 
to make some changes from the original data plan. An additional three cancer sites 
(kidney cancer, thyroid cancer, and bladder cancer) were added in order to increase the 
sample size and power of the study. Pancreatic cancer was not among the variables 
analyzed because no subject with pancreatic cancer in the BCFR study population met 
the inclusion criteria. Gender as an independent variable was not included in the analysis 
because the data set did not include any male subjects.  
This chapter starts with the presentation of the results of the baseline descriptive 
and demographic characteristics of each variable. The chapter continues with the 
presentations and descriptions of the results of the Kaplan Meier (KM) survival analyses 
and CPH to answer the stated research questions. The chapter concludes with 
recapitulation of the summary of the results.  
The first research question (RQ1) after including the additional three cancer sites 
was the following: 
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1. Is there a relationship between BRCA mutation status and the risk of 
diagnosis of second primary cancers, colorectal, endometrial, cervical, 
kidney, thyroid, or bladder, among women with breast cancer?  
H01: There is no relationship between BRCA mutation status and time to 
diagnosis of second primary cancers, colorectal, endometrial, cervical, renal, thyroid, or 
bladder, among women with breast cancer. 
Ha1: There is a relationship between BRCA mutation status and time to diagnosis 
of second primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, 
among women with breast cancer. 
 
2.  Is there a relationship between ethnicity and age status and time to 
diagnosis of second primary cancers, colorectal, endometrial, cervical, 
kidney, thyroid or bladder, among women with breast cancer?  
H02: There is no relationship between ethnicity and age status and time to 
diagnosis of second primary cancers, colorectal, endometrial, cervical, renal, thyroid, or 
bladder, among women with breast cancer. 
Ha2: There is a relationship between ethnicity and age status and time to diagnosis 
of second primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, 
among women with breast cancer. 
In each case, differences in median time distributions were examined using the 
KM survival curves and tested using the log-rank test, except during the analysis of age 
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group and time to diagnosis of second primary cancers, where the Spearman correlation 
was used to test the relationship between time to event and age. 
Baseline Characteristics of the Sample 
The epidemiological data included the following independent variables: BRCA 
status, ethnicity, and age. They also included the BRCA both 1 and 2 (for subjects with 
two BRCA mutations) and covariates smoking, BRCA1 family history, BRCA2 family 
history, and time to diagnosis of second primary cancers.  A sample data line is shown in 
Table 6 of Chapter 3.  
The descriptive statistics for the study sample are presented in Table 8. 
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Table 8 
 
Descriptive Statistics of the Study Sample (N = 702) from the BCFR 1997-2014 Dataset 
 Variable Responses Frequency Percent 
Age <46 years                             136 16.2 
 47-56 years                                                                                                           196 27.9                                         
 57 and older            370 52.7 
Breast cancer variants 1 or 2                                       702 100 
BRCA1 person status Yes 528 75.2 
BRCA2 person status Yes 539 76.8 
BRCA status both 1 and 2 Yes 500 71.2 
Race/Ethnicity White 551 78.5 
 Black 71 10.1 
 American Indian 4 0.06 
 Asian 76 10.8 
Event  Yes second cancer 81 11.5 
Site Colon and rectum 22 3.98 
 Cervix 5 0.9 
 Endometrium 32 5.76 
 Kidney 5 0.9 
 Bladder 8 1.44 
 Thyroid 9 1.62 
Smoking Yes 302 43.0 
BRCA1 Family history 
 
Yes 483 68.8 
BRCA2 Family history Yes 501 71.4 
Continuous variable Number Mean Standard 
deviation 
Time to event 702 12.73 3.642 
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Results 
The results are divided into three sections, arranged according to research 
question and additional findings from the covariates. Table 7 in Chapter 3 presented how 
each of the study variables was used to answer the two research questions. 
Research Question 1 
The first research question’s (RQ1) results of this analysis are summarized in 
Table 9, Table 10, and Table 11.  
Table 9 
 
Mean and Median Survival Time by BRCA1 (n = 702) 
 
Breast Ca Gene Mutation (n) Mean  SD* Median IQR 
BRCA1 = 0 (174)   12.546      1.1       14.000       0.4 
BRCA1 = 1 (528)   12.792     0.6       14.000       0.2 
Overall 12.731 0.5 14.000       0.2 
Note. Estimation is limited to the largest survival time if it is censored                                   
  
Table 10 
 
Mean and Median Survival Time by BRCA2 (n = 702) 
 
Breast Ca Gene Mutation (n) Mean  SD* Median IQR 
BRCA2 = 0 (163)   12.724      1.2       14.000       0.8 
BRCA2 = 1 (539)   12.733     0.6       14.000       0.2 
Overall 12.731 0.5 14.000       0.2 
Note. Estimation is limited to the largest survival time if it is censored 
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Table 11 
Mean and Median Survival Time by BRCA Both 1 and 2 (n = 702) 
Breast Ca Gene Mutation (n) Mean  SD* Median IQR 
BRCA both 1 and 2 = 0 (202)   12.663     1.1       14.000       0.4 
BRCA both 1 and 2 = 1 (500)   12.758     0.7       14.000       0.2 
Overall 12.731 0.5 14.000       0.2 
Note. Estimation is limited to the largest survival time if it is censored                                   
  
As Table 9, Table 10, and Table 11 show, the interquartile range of BRCA1, 
BRCA2, and BRCA both 1 and 2 are the same [0.2]. The BRCA1, BRCA2, and BRCA 
both 1 and 2 have the same overall time to event of 14.000 years. The BRCA1, BRCA2, 
and BRCA both 1 and 2 demonstrate the same median time to event of 14.000 years. The 
overall interquartile range of the BRCA1 was [0.2], and the overall interquartile range of 
BRCA2 was [0.2], while the overall interquartile range of BRCA both 1 and 2 was also 
[0.2]. The log- rank test for BRCA1 = 0.797, with p = 0.372, and the log-rank test for 
BRCA2 = 1.808, with p = 0.179, while the log-rank test for BRCA both 1 and 2 = 0.001, 
with p = 0.972. The BRCA1, BRCA2, and BRCA both 1 and 2 results were not 
statistically significant.  
 The survival curves by BRCA1, BRCA2, and BRCA both 1 and 2 were generated 
using the KM survival curve as shown in Figure 3, Figure 4, and Figure 5, respectively. 
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Figure 3. KM’s survival curve for BRCA1 (p-value = 0.372) 
  
Figure 4. KM’s survival curve for BRCA2 (p-value = 0.179) 
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Figure 5. KM’s survival curve for BRCA both 1 and 2 (p-value = 0.179) 
The above three KM’s survival curves show that the median time to event for 
BRCA1, BRCA2, and BRCA status both 1 and 2 are the same at 14 years respectively. 
Stratification of breast cancer by BRCA status both 1 and 2. The survival by 
different levels of the variable was compared by adding yet another layer of adjustment 
(control) in a model. Stratification by BRCA status both 1 and 2 variable was conducted. 
This was done with the breast cancer in the factor position, BRCA status both 1 and 2 
variable in the strata position, and time to event in years in the time position and events 
(with second cancers) in the event position of the analysis. Because the probability of 
survival changes over time, stratification enabled survival patterns to be compared at 
various stages or observation times (Szklo & Nieto, 2014). 
Table 12 presents a mean and median difference in survival after stratification of 
the breast cancer by BRCA status both 1 and 2. 
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Table 12 
 
Mean and Median Survival Time by BRCA Both 1 and 2 After Stratification (n = 702) 
 
Breast Ca Gene Mutation Breast 
Cancer 
Mean  SD* Median IQR 
BRCA both 1 and 2 = 0    1 12.730      1.04       14.000       0.42 
BRCA both 1 and 2 = 1 2 6.000  6.000  
 Overall 12.663 1.05 14.000       0.42 
BRCA both 1 and 2 = 0   1 12.757 0.63 14.000        
BRCA both 1 and 2 = 1 2 13.000  13.000  
 Overall 12.758 0.63 14.000       0.23 
Overall Overall 12.731      0.44 14.000       0.23 
Note. Estimation is limited to the largest survival time if it is censored 
                                                                                                                                                                        
After stratification as shown in Table 12, interquartile range of breast cancer (1) 
with BRCA both 1 and 2 (0) = 0.42, with time to event = 14 years, while breast cancer 
(2) with BRCA both 1 and 2 (1) has time to event of 6 years and 13 years respectively. 
Both breast cancer ((1) and (2)) and BRCA both 1 and 2 ((0) and (1)) have overall time to 
event estimate = 14.0 years. The log-rank test was used to ascertain the significant 
differences in the time to event for patients with breast cancer. The log-rank test of 
equality for the breast cancer = 8.849 and p = 0.003. This was statistically significant.  
Figure 6 and Figure 7 show the survival function curves for breast cancer after 
stratification with BRCA both 1 and 2. Figure 6 presents the curve when BRCA both 1 
and 2 is 0, while Figure 7 shows when that value is 1.     
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Figure 6. KM’s survival curve for breast cancer after stratification with BRCA both 1 
and 2 (p-value = 0.003) 
 
 
 
Figure 7. KM’s survival curve for breast cancer after stratification with BRCA both 1 
and 2 (p-value = 0.003) 
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Hazard ratio and the test of proportionality. I performed a Cox regression 
analysis to estimate the hazard ratio for the breast cancer gene mutations, BRCA1, 
BRCA2, and BRCA both 1 and 2. Here, I employed the composite endpoint (event) 
analysis due to the sparsity of events for the various second primary cancer sites. The 
hazard ratio generated will be the measure of association in this case. A composite 
endpoint (outcome) consists of two or more component outcomes (in the above case, 
colorectal, endometrial, cervical, kidney, thyroid, and bladder cancer). Patients who have 
experienced any one of the events specified by the components are considered to have 
experienced the composite outcome. The hazard ratios for BRCA1 and BRCA2 were 
determined. The Cox proportional hazards regression model is based on the proportional 
hazards assumption. An assessment of as to whether this assumption was met or not was 
done using the KM’s curves 
Table 13 shows the parameters for the Cox proportional hazard model for 
BRCA1, BRCA2, and BRCA both 1 and 2 gene mutations after adjusting for covariates. 
Table 13 
Cox Hazard model for Breast Cancer, BRCA1, BRCA2, and BRCA both 1 and 2 (n = 
702) 
Breast Ca and BRCA mutations Hazard ratio 95% Confidence interval 
Breast Ca unadjusted 4.031 (1.50, 10.84) 
Adjusted 4.252 (1.56, 11.44) 
BRCA1 0.781 (0.529, 1.17) 
BRCA2 1.471 (1.03, 2.11) 
BRCA both 1 and 2 0.891 (0.53, 1.50) 
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Table 13 shows hazard ratio for breast cancer unadjusted was 4.031, 95% 
Confidence Interval (CI) hazard ratio [1.50 -10.84], was statistically significant. This 
means that over 16 years of follow-up, the hazard for second primary cancers risk among 
patients diagnosed with breast cancer was 4.031 times higher than those not diagnosed 
with breast cancer. The hazard ratio of.BRCA1 mutation was 0.78, 95% CI hazard ratio 
[0.52 – 1.17], was not a statistically significant result. This means that over 16 years of 
follow-up, the hazard for second primary cancers risk among patients diagnosed of 
BRCA1 gene mutations was 7.8 times higher than those not diagnosed with breast. The 
BRCA2 mutation hazard ratio was 1.471 with 95% CI hazard ratio = [1.03 – 2.11]. This 
was statistically significant. This means that over 16 years of follow-up, the hazard for 
second primary cancers risk was 14.7 times higher than those not diagnosed with breast 
cancer. The BRCA both 1 and 2 mutations hazard ratio was 0.891, with a corresponding 
95% CI hazard ratio [0.53 – 1.50] was not statistically significant. This means that over 
16 years of follow-up, the hazard for second primary cancers risk was 8.9 times higher in 
the population under study. Therefore, I failed to reject the null hypothesis of no 
relationship between BRCA1 and BRCA both 1 and 2 and time to diagnoses of second 
primary cancers, colorectal, endometrial, cervical, kidney, thyroid or bladder, among 
women with BRCA related breast cancer. However, I rejected the null hypothesis of no 
relationship between BRCA2 and time to diagnoses of second primary cancers, 
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colorectal, endometrial, cervical, kidney, thyroid or bladder, among women with BRCA 
related breast cancer. 
In both the unadjusted and adjusted model, there is an increased risk of second 
primary cancers among participants with breast cancer (hazard ratio of 4.031, 4.252) as 
compared to those with BRCA1 and BRCA both 1 and 2. However, after adjustment for 
BRCA1 and BRCA both 1 and 2, there is no statistically significant difference between 
participants in terms of (hazard ratio = 0.781, p = 0.5038, hazard ratio = 0.891, p = 
0.667). The same is not true in the model adjusting for the BRCA2 risk factor. However, 
after adjustment, the difference in BRCA2 participants remains statistically significant, 
with hazard ratio of 1.471, p = 0.036, as compared to other participants. The hazard ratio 
by each breast cancer mutation genes, BRCA1, BRCA2, and both BRCA1 and BRCA2 
were generated using the Cox regression model. The test of proportionality that was 
checked with Kaplan-Meier curves showed hazards are proportional within the groups. 
The CPH assumption was met.  
 Research Question 2 
The second research question’s (RQ2) was divided into two. The first is:  
RQa. Is there a relationship between ethnicity and time to diagnosis of second 
primary cancers, colorectal, endometrial, cervical, thyroid, or bladder, among women 
with BRCA related breast cancer?  
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RQb. Is there a relationship between age group and time to diagnosis of second 
primary cancers, colorectal, endometrial,  cervical, thyroid, or bladder, among women 
BRCA related breast cancer?  
The results of these analyses are summarized in Table 14 and Table 15 
Table 14 
Mean and Median Survival Time by Race/Ethnicity (n = 702) 
Race/Ethnicity (n) Mean SD Median IQR 
White (551) 12.964 0.62             14.000        0.22 
Black (71) 11.634         1.49             11.000        1.94 
American I/H (4) 15.000         2.76             15.000        3.56 
Asian (76) 11.947         1.48             12.000        2.44 
Overall (702) 12.731         0.54             14.000        0.22 
Note. Estimation is limited to the largest survival time if it is censored                                   
 
Table 15 
Mean and Median Survival by Age Groups (n = 702) 
Age groups (n) Mean SD Median IQR 
<46 years (136) 12.765  1.14                    14.000        0.40 
47 – 56 years (196) 12.668 1.06 14.000        0.36 
57 years and older (370) 12.751 0.74 14.000        0.34 
Overall (702) 12.731 0.54 14.000        0.22 
Note. Estimation is limited to the largest survival time if it is censored 
 As Table 14 shows, there are observed statistically significant differences for 
White and American Indian/Hawaiian (American I/H) race/ethnicity except for “Black” 
and “Asia” race/ethnicity. Of note, are the time to event estimates for race/ethnicity, 
122 
 
 
 
White = 14.000, Black = 11.000, American I/H = 15.000, and Asia = 12.000. 
Race/Ethnicity has overall time to event = 14.000. The log rank test of equality was 
29.482 with a corresponding p = 0.000. This was statistically significant.  
 As Table 15 shows, there are no observed statistically significant differences in 
the age groups according to the interquartile range of survival by age groups. Of note, are 
the time to event estimates for age groups, <46 years = 14.000, 47-56 years = 14.000, and 
57 years and older = 14.000 years. Age groups have overall time to event = 14.000 years. 
The Spearman correlation coefficient rs = 0.026. This is not statistically significant (p = 
0.487). In the same manner, there was no statistical significant result observed after 
looking at the Spearman correlation with age at diagnosis without grouping the 
participants into age groups as well. The Spearman correlation coefficient rs was 0.018 (p 
= 0.627).  
Table 16 shows the nonparametric Spearman rank order correlation coefficient 
sample which was used to test the relationship between age groups and time to event. 
Table 16 
Spearman Correlation Test for Age groups and Time to event (n = 702) 
 Age group 
Time to event Correlation Coefficient   0.026 
 Sig. (2-tailed)      0.487 
 
Table17 shows the nonparametric Spearman rank order correlation coefficient 
sample which was used to test the relationship between age and time to event. 
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Table 17 
Spearman Correlation Test for Age at Diagnosis (not grouped) and Time to event (n = 
702) 
 Age group 
Time to event Correlation Coefficient   0.018 
 Sig. (2-tailed)      0.627 
 
In Figure 8 and Figure 9, I present the survival by race/ethnicity and age groups 
using the KM’s survival curve of differences between times to event of second primary 
cancers. 
 
Figure 8. Kaplan Meier’s survival curve of Race/Ethnicity, p = 0.000, 1 = White 
(includes the Ashkenazi Jews), 2 = Black, 3 = American I/H, and 4 =Asian 
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Figure 9. Kaplan Meier’s survival curve of Age groups, p = 0.487  
As presented in Figure 9, both race/ethnicity and age groups have the same 
overall median time to event of 14 years.  
Hazard ratio and the test of proportionality. I performed a Cox regression 
analysis to determine the hazard ratio for race/ethnicity and age groups.  I employed the 
composite endpoint (event) analysis due to the sparsity of events for the various second 
primary cancer sites. The hazard ratio generated will be the measure of association in this 
case.  The assumption of proportional risks required to use CPH was also checked with 
Kaplan-Meier curves. 
 Table 18 shows the CPH of the samples with hazard ratios.  
Table 18 
Cox Hazard model for Race/Ethnicity and Age groups (n =702) 
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Ethnicity and age groups Hazard ratio 95% Confidence 
interval 
Ethnicity White 1.511 (1.88, 1.94) 
 Black 0.647 (0.23, 1.67) 
 American I/H 1.424 (1.12, 1.81) 
 Asian Ref.  
Age group <46 years 0.942 (0.76, 1.17) 
 47-56 years 0.925 (0.76, 1.13) 
 
In Table 18, Asian race is the referent group. The hazard ratios for White 
(includes the Ashkenazi Jews) and American I/H at 95% CIs hazard ratio [1.17 – 1.93] 
and [1.12 – 1.81] are statistically significant, while the hazard ratio for Black was not a 
statistically significant result [0.742 – 1.730]. This means for over 16 years of follow-up, 
the hazard ratio for second primary cancers risk among White and American I/H races 
diagnosed of breast cancer were 15.1 times and 14.2 times respectively higher compared 
to the reference group (Asian race). Over the same follow-up years, the hazard ratio for 
second primary cancers risk among Black race was 6.5%. This implies that both White 
(includes the Ashkenazi Jews) and American I/H (though there are really too few of those 
to have any meaningful results are significantly different, but that Blacks and Asians are 
not.  Therefore, I rejected the null hypothesis of no relationship between race/ethnicity 
(White and American I/H) and time to diagnosis of second primary cancers, colorectal, 
endometrial, cervical, kidney, thyroid and bladder. I also failed to reject the null 
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hypothesis of no relationship between Black race and Asian race and diagnosis of second 
primary cancers, colorectal, endometrial, cervical, kidney, thyroid and bladder. 
 For age groups, 57 years and older is the referent group. The hazard ratios for <46 
years and 47-56 years at 95% CIs [0.76 – 1.17] and [0.76 – 1.13] are not statistically 
significant. This means for over 16 years of follow-up, the hazard ratio for second 
primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder risk of 
diagnosis among age group <46 years and 47-56 years was 6.7 times higher compared to 
the reference group. This implies though 57 and older have greater number, they may not 
also be statistically significant. Therefore, I failed to reject the null hypothesis of no 
relationship between age group and time to diagnosis of second primary cancers, 
colorectal, endometrial, cervical, kidney, thyroid and bladder. The test of proportionality 
that was checked using the KM’s curves showed hazards are proportional within the 
groups. The CPH assumption was met.  
 When I analyzed race/ethnicity without merging all the Asian races into one as 
demonstrated in the above analyses, the following results were generated as shown in 
Table 19 
Mean and Median Survival Time by Race/Ethnicity (without merging) (n = 702) 
 
Race/Ethnicity ( n)                    Mean SD Median IQR 
White  
(includes the 
Ashkenazi Jews) 
12.964 0.62 14.000 0.22 
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Black 
 
11.634 1.49 11.000 1.94 
American Indian 
 
15.000 2.72 15.000 3.56 
Chinese  
 
12.421 1.88 12.000 3.44 
Japanese  
 
10.400 3.75 10.000 4.04 
Filipinos 
 
11.957 3.10 13.000 3.10 
Asian 
 
12.500 6.09 13.000 1.76 
Overall      12.731         0.54 14.000 0.21 
Note. Estimation is limited to the largest survival time if it is censored                                   
As Table 19 shows, the number (n) for Asian is 76, then it is likely I do not have 
enough data to draw any conclusions on the Asian sub groups. This evidence is provided 
based on an analysis of the survival times for the various Asian races represented to 
suggest that combining them as I demonstrated did not significantly alter my results from 
the previous analysis.   
Adjusting for Confounders 
 In RQ2a, I presented that race/ethnicity was a confounder. In order to further 
examine this, I evaluated BRCA status using the confounder in the analysis. I reevaluated 
the relationship between BRCA gene mutations (BRCA1, BRCA2, and BRCA both 1 and 
2) and White (includes the Ashkenazi Jews) to American I/H race by conducting 
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multivariate test (CPH) to see if there could be a difference. The test of proportionality 
was checked using the KM’s curves.  
 Table 20 shows the CPH of the samples with hazard ratios.  
Table 20 
Cox Hazard model for Confounder Race/Ethnicity and BRCA status (BRCA1, BRCA2, 
and BRCA both 1 and 2) (n =702. 
BRCA status Race/Ethnicity Hazard ratio 95% Confidence interval 
BRCA1  0.867 0.73, 1.04 
 White 1.559                                  1.21, 2.01
 Black 0.673                                 0.25, 1.80
 American I/H 1.476 1.16, 1.87 
 Asian Ref.  
BRCA 2  1.025                                   0.86, 1.23
 White 1.495                                  1.16, 1.92
 Black 0.642                                 0.24, 1.72
 American I/H 1.414                                  1.12, 1.81
 Asian Ref.  
BRCA 1 and 2  0.925                                 0.78, 1.10
 White 1.537                                  1.19. 1.98
 Black 0.664                                 0.25, 1.78
 American I/H 1.459                                  1.14, 1.87
 Asian Ref.  
 
Table 20 shows hazard ratio for White race when analyzed with BRCA1 was 
1.559, 95% CI hazard ratio [1.21 - 2.01], was statistically significant. This means that 
over 16 years of follow-up, the hazard for second primary cancers risk among White race 
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diagnosed of BRCA1 gene mutation was 15.6 times higher compared to the reference 
group (Asian race). The hazard ratio for Black race with BCA1 was 0.673, 95% CI 
hazard ratio [0.25 – 1.80] was not statistically significant. This means for over 16 years of 
follow-up, the hazard ratio for second primary cancers risk among Black race diagnosed 
of BRCA1 gene mutation was 6.7 times higher compared to the reference group (Asian 
race). The hazard ratio for American I/H races with BCA1 was 1.476, 95% CI hazard 
ratio [1.16 – 1.87] was statistically significant. This means for over 16 years of follow-up, 
the hazard ratio for second primary cancers risk among the American I/H races diagnosed 
of BRCA1 gene mutation was 14.8 times higher compared to the reference group (Asian 
race). 
The hazard ratio for White race (includes the Ashkenazi Jews) when analyzed 
with BRCA2 was 1.495, 95% CI hazard ratio [1.16 – 1.92], was statistically significant. 
This means that over 16 years of follow-up, the hazard for second primary cancers risk 
among White race diagnosed of BRCA2 gene mutation was 15.0 times higher compared 
to the reference group (Asian race). The hazard ratio for Black race when analyzed with 
BRCA2 was 0.642, 95% CI hazard ratio [0.24 – 1.72], was not statistically significant. 
This means that over 16 years of follow-up, the hazard for second primary cancers risk 
among Black race diagnosed of BRCA2 gene mutation was 6.4 times higher compared to 
the reference group (Asian race). The hazard ratio for American I/H races when analyzed 
with BRCA2 was 1.415, 95% CI hazard ratio [1.12 – 1.81], was statistically significant. 
This means that over 16 years of follow-up, the hazard for second primary cancers risk 
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among American I/H races diagnosed of BRCA2 gene mutation was 14.2 times higher 
compared to the reference group (Asian race). 
The hazard ratio for White race when analyzed with BRCA both 1 and 2 was 
1.537, 95% CI hazard ratio [1.19 – 1.98], was statistically significant. This means that 
over 16 years of follow-up, the hazard for second primary cancers risk among White race 
diagnosed of BRCA both 1 and 2 gene mutations was 15.4 times higher compared to the 
reference group (Asian race). The hazard ratio for Black race when analyzed with BRCA 
both 1 and 2 was 0.664, 95% CI hazard ratio [0.25 –1.78] was not statistically significant. 
This means that over 16 years of follow-up, the hazard for second primary cancers risk 
among Black race diagnosed of BRCA both 1 and 2 gene mutations was 6.6 times higher 
compared to the reference group (Asian race). The hazard ratio for American I/H races 
when analyzed with BRCA both 1 and 2 was 1.459, 95% CI hazard ratio [1.14 – 1.87], 
was statistically significant. This means that over 16 years of follow-up, the hazard for 
second primary cancers risk among American I/H races diagnosed of BRCA both 1 and 2 
gene mutations was 14.6 times higher compared to the reference group (Asian race). 
The result summary showed that race/ethnicity as a confounder may have a 
relationship with diagnosis of second primary cancers, colorectal, endometrial, cervical, 
kidney, thyroid, or bladder in the population under study. The KM’s curves showed 
hazards are proportional within the groups. The CPH assumption was met. 
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Adjusting for Covariates 
The relationship between the study covariates such as smoking status, BRCA1 
family status, and BRCA2 family status and time to event of second primary cancers, 
colorectal, endometrial, cervical, kidney, thyroid, and bladder were also analyzed. The 
survival by each of the covariates was generated using the KM’s survival curve of 
differences between time of diagnosis with breast cancer and time to event of second 
primary cancers. The log-rank test was used to identify significant differences in the 
median time to event. The hazard ratios of the covariates were determined and the 
assumption of proportional risks required to use CPH was also checked.  
Smoking Status  
 Table 21 shows the summary of the smoking status analysis.  
Table 21 
Mean and Median Survival Time by Smoking status (n = 702) 
Race/Ethnicity (n) Mean SD Median IQR 
Smoking = 0 (400) 12.975 0.67 14.000        0.3 
Smoking = 1 (302) 12.407 0.88 14.000        0.33 
Overall (702) 12.731         0.74             14.000        0.22 
Note. Estimation is limited to the largest survival time if it is censored                                
 
As Table 21 shows, there are observed no statistically significant differences in 
the relationship between smoking status and time to diagnosis of second primary cancers. 
Of note, are the median time to event estimates at 95% CIs and overall time to event 
estimates of both Smoking (0) and Smoking (1) are 14.000 years respectively. The log- 
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rank test for smoking status was 1.844, and p = 0.174 and did not show any statistical 
significance. 
Figure 10 shows the KM’s survival curve for smoking status and time to 
diagnosis of second primary cancers.  
 
 
 
Figure 10. KM’s survival curve of Smoking status (p-value = 0.174). 
BRCA1/BRCA2 Family Status 
BRCA1/BRCA2 family status and time to event. The survival by each BRCA1 
family status and BRCA2 family status was generated using the KM’s survival curve of 
differences between times to event of second primary cancers.  Table 21 and Table 22 
present the results summary.  
Table 22 
Mean and Median Survival Time by BRCA1 Family History (n = 702) 
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Family status (n) Mean SD Median IQR 
BRCA1 = 0 (219) 13.114 1.33             14.000        0.48 
BRCA1 = 1 (483) 12.557         0.65 14.000        0.22 
Overall (702) 12.731         0.54             14.000        0.22 
Note. Estimation is limited to the largest survival time if it is censored                                             
 
 
 
Table 23 
Mean and Median Survival Time by BRCA2 Family History (n = 702)                   
Family status (n) Mean SD Median IQR 
BRCA2 = 0 (201) 13.095 1.03             14.000        0.48 
BRCA2 = 1 (501) 12.285         0.79             14.000        0.24 
Overall (702) 12.731         0.54             14.000        0.22 
Note. Estimation is limited to the largest survival time if it is censored                      
      
As Table 22 and Table 23 show, there are observed statistically significant 
differences in the relationship between both BRCA1 and BRCA2 family status and time 
to diagnosis of second primary cancers. Of importance, are the median time to event 
estimates for BRCA1 family status and BRCA2 family status at 95% CI are [13.89 - 
14.11] and [13.88 - 14.12] respectively. The BRCA1 family status and BRCA2 family 
status have the same overall time to event estimate of 14.000 years.  The log- rank test for 
BRCA1 family status was 14.116, with p = 0.000, while the log-rank test for BRCA2 
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family status was 11.359, with p = 0.001. Both BRCA1 family status and BRCA2 family 
status results are statistically significant.  
 Figure 11 and Figure 12 show the KM’s survival curve of differences between 
BRCA1/BRCA2 family statuses and time to event of second primary cancers. 
 
 
 
Figure 11. KM’s survival curve of BRCA1 family status (p = 0.000) 
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Figure 12. KM’s survival curve of BRCA2 family status (p = 0.001) 
Both BRCA1 and BRCA 2 family histories had 14 years for median estimated time to 
event.  
Hazard ratio and the test of proportionality. I present the summary of a Cox 
regression conducted to determine the hazard ratio for smoking status, BRCA1 family 
status, and BRCA2 family status.  I employed the composite endpoint (event) analysis 
due to the sparsity of events for the various second primary cancer sites. The hazard ratio 
generated will be the measure of association in this case. The hazard ratios of the 
covariates were determined and the assumption of proportional risks required to use CPH 
was also checked using the KM’s curves. 
Table 24 shows the Cox model for smoking status, BRCA1/BRCA2 family 
statuses sample with hazard ratios.  
Table 24 
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Cox Hazard model for Smoking status, BRCA1, and BRCA2 Family status (n = 702) 
Status (n) Hazard ratio 95% Confidence interval 
Smoking (302) 1.086 0.94, 1.26 
BRCA1 Family status (483) 1.193 0.95, 1.51 
BRCA2 Family status (501 1.086 0.86, 1.38 
 
In Table 24, the hazard ratios at 95% CI risk ratio for smoking status is not 
statistically significant [0.94 – 1.26].  BRCA1 and BRCA2 family statuses are not also 
statistically significant, as shown with the 95% CIs risk ratio (B) [0.94 – 1.26], [0.95 – 
1.51], and [0.86 – 1.38] respectively. This means that over 16 years of follow-up, the 
hazard for second primary cancers risk among patients who smoked was 10.9 times 
higher than those not diagnosed with breast cancer. Consequently, over 16 years of 
follow-up, the hazard for second primary cancers risk among BRCA1 family status and 
BRCA2 family status are 11.9 times and 10.9 times higher respectively in the population 
than those not diagnosed with breast cancer. The hazard ratio by smoking status, BRCA1 
family status, and BRCA2 family status were determined and the test of proportionality 
was ascertained using the Kaplan-Meier curves. The Kaplan-Meier curves showed 
hazards are proportional within the groups. The CPH assumption was met. 
Summary 
In this chapter, I examined the risks of diagnosis of second primary cancers 
including colorectal, endometrial, cervical, kidney, thyroid, and bladder among women 
who had been diagnosed with breast cancer using the composite endpoint method by 
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employing data from the Breast Cancer Family Registries. Three risk factors, BRCA gene 
mutation status (BRCA1, BRCA2 and BRCA both 1 and 2), race/ethnicity, and age at 
diagnosis (NCI, 2015) were used to answer the research questions. The role of 
confounder and interaction between the covariates, smoking, and BRCA1/BRCA2 family 
status were also examined. As observed in this study, all of my findings associated with 
the two research questions and covariates suggest that it is possible to predict the risk of 
diagnosis of second primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or 
bladder, among women with breast cancer. In KM’s analysis, I identified the overall 
median time to event of second primary cancers to be 14 years. In the inferential 
multivariate Cox proportional hazard regression model, I also identified BRCA2 gene 
mutation and race/ethnicity as significant risk factors for diagnosis of second primary 
cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, among women 
with breast cancer. 
In Chapter 5, I summarize, analyze, and interpret key findings from these results 
and discuss whether they confirm, disconfirm, or extend existing knowledge per the 
literature review and the conceptual framework for this study. I also acknowledge and 
discuss the limitations of the study in terms of generalizability and/or trustworthiness, 
validity, and reliability. Recommendations for further research grounded in the strengths 
and limitations of the study and the literature reviewed in chapter 2 will be suggested, 
specifically as related to BRCA testing in the various communities and locations with the 
BCFR sites in the United States, Canada, and Australia. In this context, implications for 
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positive social change and recommendations for practice will be discussed, along with 
methodological, theoretical, and/or empirical implications. Finally, conclusions will be 
drawn to capture the key essence of the study. 
Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
There are limited data on risk factors of BRCA1/BRCA2 gene mutations and risk 
of diagnosis of second cancers after breast cancer diagnosis among varying age, gender, 
and racial and ethnic groups in the United States. The role of age and ethnicity in 
diagnosis of BRCA-related cancers has been investigated (Al-Mulla et al., 2009; Jemals 
et al., 2003), but needs further clarification. There are data indicating that the risk for 
developing a second cancer may be significant for patients already diagnosed with breast 
cancer (Lee et al., 2008; Lee et al., 2006). The purpose of this quantitative study was to 
examine whether a relationship exist between BRCA gene mutations, ethnicity, age and 
gender, and risk of diagnosis of second primary cancers, including colorectal, 
endometrial, cervical, kidney, thyroid, and bladder cancer, among women diagnosed with 
breast cancer. Previous scholars observed a shared relationship with BRCA gene 
mutations and second primary cancers (Mocci et al., 2013; Kadouri et al., 2007). Mocci 
et al. (2013) observed that the women diagnosed with a BRCA-mutation-related breast 
cancer before 50 years of age were at a higher risk for developing a second cancer. The 
premise of this study was based on empirical findings that certain subsets of breast 
139 
 
 
 
cancer patients have demonstrated an elevated risk of developing second primary cancers 
(Kmet et al., 2003; Youlden & Baade, 2011).  
According to the findings of this study, the overall median time to event of second 
primary cancer, colorectal, endometrial, cervical, kidney, thyroid, or bladder among 
women with BRCA-related breast cancer was 14 years. The log-rank test of the three 
BRCA mutation status did not show any statistical significance (BRCA1 = 0.797, with p 
= 0.372; BRCA2 = 1.808, with p = 0.179; and BRCA both 1 and 2 = 0.001, with p = 
0.972). The multivariate CPH analysis hazard ratio for BRCA1 mutation was 0.781, p = 
0.234, while the BRCA both 1 and 2 mutation hazard ratio was 0.891, with p = 0.667. I 
found no relationship between BRCA1 and risk of diagnosis of second primary cancers. I 
also found no relationship between BRCA both 1 and 2 and risk of diagnosis of second 
primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, among 
women with breast cancer. Similarly, race/ethnicity had an overall time to event of 14 
years. The log-rank test of equality showed 29.482 with a corresponding p = 0.000. The 
hazard ratios for White (includes the Ashkenazi Jews) and American I/H at 95% CIs 
hazard ratio [1.17 – 1.93] and [1.12 – 1.81] showed a relationship between race/ethnicity 
and risk of diagnosis of second cancers, while the hazard ratio for Black did not show any 
relationship [0.742 – 1.730]. The overall median time to event estimates of age groups 
<46 years, 47-56 years, and 57 years and older was 14 years. The Spearman correlation 
coefficient rs = 0.026. The hazard ratios for <46 years and 47-56 years at 95% CIs [0.76 – 
1.17] and [0.76 – 1.13] did not demonstrate a relationship between age groups and risk of 
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diagnosis of second primary cancers among women with BRCA-related breast cancer. 
Similarly, the three study covariates, smoking status, BRCA1 family status, and BRCA2 
family status, had overall median time to event of 14 years. The log-rank test for smoking 
status was 1.844, and p = 0.174, while the log-rank test for BRCA1 family status was 
14.116, with p = 0.000. The log-rank test for BRCA2 family status was 11.359, with p = 
0.001. None of the covariates showed a positive relationship with risk of diagnosis of 
second primary cancers. The hazard ratio at 95% CI of smoking status was [0.94 – 1.26]. 
The 95% CI hazard ratios of BRCA1 and BRCA2 family statuses at 95% CI were [0.94 – 
1.26], [0.95 – 1.51] and [0.86 – 1.38] respectively.  
In Chapter 5, I begin with a brief review of the second primary cancers and 
various relationships with the predictor variables, BRCA gene mutation status, that relate 
to my first cohort and first research question and race/ethnicity and age at diagnosis that 
relate to my second cohort and research question. I follow this with a comprehensive 
interpretation of the findings as they relate to existing literature, my theoretical 
framework, and the study population. I present the limitations of the study in terms of 
generalizability and/or trustworthiness, validity, and reliability. Finally, I provide 
recommendations for further research and discuss the implications for social change 
based on my research conclusions.  
Interpretation of the Findings 
I conducted a prospective cohort study using 702 patients with breast cancer from 
the NCI-BCFR database to determine if there was a relationship between the risk of 
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diagnosis of second primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or 
bladder, and the independent variables of BRCA status, race/ethnicity, and age at 
diagnosis. The relationship between the dependent variable and study covariates BRCA1 
family history/BRCA2 family history was also examined. Composite endpoints approach 
was used in defining events and testing the stated associations. The study participants and 
controls were then used to ascertain the extent and significance of associations between 
the risk of diagnosis of second primary cancers, colorectal, endometrial, cervical, kidney, 
thyroid, or bladder and the independent variables of BRCA status, race/ethnicity, and age 
at diagnosis. Direct relationships were observed between the risk of diagnosis of second 
primary cancers and BRCA2 and race/ethnicity. There was no relationship between risk 
of diagnosis of second primary cancers and BRCA1, BRCA both 1 and 2, and age 
groups. I found no statistically significant association between risk of diagnosis of second 
primary cancers and covariates BRCA1 family history/BRCA2 family history. 
Demographics 
The variables I examined in this study included BRCA gene mutation status 
(BRCA1, BRCA2, and BRCA both 1 and 2), race/ethnicity (White, Black, American I/H 
and Asian), age groups (<46 years, 47-56 years, and 57 years and older), smoking, 
BRCA1/ BRCA2 family history, and time to event of second primary cancers (colorectal, 
endometrial, cervical, kidney, thyroid, and bladder). The descriptive statistics for each of 
these variables (Table 7) was computed. Frequencies were used to describe the 
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dichotomous and categorical variables, while mean and standard deviation were used for 
the continuous variables time to event as well as age in a noncategorical form.  
BRCA status. In my study, BRCA1 and BRCA2 referred to BRCA gene 
mutations that are correlated with a high risk of breast and other cancers. BRCA both 1 
and 2 refers to individuals diagnosed with both BRCA1 and BRCA2 gene mutations. In 
another study on BRCA1/2 founder mutations in Southern Chinese breast cancer patients, 
Kwong et al. (2012) observed the frequency of 69 (15.3%) deleterious BRCA mutations, 
comprising 29 in BRCA1 and 40 in BRCA2 out of the 451 probands analyzed. I 
computed and organized descriptive statistics for the BRCA status categorical variable 
(BRCA1, BRCA2, and BRCA both 1 and 2). About 67% of all the study subjects I 
investigated had one or two of the BRCA gene mutations after the initial diagnosis of 
breast cancer. I observed the highest frequency of BRCA gene mutation-related breast 
cancer status was for BRCA2 at 76.8%, followed by BRCA1 cases at 75.2%; 71.2% of 
subjects/cases had both BRCA1 and BRCA2 mutations. These results are similar to the 
findings of John et al. (2011) in which the BRCA1 mutation frequency in non-Hispanic 
White is much higher than the observed frequency in African Americans (Blacks) in the 
population (Table 8). However, I did not analyze frameshift mutations. Similarly, my 
study was consistent with Kwong et al.’s (2012) report of higher frequency of BRCA2 
mutations than BRCA1 mutations in the study population. However, I did not use DNA 
sequencing such as was used in Kwong et al. study. Petrucelli et al. (2011) inferred that 
prognosis for BRCA1/2-related second cancers other than breast cancer depended on the 
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stage at which the cancer is diagnosed. In my review of the literature, I did not find many 
studies on BRCA both 1 and 2 mutations and their association with second primary 
cancer diagnosis (Petrucelli et al., 2011). Due to this limited literature, I investigated the 
relationship between BRCA both 1 and 2 gene mutations and time to diagnosis of second 
primary cancers (colorectal cancer, endometrial, cervical, kidney, thyroid, and bladder) 
among patients with BRCA-related breast cancers.  
Race/ethnicity. Four distinct races/ethnicities were examined in this study: White 
(including the Ashkenazi Jews), Black, American Indian/Hawaiian, and Asian (including 
Chinese, Filipinos, Japanese, and Korean). My use of data from six BCFR sites, in 
different countries and geographic locations, was intended to ensure ethnic and racial 
diversity among study subjects. Several researchers have suggested that the prevalence of 
harmful BRCA1 and BRCA2 mutations may be different among individual ethnic and 
racial groups in the United States (Bougie & Weberpals, 2011; John et al., 2011; Malone 
et al., 2006). Malone et. al. (2006) found that BRCA1 mutations were significantly more 
common in White (2.9%) versus Black (1.4%) cases and in Jewish (10.2%) versus non-
Jewish (2.0%) cases; BRCA2 mutations were slightly more frequent in Black (2.6%) 
versus White (2.1%) cases. I computed and organized descriptive statistics for 
race/ethnicity categorical variable into White, Black, American I/H, and Asian. John et 
al. (2011) found that non-Hispanic White patients had increased frequencies of BRCA1 
frameshift gene mutations compared to the African Americans. John et al. noted that the 
non-Hispanic White study population diagnosed with BRCA1 mutations showed 36% 
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mutations, whereas in African Americans, 25% of BRCA1 mutations were identified. In 
my study, I had similar observations with White participants (78%), followed by Asian 
(10.8%), Black (10.1%), and American I/H (0.06%). Conversely, my findings did not 
align w Malone et al.’s (2006) that the prevalence of BRCA2 mutations related to breast 
cancer is highest in Blacks compared to the White cases in the study population. The high 
number of White paricipants in my study probably reflects the demographics of the 
communities in which the six BCFR sites are located. Therefore, the generalizability of 
my study result might be limited to the BCFR sites and various populations recruited for 
the study.   
Age. I defined age in my study as the initial age at diagnosis of breast cancer 
among the study participants. I organized and computed descriptive statistics of age at 
diagnosis into categorical (age groups) from the initial continuous form. The frequency 
for study subjects were <46 years = 136 (19.4%), 47-56 years = 196 (26.9%), and 57 
years and older = 370 (52.7%). For age in a continuous form, the median age of my study 
participants (702) was 57 years, with mean age = 57.07 and standard deviation of 11.118, 
positioning the average study subject in the midyears of life. This corroborates with the 
findings of Nussbaum et al. (2007) and Singletary et al. (2004) who found that most 
cancers of the breast occur after 50 years of age. Similarly, my study age demographics 
were in conformity with Beineret al.’s (2007) findings of diagnosis of endometrial cancer 
among women with BRCA1- or BRCA2-related breast cancer, aged 45 to 70. In contrast, 
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Papelard et al. (2000) and Sing et al. (2000) found that BRCA1 and BRCA2-mutation-
related breast cancer develops often before 50 years of age.  
Time to event. In this study, time to event was presented as the time it takes for a 
patient with a BRCA1- or BRCA2-mutation-related breast cancer to be diagnosed with 
another form of cancer. For this study, I organized and calculated the time to event 
descriptive statistics as a continuous variable. For the study cohort, the mean time to 
event of second primary cancers among women diagnosed with BRCA-related breast 
cancer was 12.73, with a standard deviation of 3.642; the median time to event was 14 
years with inter quartile range of 0.2 My study results are consistent with Youlden and 
Baade’s (2011) findings. Youlden and Baade observed that one in every 10 (10.6%) of 
the second primary cancers were diagnosed within a year of the first diagnosis and more 
than one in five (20.6%) were diagnosed at least 10 years afterwards. While both studies 
examined the same cancer sites, colon/rectum, endometrium, cervix, kidney, thyroid and 
bladder, the Youlden and Baade study differed from mine because they estimated various 
years of second cancers diagnosis after initial breast cancer, and they did not indicate if 
the female study participants had BRCA gene mutation diagnosis.  
Smoking. Smoking is a known risk factor for breast cancer (Leet al., 2011). The 
latest American Cancer Society study on smoking and association with breast cancer 
reported an increased frequency pertaining to the risk of breast cancer among smokers 
compared to nonsmokers (American Cancer Society, 2013). The American Cancer 
Society, (2013) reported that 24% higher cases of breast cancer among women smokers 
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than in nonsmokers and 13% higher in former women smokers than in nonsmokers. 
However, smoking is not known to be a risk factor for BRCA1 and BRCA2 germline 
pathogenic variant-related breast cancer (Ginsberg et al., 2009). My descriptive statistics 
suggested that 42% of my study participants had a history of smoking. The relatively low 
percentage of smokers in my study seems to be consistent with Ginsberg et al.’s (2009) 
findings that it is likely that non-BRCA-related breast cancer is occurring by a different, 
environmental mechanism, which may involve carcinogenic exposure.   
BRCA1/BRCA2 family history. In my study, BRCA1 and BRCA2 family 
history referred to BRCA1 or BRCA2 gene mutations diagnosed from an individual with 
a history of a close family member previously diagnosed with either gene mutation. The 
influence of family history in BRCA1 and BRCA2 gene mutation carriers and increased 
risk of breast and other cancers remains unclear (Metcalfe et al., 2010). Metcalfe et al. 
(2010) reported a 18.1% in a 10-year cumulative risk of breast cancer for BRCA1 and 
15.2% for BRCA2 in a multinational cohort consisting of 3,011 women with BRCA1 or 
BRCA2 mutations who were followed up for a mean of 3.9 years, during which time 243 
incident breast or other cancers were recorded. Further, Metcalfe et al. observed that the 
risk of breast cancer increased by 1.2-fold for each first-degree relative with breast cancer 
before age 50 years. In the BCFR cohort recruited for this study, 68.8% of my study 
participants reported a family history of a BRCA1 gene mutation, while 71.4% reported 
family history of a BRCA2 gene mutation. My result was not consistent with the findings 
of Metcalfe et al. who reported a higher percentage (18.1%) for BRCA1 mutation carriers 
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and lower percentage (15.2%) for BRCA2 gene mutation carriers. However, my study 
population differred from that of Metcalfe et al., and this difference may have influenced 
the results.  
Research Question 1 
My first research question was aimed at the relationship between the dependent 
variable, time to diagnosis of second primary cancers (colorectal, endometrial, cervical, 
kidney, thyroid, and bladder) and the independent variable of BRCA gene mutation 
status.  
Survival analysis. As shown in Tables 9, 10, and 11, after analyzing the 
relationship between breast cancer mutation genes, BRCA1, BRCA2, and BRCA both 1 
and 2 and time to diagnosis of second primary cancers, I found the overall median time to 
diagnosis was 14 years. The log-rank test of equality for each of the three BRCA 
mutation statuses did not demonstrate a statistical significance (BRCA1 = 0.797, p = 
0.372; BRCA2 = 1.808, p = 0.179, and BRCA both 1 and 2 = 0.001, p = 0.972). 
Similarly, after stratification of the breast cancer by BRCA status both 1 and 2 as shown 
in Table 12, the overall median time to diagnosis of a second primary cancer was 14 
years. It may take an average of 14 years for a person with either or both of the BRCA 
gene mutations to be diagnosed with second primary cancers in the study population. 
Further, there was no relationship between BRCA1, BRCA2, and BRCA both 1 and 2 
and time to diagnosis of second primary cancers (colorectal, endometrial, cervical, 
kidney, thyroid or bladder) among women with breast cancer. Similarly, after 
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stratification of breast cancer (without gene mutation) by BRCA both 1 and 2, the median 
time to diagnosis of second primary cancers remained 14 years. My study findings of no 
relationship between BRCA1, BRCA2, and BRCA both 1 and 2 and time to diagnosis of 
second primary cancers were not consistent with Mocci et al.’s (2013) study that applied 
survival analysis using the time in years from birth to diagnosis of pancreatic cancer after 
initial breast cancer diagnosis in a BCFR study cohort, likely because my study sample 
did not include women without the mutation as a comparison. Mocci et al. observed a 
relationship and increased risk of second primary pancreatic cancer diagnosis in BRCA-
mutation-related breast cancer patients. Moreover, Mocci et al.’s study was not designed 
to study time to diagnosis of second primary cancers using the composite endpoints, but 
rather to examine the risk for developing second primary cancers. 
Kaplan Meier analysis. The KM’s survival curves confirmed my observations 
that the median time to event for BRCA1, BRCA2, and BRCA status both 1 and 2 were 
the same at 14 years respectively (Figures, 3, 4, and 5). Similarly, after stratification, the 
KM’s survival curve suggested the median time to event of 14 years as demonstrated in 
Figures 6 and 7.  
Cox Proportional Hazards model. I performed a Cox regression analysis to 
estimate the hazard ratio for the breast cancer gene mutations, BRCA1, BRCA2, and 
BRCA both 1 and 2. CPH provides hazard ratios, which are defined as an estimate of the 
ratio of the hazard rate in patients with BRCA and non-BRCA breast cancer (Table 13). 
The hazard rate represents the likelihood that if the event in question has not already 
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occurred, it is expected to occur in the next time interval, divided by the length of the 
interval (Spruance et al., 2004). KM curves were used to confirm the assumption of 
proportionality needed to use CPH.  
BRCA1/ BRCA both 1 and 2. The hazard ratio associated with BRCA1 was 0.781 
with CI [0.529 – 1.17]. This result is not statistically significant. This means that over 16 
years of follow-up, the hazard for second primary cancers risk among patients diagnosed 
of BRCA1 gene mutations was 7.8 times higher than those not diagnosed with breast 
cancer. Further, my study result means there is no relationship between BRCA1 gene 
mutation and risk of diagnosis of second primary cancers when compared to BRCA2 
mutations. The hazard ratio of BRCA both 1 and 2 was 0.891 with CI [0.53 – 1.50]. This 
is not a statistically significant result. This means that over 16 years of follow-up, the 
hazard for second primary cancers risk among patients diagnosed of BRCA1 gene 
mutations was 8.9 times higher than those not diagnosed with breast cancer. My study 
results also demonstrated no relationship between BRCA both 1 and 2 gene mutation and 
risk of diagnosis of second primary cancers. Therefore, I failed to reject the null 
hypothesis of no relationship between BRCA1/BRCA both 1 and 2 and time to diagnosis 
of second primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, 
among women with breast cancer. These findings are not consistent with the conclusion 
of Kadouri et al. (2007) that there is an association between BRCA gene mutations and 
diagnosis of second cancers. Kadouri et al. (2007) observed  a 2.5‐fold increase in any 
other cancer and a fourfold risk of colon cancer among BRCA1 carriers. The 
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corresponding hazard ratios in BRCA2 carriers were non‐significant, except for the 
markedly elevated risk of lymphoma. Their findings suggest a role for BRCA1/2 
mutations in colorectal cancer risk in a subgroup of breast cancer/ovarian cancer‐affected 
carriers. None of the women with a BRCA2 mutation were diagnosed with uterine 
cancer. These data suggest that BRCA1 may be responsible for an increased risk of an 
aggressive form of uterine cancer, but there is insufficient data on the potential 
relationship to endometrial cancer. The study was not designed to look at time to 
diagnosis of second primary cancers in a population with breast cancer.  
BRCA2. The hazard ratio associated with BRCA2 was 1.471 with CI [1.03 – 
2.11].  This result is statistically significant. This means that over 16 years of follow-up, 
the hazard for second primary cancers risk among patients diagnosed of BRCA1 gene 
mutations was 14.7 times higher than those not diagnosed with breast cancer. Further, my 
study result means there is a relationship between BRCA2 gene mutation and risk of 
diagnosis of second primary cancers. Therefore, I rejected the null hypothesis of no 
relationship between BRCA2 and time to diagnosis of second primary cancers, 
colorectal, endometrial, cervical, kidney, thyroid, and bladder. This result confirms 
literature (Shu et al., 2014; Al-Mulla et al., 2009; Johannesdottir et al., 1996) regarding 
BRCA2 as a potential risk factor to diagnosis of second primary cancers. My research 
result goes further not only to determine the relationship between BRCA2 and second 
primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, among 
women with breast cancer, but also examined the median time to event. The median time 
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to event as observed in all the BRCA gene mutation statuses and diagnosis of second 
primary cancers was 14 years. This provides additional insight pertaining to what was 
known previously about BRCA2 as a risk factor for second primary cancers among 
women diagnosed with breast cancer in susceptible populations.  
Similarly, a recent study that used survival analysis CPH investigated the 
association between germline mutation in BRCA1 or BRCA2 and ten years of survival 
among women with epithelial ovarian cancer diagnosis (Candido-dos-Reis et al; 2015). 
Candido-dos-Reis and colleagues aim was to analyze the effect of germline mutations in 
BRCA1 and BRCA2 on mortality in patients with ovarian cancer up to 10 years after 
diagnosis. The researchers used unpublished survival time data for 2,242 patients from 
two case-control studies and extended survival time data for 4,314 patients from 
previously reported studies (Candido-dos-Reis et al., 2015). Survival time was analyzed 
for the combined data using CPH with BRCA1 and BRCA2 as time-varying covariates. 
Competing risks were analyzed using Fine and Gray model. The hazard ratio (HR) for 
BRCA1 was 0.53 at time zero and increased over time becoming greater than one at 4.8 
years. For BRCA2, the HR was 0.42 at time zero and increased over time (predicted to 
become greater than 1 at 10.5 years) (Candido-dos-Reis et al., 2015). Unlike my study, 
the above study mainly employed survival analysis in BRCA1 or BRCA2 and ten-year 
survival for women diagnosed with epithelial ovarian cancer. The researchers did not 
investigate other potential cancer sites and the time to diagnosis of second primary 
cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, among women 
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with breast cancer. My study further extends knowledge in the discipline by using the 
KM’s analysis and CPH model to examine relationship between several risk factors such 
as BRCA status, and time to diagnosis of second primary cancers, colorectal, 
endometrial, cervical, kidney, thyroid, or bladder, among women with breast cancer. 
Therefore, in addition to the large risks of ovarian and breast cancers observed by 
Candido-dos Reis et al. (2015), my study finding confirms that BRCA2 may have a 
relationship with increased risk of second primary cancers, colorectal, endometrial, 
cervical, kidney, thyroid, or bladder, among women with breast cancer in a susceptible 
population. 
The conceptual framework for Research Question 1 was based on literature 
showing that certain subsets of BRCA related breast cancer patients may have 
demonstrated elevated risk of developing second primary cancers (Menes et al., 2015; 
Brose et al., 2002). Menes and colleagues followed 800 women diagnosed with breast 
cancer from the Breast Cancer Family Registry (BCFR) who were carriers of a BRCA1 
or BRCA2 pathogenic mutation or a variant of unknown clinical significance and 
estimated the 10-year cumulative risk of second primary breast cancer including more 
testing information on family members (Menes et al., 2015). In addition, Brose et al. 
(2002) observed a two-fold increased risk of colon cancer, threefold risk of pancreatic 
cancer, fourfold risk of stomach cancer, and 120-fold increased risk of fallopian tube 
cancer among BRCA1 mutation carriers with breast cancer (Brose et al., 2003). In this 
study, I have shown that BRCA1 and BRCA both 1 and 2 gene mutations in breast cancer 
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patients may not be related to risk of diagnosis of second primary cancers, colorectal, 
endometrial, cervical, kidney, thyroid, or bladder. This is a notable finding. I have also 
demonstrated that there is a positive association between BRCA2 gene mutation in breast 
cancer patients and risk of diagnosis of second primary cancers, colorectal, endometrial, 
cervical, kidney, thyroid, or bladder. H01 was: There is no relationship between BRCA 
mutation status and time to diagnosis of second primary cancers, colorectal, endometrial, 
cervical, kidney, thyroid, or bladder, among women with breast cancer. HA1 was: There is 
a relationship between BRCA mutation status and time to diagnosis of second primary 
cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, among women 
with breast cancer. Therefore, there was sufficient statistical rigor to assert the strength of 
no relationship between the BRCA1/BRCA both 1 and 2 gene mutations among patients 
with breast cancer and time to diagnosis of second primary cancers. In addition, there was 
also sufficient statistical rigor to assert the strength of a relationship between the BRCA2 
gene mutation among patients with breast cancer and time to diagnosis of second primary 
cancers. There was also sufficient statistical power to maintain the negative associations 
between the presence of the BRCA1/BRCA both 1 and 2 gene mutations and BRCA2 
positive association  and second primary cancers, colorectal, endometrial, cervical, 
kidney, thyroid, or bladder were not the result of chance alone. Thus, I failed to reject the 
null hypothesis of relationship between BRCA1/BRCA both 1 and 2 gene mutations and 
the time to diagnosis of second primary cancers. In addition, the null hypothesis of no 
relationship between BRCA2 gene mutation and time to diagnosis of second primary 
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cancers was rejected. This suggest there may not be any relationship between 
BRCA1/BRCA both 1 and 2 gene mutations status and  risk of diagnosis of second 
primary cancers, and there may be a relationship between BRCA2 gene mutation and risk 
of diagnosis of second primary cancers, colorectal, endometrial, cervical, kidney, thyroid, 
or bladder, among patients with breast cancer. 
Research Question 2  
My second research question aimed at the relationship between the dependent 
variable time to diagnosis of second primary cancers, colorectal, endometrial, cervical, 
kidney, thyroid, or bladder, among patients with BRCA related breast cancer and the 
independent variables of race/ethnicity and age at diagnosis. 
Survival analysis.  I presented in Table 14, Table 15, Table 16 and Table 17 
analyses of the relationship between race/ethnicity and age at diagnosis and time to 
diagnosis of second primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or 
bladder among women with BRCA-related breast cancer. I observed that the overall 
median time to diagnosis of a second primary cancer was 14 years as observed in other 
variables. The log-rank test of equality for race/ethnicity showed statistical significance 
(race/ethnicity = 29.482, with p = 0.000). The Spearman correlation coefficient rs for age 
groups did not demonstrate any statistical significance (rs= 0.026, p = 0.487) as well as 
the Spearman correlation coefficient rs for age in a continuous form (rs= 0.018, p = 
0.627). This means that it may take an average of 14 years for an individual of White, 
Black, American I/H or Asian race to be diagnosed with second primary cancers in the 
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study population. Further, there is a relationship between race/ethnicity and time to 
diagnosis of second primary cancers, colorectal, endometrial, cervical, kidney, thyroid or 
bladder, among women with breast cancer. My result is consistent with the the 
observation of Al-Mulla et al. (2009) in their cohort study that used survival analysis and 
found a significant association in Yorkshire and Humberside, United Kingdom families 
with breast and/or ovarian cancer and BRCA1 or BRCA2 mutation and the occurrence of 
a second cancer including vaginal, colon, prostate, and pancreatic. My study differs from 
Al-Mulla et al. study in that my study involved many races/ethnicities whereas Al-Mulla 
et al. study only involved the White population. My study age groups as noted also in 
race/ethnicity variable presented an average time of 14 years for diagnosis of second 
primary cancers in the study population. Further, the age groups result also showed that 
there is no association between age groups and time to diagnosis of second primary 
cancers. This finding was not consistent with Al-Mulla et al. (2009) study that 
demonstrated a positive association between age at diagnosis (median age of 55 years) 
and second primary cancers among the study participants with BRCA1/BRCA2 related 
breast cancer. My study result may not be generalized in that it is limited to the data in 
the BCFR data set and the study population. 
Kaplan Meier analysis. The KM’s survival curves of race/ethnicities and age 
groups showed that the overall median time to event for race/ethnicity and age groups are 
the same at 14 years respectively as demonstrated in Figures 7 and 8. 
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Cox Proportional Hazards model. I performed a CPH analysis to estimate the 
hazard ratio for race/ethnicity and age groups. CPH provides hazard ratios, which are 
defined as an estimate of the ratio of the hazard rate in patients with different 
races/ethnicities (White, Black, American I/H, and Asian) and age groups as shown in 
Table 17. The hazard rate represents the likelihood that if the event in question has not 
already occurred, it is expected to occur in the next time interval, divided by the length of 
the interval (Spruance, Reid, & Samore, 2004). The KM’s curves were used to confirm 
the assumption of proportionality. 
Race/Ethnicity. The hazard ratios associated with race/ethnicity are White, 1.511 
with CI [1.18 – 1.94], Black, 0.647 with CI [0.23 -1.67], and American I/H, 1.424 with 
CI [1.12 – 1.81]. This result is statistically significant for the White and American I/H 
races/ethnicities, but not statistically significant for Black race. There was no result 
generated for the Asian race/ethnicity. This implies that both White and American 
Indians and Hawaiians (though there are really too few of both to have any meaningful 
results that are significantly different), but that Blacks and Asians are not. Further, this 
means that over 16 years of follow-up, the hazard for second primary cancers risk among 
White and American I/H patients was 15.1 times and 14.2 times respectively higher than 
those not diagnosed with breast cancer. The results also mean that over 16 years of 
follow-up, the hazard for second primary cancers risk among Black race/ethnicity was 
6.5%. Further, my study result means there is a relationship between race/ethnicity 
(White and American I/H) and risk of diagnosis of second primary cancers. The 95% CI 
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of Black race result demonstrated no relationship between race/ethnicity (Black and 
Asian, though Asian data was not generated after running the CPH as shown in Table 17) 
and risk of diagnosis of second primary cancers. Therefore, I rejected the null hypothesis 
of no relationship between race/ethnicity (White and American I/H) and time to diagnosis 
of second primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, 
among women with breast cancer. I also failed to reject the null hypothesis of no 
relationship between race/ethnicity (Black) and time to diagnosis of second primary 
cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder, among women 
with breast cancer. My study result is consistent with the study of Al-Mulla et al. (2009) 
that noted an association between second primary cancers and BRCA1/BRCA2 related 
breast cancer in White English Yorkshire/Humberside population. Similarly, it is also 
consistent with Mocci et al. (2013) study that found a higher risk of developing a second 
primary cancer in White women with BRCA1/BRCA2 related breast cancer families 
from the breast cancer family registry. My study and Mocci et al. (2013) used the same 
BCFR database. A majority of the study participants were of the White race/ethnicity. 
The Mocci et al.’s study was limited in that it did not examine second primary cancer risk 
estimates based on a larger variety of ethnic groups. 
Differences in race/ethnicity do, however, appear to affect the diagnosis of breast 
cancer and second primary cancers (Al-Mulla et al., 2009; Beiner et al., 2007).Few 
studies have been done that explored the relationship between Native-American and 
Hawaiian races/ethnicities and BRCA1/BRCA2 gene mutations as risk factors for breast 
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cancer. During this study, I did not locate any published article about American I/H and 
risk for second primary cancer diagnosis among women with BRCA- related breast 
cancer. According to Jardines et al. (2015), breast cancer risk is extremely low in 
American Indian (Native-American) women. Fred Hutch.org (2016) suggested that 
nationwide, American Indians and Alaska Natives generally have lower reported rates of 
cancer than all other racial groups, but those rates have been increasing in recent years, 
according to U.S. government data. In addition, these numbers may be underreported 
because of past flaws in collecting this information. However, of all racial and ethnic 
groups in the United States, American Indians and Alaska Natives have the poorest 
survival rates for all types of cancer combined (Fred Hutch.org, 2006). Death rates from 
breast cancer disease, however, were higher than Hispanics and Asian Americans/Pacific 
Islanders as reported by the NCI between 2002 and 2006 (Fred Hutch.org, 2016).  
More research needs to be done in order to examine Native-American and 
Hawaiian women and associated risk for BRCA-related breast cancer in susceptible 
populations. My study provides additional insight by exploring various risk factors and 
time to diagnosis of second primary cancers, including colorectal, endometrial, cervical, 
kidney, thyroid, or bladder, among women with BRCA-related breast cancer. The fact 
that BRCA-related breast cancer is more common among the White race than the other 
races/ethnicities (Mocci et al., 2013; Dite et al., 2010; Neil et al., 2004; Thompson & 
Easton, 2002; Johannesdottir et al., 1996) supports my conclusion that second primary 
cancer may be dependent on BRCA-related breast cancer among susceptible racial/ethnic 
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populations. For these reasons, it is possible that the risk of diagnosis of second primary 
cancers may be confounded by race/ethnicity. 
My result of no association between risk of diagnosis of second primary cancers 
and Black race seems to be consistent with the findings of Newman et al. (1998) and 
suggests that the incidence of BRCA mutations might be lower among breast cancer 
patients of African American ancestry.  Newman et al. in their population-based study 
that included 99 women of African origin with breast cancer failed to find any disease 
related BRCA mutations in any of the women. Pal, Permuth-Wey, Holtje, and Sutphen 
(2004), had argued that sufficient empirical data may be helpful in estimating mutation 
risk among women of Black race/ethnicity. Further, my study finding of no association 
between risk of diagnosis of second primary cancers and Asian race/ethnicity was not 
consistent with Sing et al. (2000) who reported BRCA as a risk factor of second primary 
cancers among Asian populations with breast cancer. My study findings may have been 
impacted by the dominant White race (including the Ashkenazi Jews) among the study 
participants recruited from the various BCFR sites. Therefore, it may not be necessary to 
generalize my findings, because it is limited to the study population used for the study. 
Age. The hazard ratios associated with age groups include <46 years at 95% CIs, 
0.942 [0.76 – 1.17] and 47-56 years at 95% CIs, 0.925 [0.76 – 1.13]. These results are not 
statistically significant for any of the age groups. Further, these results failed to show an 
association between age groups and risk of diagnosis of second primary colorectal, 
endometrial, cervical, kidney, thyroid, or bladder cancers, among women with BRCA 
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related breast cancer. My study result was not consistent with Beiner et al. (2007) and 
Brose et al. (2002) who suggested age has an association with the diagnosis of second 
primary cancers.  However, the gap between the association of second primary cancer 
diagnosis and age is dialogued with different study findings (Patrucelli, Daly, & 
Feldman, 2011; Al-Mulla et al., 2009). According to Patrucelli et al., there is no clear 
explanation presently for the observation that some individuals with a cancer-
predisposing germline variant (BRCA1/BRCA2) may have multiple primary cancers 
before age 50 years, while others with the same cancer-predisposing germline variant 
may develop cancer only after age 70 years, or not at all. Younger age at diagnosis of 
BRCA related breast cancer have been proposed to show association with second primary 
cancers in a susceptible population (Mocci et al., 2013; Brose et al., 2002; Johannesdottir 
et al., 1996). Mocci et al. (2013) demonstrated that the women diagnosed with a BRCA 
mutation related breast cancer before 50 years of age were at a higher risk of developing 
a second cancer. The study was limited in that it examined only pancreatic cancer and no 
other second primary cancer risk estimate based on many ethnic groups. Additionally, 
Brose et al. (2002) investigated BRCA1-related cancer risks for individuals ascertained in 
a breast cancer risk evaluation clinic. Brose and colleagues found by age 70, female 
breast cancer risk was 72.8%, the risk for developing a second primary breast cancer by 
age 70 was 40.5%, a two-fold increased risk of colon cancer, threefold risk of pancreatic 
cancer, fourfold risk of stomach cancer, and 120-fold increased risk of fallopian tube 
cancer among BRCA1 mutation carriers with breast cancer (Brose et al., 2002). Similarly, 
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a Taiwanese breast cancer population demonstrated the peak incidence of diagnosis of 
second cancer was among women in their 40s, with approximately 2% developing a non-
breast second primary cancer, with an average survival time of 2.87 years after the 
second cancer diagnosis (Lee et al., 2008). Therefore, there remains a gap in the literature 
between association of age at diagnosis and time to diagnosis of second primary cancers 
among patients with BRCA-related breast cancer. My findings suggest that recognizing 
differences in age at diagnosis is important to developing the most appropriate screening 
and follow-up procedures. 
The conceptual framework for Research Question 2 focused on the existing 
literature showing certain subsets of BRCA gene mutation related breast cancer patients 
may have demonstrated elevated risk of developing second primary cancers with 
race/ethnicity and age at diagnosis (Mocci et al., 2013; Brose et al., 2002). Al-Mulla et al. 
(2009) reported of identifying 14 new BRCA1/BRCA2 gene mutations among the 
Yorkshire/Humberside population and their association with second primary cancers. 
Similarly, Youlden & Baade (2011) found in a retrospective cohort study conducted in 
Queensland, Australia, that the highest proportion of second primary cancers occurred 
after initial diagnosis of female breast cancer (12.6%). The second primary cancers 
observed in their study included, pancreatic, colorectal, endometrial, cervical, thyroid, 
kidney, and bladder cancers (Youlden & Baade, 2011). This study did not assess BRCA 
status. Similarly, Kmet et al. (2003) found that incidence of colorectal cancer was 
associated with a family history of breast cancer, high body mass index and lobular breast 
162 
 
 
 
cancer histology. I have shown that race/ethnicity (White and American I/H) among 
BRCA gene mutation related breast cancer patients is associated with the risk to 
diagnosis of second primary cancers, colorectal, endometrial, cervical, kidney, thyroid, or 
bladder. My study did not show any association between Black and Asian races and the 
time to diagnosis of second cancers, among patients with BRCA-related breast cancer. 
These are important findings. I have also demonstrated that there is no positive 
association between age at diagnosis among BRCA gene mutation-related breast cancer 
patients and risk to diagnosis of second primary cancers, colorectal, endometrial, 
cervical, kidney, thyroid, or bladder. HA2a was: There is a relationship between ethnicity 
and time to diagnosis of second primary cancers, colorectal, endometrial, cervical, renal, 
thyroid, or bladder, among women with BRCA-related breast cancer. H02a was: There is 
no relationship between ethnicity and time to diagnosis of second primary cancers, 
colorectal, endometrial, cervical, renal, thyroid, or bladder, among women with BRCA-
related breast cancer. The H02b was: There is no relationship between age status and time 
to diagnosis of second primary cancers, colorectal, endometrial, cervical, renal, thyroid, 
or bladder, among women with BRCA-related breast cancer. Therefore, there was 
sufficient statistical rigor to assert the strength of a positive relationship between 
race/ethnicity (White and American I/H) and time to diagnosis of second primary 
cancers, among women with BRCA-related breast cancer. There was also sufficient 
statistical rigor to maintain the negative associations between Black and Asian races, age 
at diagnosis and time to diagnosis of second primary cancers, among women with 
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BRCA-related breast cancer. In addition, there was also sufficient statistical power to 
maintain the positive associations between the presence of White and American I/H 
positive association, and age at diagnosis and second primary cancers, colorectal, 
endometrial, cervical, kidney, thyroid, or bladder were not the result of chance alone. 
Thus, I rejected the null hypothesis of no relationship between race/ethnicity and the time 
to diagnosis of second primary cancers. In addition, the null hypothesis of no relationship 
between age at diagnosis and time to diagnosis of second primary cancers was not 
rejected. This suggests there may be a relationship between race/ethnicity and time to 
diagnosis of second primary cancers, and there may not be a relationship between age at 
diagnosis and time to diagnosis of second primary cancers, colorectal, endometrial, 
cervical, kidney, thyroid, or bladder, among women with BRCA-related breast cancer.  
 I presented in Table 21 and table 22 analyses of the relationship between 
smoking and BRCA1/BRCA2 family history and time to diagnosis of second primary 
cancers, colorectal, endometrial, cervical, kidney, thyroid, or bladder among women with 
BRCA-related breast cancer. I observed that the overall median time to diagnosis of a 
second primary cancer for smoking variable was 14 years as observed in other variables. 
The log-rank test for smoking status was 1.844, and p = 0.174 and did not show any 
statistical significance.  
Similarly, BRCA1/BRCA2 family history presented an overall median time to 
event of 14 years.  The log-rank test for BRCA1 family status was 14.116, with p = 
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0.000, while the log-rank test for BRCA2 family status was 11.359, with p = 0.001. Both 
BRCA1 family status and BRCA2 family history results are statistically significant.  
This means that it may take an average of 14 years for an individual with a 
positive smoking history to be diagnosed with second primary cancers in the study 
population. The log-rank test result means, there is no relationship between smoking 
history and time to diagnosis of second primary cancers, colorectal, endometrial, cervical, 
kidney, thyroid or bladder, among women with breast cancer. This result was not 
consistent with the observations of Le et al. (2011) and Ginsberg et al. (2009) that 
smoking is associated with breast cancer and also increases breast camcer risk in people 
diagnosed with BRCA1 or BRCA2 gene mutations. My study also noted in 
BRCA1/BRCA2 family history variables an average time of 14 years for diagnosis of 
second primary cancers in the study population. This means it may take an individual 
with BRCA1/BRCA2 family history an average of 14 years to be diagnosed with second 
primary cancer. The statistical significance of my result pertaining to BRCA1/BRCA2 
family history show that there is a relationship between BRCA1/BRCA2 family history 
and time to diagnosis of second primary cancers, colorectal, endometrial, cervical, 
kidney, thyroid or bladder, among women with breast cancer. My result is consistent with 
the the observation of Al-Mulla et al. (2009) cohort study that used survival analysis and 
found a significant association in Yorkshire and Humberside, United Kingdom families 
with breast and/or ovarian cancer and BRCA1 or BRCA2 mutation and the occurrence of 
a second cancer including vaginal, colon, prostate, and pancreatic. My study differs from 
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Al-Mulla et al. study in that my study involves BRCA1/BRCA2 family history from 
many countries, whereas the Al-Mulla et al. study only involved the United Kingdom 
families’ population. My study result may not be generalized, in that it is limited to the 
data in the BCFR data set and the study population. 
Kaplan Meier analysis. The KM’s survival curves for smoking and BRCA1 and 
BRCA2 family history show that the overall median time to event for race/ethnicity and 
age groups are the same at 14 years respectively as demonstrated in Figures 9 and 10 and 
11. 
Cox Proportional Hazards model. I performed a CPH analysis to estimate the 
hazard ratio for smoking and BRCA1 and BRCA2 family history. CPH provides hazard 
ratios, which are defined as an estimate of the ratio of the hazard rate in patients with 
smoking history and BRCA1 and BRCA2 family history as shown in Table 23. The 
hazard rate represents the likelihood that if the event in question has not already occurred, 
it is expected to occur in the next time interval, divided by the length of the interval 
(Spruance, Reid, & Samore, 2004). The KM’s curves were used to confirm the 
assumption of proportionality. 
Smoking. The hazard ratio of smoking at 95% CI, was 1.086 [0.94 – 1.26]. This is 
not a statistically significant result. This result infers that participants with smoking 
history are less likely to be diagnosed with second primary cancers, colorectal, 
endometrial, cervical, kidney, thyroid, or bladder. This means for over 16 years of 
follow-up, the hazard ratio for second primary cancers risk among smokers was 10.9 
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times higher than those not diagnosed with breast cancer. This finding did not confirm 
literature that smoking history is implicated as a risk factor of breast cancer and other 
cancers (Le et al; 2011; Le et al., 2006). Individuals that carry BRCA1 or BRCA2 gene 
mutations have increased risk of developing breast cancer (Ginsberg et al., 2009; Russo, 
2002). However, smoking seems not to appear as a risk factor for BRCA1 and BRCA2 
germline pathogenic variant related breast cancer (Ginsberg et al., 2009). It has also been 
hypothesized that smoking may even lower breast cancer risk among BRCA1 and 
BRCA2 gene mutation carriers (Greer & Whitcomb, 2007). The reduction in breast 
cancer incidence specific to BRCA1 and BRCA2 mutation positive smokers was 
hypothesized to be associated with the effect that cigarette smoking has on estrogen 
levels. Cancer risk in BRCA1 and BRCA2 mutation carriers peaks at about age 40–45 
years, when estrogen levels are still high before the majority of women experience 
menopause, and then declines, in contrast with the general population in which the risk 
steadily increases throughout the life course (Narod, 2001). I have demonstrated in this 
study that smoking among women diagnosed with BRCA gene mutation related breast 
cancer is not associated with risk of diagnosis of second primary cancers, colorectal, 
endometrial, cervical, kidney, thyroid, or bladder. Further empirical studies are needed in 
order to draw a conclusion pertaining to the relationship between smoking and 
association with second cancers among women diagnosed with BRCA-related breast 
cancer. This will be useful for screening and early treatment for women who may be at 
risk in the affected population. 
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BRCA1/BRCA2 family history. My study multivariate CPH analyses showed the 
hazard ratios at 95% CI for BRCA1 family history = 1.193 [0.95 – 1.51] and BRCA2 
family history = 1.086 [0.86 – 1.38].  This is not a statistically significant result. This 
result infers that over 16 years of follow-up, the hazard ratio for second primary cancers 
risk among women with BRCA1/BRCA2 family history were 11.9 times and 10.86 times 
respectively higher than those not diagnosed with breast cancer. My study CPH result 
corroborates the results of Niell, et al. (2004). Niell and colleagues genotyped a northern 
Israeli population for the BRCA1 187delAG, BRCA1 5385insC, and BRCA2 6174delT 
founder mutations. A family history of breast cancer in a female relatives was not 
associated with an increased risk of colorectal cancer, even after adjustment for the 
presence of a BRCA founder mutation. Ashkenazi BRCA founder mutations may not 
confer a strong high risk of colorectal cancer and do not seem to be risk factor for 
colorectal cancer in that population (Niell et al., 2004). On the contrary, my study finding 
is not consistent with Shih et al.’s (2000) study that examined BRCA1 and BRCA2 
mutations in Breast Cancer Families with Multiple Primary Cancers and observed that 
BRCA1 and BRCA2 mutations were twice as common in the presence of a reported 
second non-ovarian cancer. Shih et al. (2000) in their cohort study that examined 98 
women with BRCA1 and BRCA2 mutations in Breast Cancer Families with Multiple 
Primary Cancers noted fifteen families with colorectal cancer as the second primary, 
endometrial and cervical cancers were reported as the second primaries in eight families 
each, and thyroid cancers were reported in seven families. On the premise of these two 
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studies and my study result, it is clear that my study not only attempted to explore the 
relationship between BRCA1/BRCA2 family history and second primary cancers, but 
went further to examine the time to diagnosis of second primary cancers, colorectal, 
endometrial, cervical, kidney, thyroid, or bladder, among women with BRCA-related 
breast cancer. More studies with larger sample size and families from diverse populations 
may be needed to examine the association between BRCA1/BRCA2 family status as risk 
factors and time to diagnosis of second primary cancers in susceptible populations. I have 
demonstrated in this study that there is not a positive association between 
BRCA1/BRCA2 family history and the time to diagnosis of second cancers, among 
patients with BRCA-related breast cancer. More studies with larger sample size and 
families from diverse populations may be needed to examine the association between 
BRCA1/BRCA2 family status as risk factors and time to diagnosis of second primary 
cancers in susceptible populations. 
The conceptual framework of this study relied upon genetic fundamental 
principles and published empirical data that support a mechanism of action for BRCA 
gene mutations in breast and other cancers. Smoking is implicated as a risk factor for 
breast cancer and other cancers (Le et al., 2011; Le et al., 2006). Individuals that carry 
BRCA1 or BRCA2 gene mutations have increased risk of developing breast cancer 
(Ginsberg et al; 2009; Russo, 2002). BRCA1 or BRCA2 family his may serve as a risk 
factor of second primary cancer.  There was little information in the literature regarding 
the length of time to the diagnosis of a second, primary, non-breast cancer after a BRCA 
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related breast cancer diagnosis. Therefore, I identified smoking history, BRCA1 and 
BRCA2 family history as important factors to examine pertaining to time to diagnosis of 
second primary cancers. The inclusion of colorectal, endometrial, cervical, kidney, 
thyroid, and bladder cancers as dependent variables were selected based on data 
availability. 
Limitations of the Study 
This study was limited to the data available in the dataset. One limitation of this 
study was the non-availability of data from all 50 states in the BCFR databases. Another 
potential limitation was inherent to the size of the dataset. I originally intended to analyze 
only pancreatic and colorectal cancer as second primary cancers, but due to insufficient 
sample size and inclusion criteria, no subjects with pancreatic cancer were included. I 
used two cohorts instead of the initial intended three cohorts to answer my research 
questions. Unfortunately, no gender comparison was done because no male data was 
observed in the BCFR data set used. Here, gender may have served as a potential 
unmeasurable confounder because only the female gender was used for this study. In this 
study, the use of composite endpoints approach was used in defining events. Maybe a 
different result would have been observed if the events were analyzed individually based 
on the second primary sites studied. Despite composite end points may increase the study 
statistical power due to increase of the event rate, they may mislead if composite end 
points are of widely differing importance to patients, the number of events in the 
components of greater importance is small, and the magnitude of effect differs 
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considerably across components (Montori et al; 2005). Another potential limitation of 
using the composite endpoint in assessing risk is that if the study variable components are 
unreasonably combined or inconsistently defined, it may lead to inadequate reporting of 
result (The University of Texas Health Science Center, 2016). Further, not all family 
registry participants provided a blood sample for BRCA gene mutation testing, thus 
raising concern about potential selection bias. Recall bias related to family history may 
impact responses provided by the study participants when completing the questionnaire. 
Further, analyses of relationships among variables were limited by what information that 
were collected originally. It was not possible for me to gain additional information about 
the subjects in the cohorts, such as other genetic or non-genetic risk factors. This lack of 
information on women without the BRCA gene mutation may have limited a comparative 
analysis with those diagnosed with the BRCA gene mutation. My study findings may not 
be generalized because they are based on the BCFR data set used for the study and the 
study population. 
Recommendations for Further Research 
The NCI-BCFR database included registry data from three countries: Australia, 
Canada, and the United States.  Four out of the six sites are located in the United States 
(California, New York, Pennsylvania, and Utah). Future studies could benefit from 
examining other geographical regions, to further elucidate the relationship between 
different risk factors and time to diagnosis of second primary cancers among women with 
BRCA-related breast cancer. Future studies that examine BRCA mutations and second 
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primary cancers in different populations could also look at potentially important 
confounders for cancer, such as gender, nutritional status, other genes, or radiation 
therapy status. Alternative study methodologies, such as a mixed method study design 
may provide additional information on factors that influence the time to diagnosis, such 
as attitudes and beliefs of clinicians and breast cancer patients regarding screening for 
second primary cancers. The findings of the study have potential implications to 
recommend for early screening for second primary cancers in high-risk breast cancer 
families.  
Implications for Social Change 
This study advanced the understanding of the relationship between BRCA gene 
mutations and time to diagnosis of second primary colorectal, endometrial, cervical, 
kidney, thyroid, and bladder cancer among women with breast cancer. The importance of 
early detection of a second cancer in this population is undeniable and has implications 
for treatment and recovery. My result finding of positive association between BRCA2 
gene mutation and risk of diagnosis of second primary cancers and also between ethnicity 
and time to diagnosis of second primary cancers will be helpful to clinicians by providing 
early screening/testing for second cancers among women in the susceptible populations. 
Prophylactic surgery, which may occur before cancer is detected, remains an option for 
women who carry BRCA1 and BRCA2 mutations. This is usually done by surgically 
removing as much “tissue at risk” as possible with the option of bilateral mastectomy 
(removal of both breasts) (NCI, 2012). However, this approach may not be practical for 
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non-breast cancer. Chemoprevention has been used extensively in delaying the 
recurrence and reducing risk of cancer. Chemoprevention therapy involves the use of 
drugs, vitamins and other agents in cancer treatment (NCI, 2014). Understanding the 
factors associated with time to development of a second cancer allows for more and 
better options to be determined.  
In this study, the overall median time to event for diagnosis of a second primary 
colorectal, endometrial, cervical, kidney, thyroid, or bladder cancer among women who 
had been diagnosed with breast cancer was 14 years. Race/ethnicity as a risk factor also 
shows White and American I/H have increased likelihood of being diagnosed with 
second primary cancers compared to other races in the study population. Thus, for over 
16 years of follow-up, the risk for second primary cancers among White and American 
I/H races diagnosed with BRCA gene mutation related breast cancer were 15.1 times and 
14.2times respectively higher than those not diagnosed with breast cancer. These data 
provide important information for health care providers of patients with BRCA 
mutations, to know better who is at risk for a second cancer and how long it may take to 
develop. Further, data on risk factors for development of second cancers would allow for 
identification of appropriate and timely screening procedures, determining the best course 
of action for prevention and treatment, and improving quality of life among breast cancer 
survivors.  
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Conclusion 
The risk of second primary cancers has been observed among women after initial 
diagnosis of BRCA gene mutation related breast cancer. There is substantial evidence 
that BRCA gene mutations are associated with a variety of cancers, including new 
cancers that occur after a diagnosis of breast cancer. This study filled a gap in the 
literature on time to diagnosis of second primary cancers after initial diagnosis with a 
BRCA related breast cancer using the composite endpoint approach. Early detection of 
cancer remains one of the most valuable interventions to improve health outcomes. A 
greater understanding of the risk factors for the development of a second primary cancer 
and the length of time to development of a second primary cancer will allow for positive 
social change through a reduction in morbidity and mortality among women with breast 
cancer. I found the hazard ratios (HRs) for BRCA2 = 1.47, 95% CI [1.03 – 2.11], White 
= 1.511, 95% CI [1.18 – 1.94], and American I/H = 1.424, 95% CI [1.12 – 1.81] showed 
a positive association with time to diagnosis of second primary colorectal, endometrial, 
cervical, kidney, thyroid, and bladder cancers. These data provide useful information for 
risk assessment and therapy strategies, allowing clinicians to develop the most useful 
strategies for their breast cancer patients.  
 
 
 
 
 
174 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
Abeliovich, D., Kaduri, L., Lerer, I., Weinberg, N., Amir, G., Sagi, M.…Zlotogora, J. 
(1997). The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT 
in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer 
patients among Ashkenazi women. American Journal of Human Genetics, 60(3), 
505-14. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/?term=Abeliovich%2C+Kaduri%2C+Lerer
175 
 
 
 
%2C+1997 
Agalliu, I., Karlins, E., Kwon, E. M., Iwasaki, L. M., Diamond, A., Ostrander, E. A., & 
Standford, J. L. (2007). Rare germline mutations in the BRCA2 gene are 
associated with early-onset prostate cancer. British Journal of Cancer, 97(6), 826-
31. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/17700570?dopt=Abstract 
Al-Mulla, F. A., Bland, J. M., Serrat, D., Miller, J., Chu, C., & Taylor, G. T. (2009). Age-
dependent penetrance of different germline mutations in the BRCA1 gene. 
Journal of Clinical Pathology, 62, 350-356. Retrieved from 
http://jcp.bmjjournals.com/content/62/4/350.full 
American Cancer Society. (2014). Cancer facts and statistics. Retrieved from 
http://www.cancer.org/research/cancerfactsstatistics/index 
American Cancer Society. (2015). Endometrial (uterine) cancer. Retrieved from 
http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-
uterine-cancer-what-is-endometrial-cancer 
American Cancer Society. (2003). Breast cancer incidence and mortality among US by 
race, 2001. In S. E. Singletary, G. L. Robb, & G. N. Hortobagyi (2004). Advanced 
therapy of breast cancer (2nd ed.). Hamilton, England: BC Decker Inc. 
American College of Obstetricians and Gynecologists. (2003). Clinical management 
 guidelines for obstetricians-gynecologists. ACOG Practice Bulletin, 45,1–11.  
176 
 
 
 
Althuis, M., Dozier, J. M., Anderson, W. F., Devesa, S. S., & Brinton, L. A. (2005). 
Global trends in breast cancer incidence and mortality 1973–1997. International 
Journal of Epidemiology, 34(2), 405-412. Retrieved from 
http://ije.oxfordjournals.org/content/34/2/405.short 
Amir, A., Moshiro, C., & Kwesigabo, G. (1996). Carcinoma of the male breast: A 
sexually transmitted disease? East African Medical Journal; 73(3), 187-190. 
Retrieved from 
http://www.journals.elsevierhealth.com/medline/record/ivp_0012835X_73_187 
Aschengrau, A., & Seage III, G. R. (2008). Essentials of epidemiology in public health 
(2nd ed.). Sudbury, MA: Jones and Bartlett Publishers. 
Basham, V. M., Lipscombe, J. M., Ward, J. M., Gayther, S. A., Ponder, B. A., Easton, 
D.F.…Pharoah, P. D. (2002). BRCA1 and BRCA2 mutations in a population-
based study of male breast cancer. Breast Cancer Research, 4(1). Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/?term=Basham%2C+Lipscombe%2C+War
d%2C+2002) 
Beckmann, M. W., Picard, F., An, H. X., Van Roeyen, C. R., Dominik, S. I., & Mosny, 
 D. S. (1996). Clinical impact of detection of loss of heterozygosity of BRCA1 and 
 BRCA2 markers in sporadic breast cancer. British Journal Cancer, 73(10), 1220-
 1226. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Beckmann%2C+Picard%2C+An%2C+Van+
 Roeyen%2C+Dominik%2C+Mosny%2C+1996 
177 
 
 
 
.Beiner, M. E., Finch, A., Rosen, B., Lubinski, J., Moller, P., Ghadirian…Lynch, E. F. 
 (2007). The risk of endometrial cancer in women with BRCA1 and BRCA2 
 mutations. A prospective study. Gynecology Oncology, 104(1), 10. Retrieved 
 from http://www.sciencedirect.com/science/article/pii/S0090825806006184 
Bell, D. W., Gore, I., Okinoto, R. A., Godin-Heymann, N., Sordella, R.,   
 Mulloy, R…Sharma, S. V. (2005). Inherited susceptibility to lung cancer   
 may be associated with the T790M drug resistance mutation in EGFR.   
 Nature Genetics, 37, 1315-1316. Retrieved from      
 http://www.nature.com/ng/journal/v37/n12/abs/ng1671.html 
Beiner, M. E., Finch, A., Rosen, B., Lubinski, J., Moller, P., Ghadirian, P…Lynch, H. 
 T. (2007). The risk of endometrial cancer in women with BRCA1 and 
 BRCA2 mutations. A prospective study. Gynecology Oncology, 104 (1), 7-
 10. Retrieved  from 
 http://www.sciencedirect.com/science/article/pii/S0090825806006184 
Bermejo, J. L., & Hemminki, K. (2004). Risk of cancer at sites other than the breast in 
 Swedish families eligible for BRCA1 or BRCA2 mutation testing. Annals of  
 Oncology, 15, 1834-1841. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/15550590 
Bethesda System for reporting cervical/vaginal cytological diagnoses. (1989). National 
Cancer Institute Workshop. JAMA, 262(7), 931-4, 1989. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/2754794?dopt=Abstract 
178 
 
 
 
Blackwood, M. A., Weber B. L. (1998). BRCA1 and BRCA2: from molecular genetics to 
 clinical medicine. Journal of Clinical Oncology, 16, 1969-1977. Retrieved from 
 http://jco.ascopubs.org/content/16/5/1969.abstract?ijkey=ca1d6a277ede80434f61
 6caadc200bd29420835a&keytype2=tf_ipsecsha 
Bloodgood, J. C. (1921). The remaining breast after radical removal of the opposite side 
for carcinoma. In S. E. Singletary, G. L. Robb,, & G. N. Hortobagyi (2004). 
Advanced therapy of breast cancer (2nd ed.). Hamilton, England: BC Decker Inc. 
 Boice, J. D. (2001). Radiation and breast cancer carcinogenesis. Medical Pediatric 
 Oncolology, 36, 508-513. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/11340604 
Bougie, O., & Weberpals, J. I. (2011). Clinical Considerations of BRCA1 and BRCA2 
 mutation carriers. A review. International Journal of Surgical Oncology, 
 2011:374012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17213823 
Boyle, P., Leon, M. E. (2002). Epidemiology of colorectal cancer. British Medical 
 Bulletin, 64 (1), 1-25. doi: 10.1093/bmb/64.1.1. Retrieved from 
 http://bmb.oxfordjournals.org/content/64/1.toc 
Boyle P. (1989). Relative value of incidence and mortality data in cancer 
 research. Recent Results Cancer Research, 114, 41–63. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/2813944?dopt=Abstract 
Breast Cancer Family Registry. (2014). About breast cancer family registries. 
 Retrieved from http://epi.grants.cancer.gov/CFR/about_breast. 
179 
 
 
 
Breast Cancer Family Registry. (2014). Our history. Retrieved from 
 http://www.bcfamilyregistry.org/about-us/our-history 
Breast Cancer.org. (2014). Genetics. Retrieved from 
 http://www.breastcancer.org/risk/factors/genetics 
Brose, M. S., Rebbeck, T. R., Calzone, K. A., Stopfer, K. E., Nathanson, K. L.,&  Weber, 
 J. E. (2002). Cancer risk estimates for BRCA1 mutation carriers identified in a 
 risk evaluation program. Journal of National Cancer Institute, 94, 1365–1372. 
 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12237282 
 Buiatti, E., Crocetti, E., Acciai, S., Gafa, L., Facini, F., Milandri, C., La Rosa, M. 
 (1997). Incidence of second primary cancers in three Italian population-based 
 cancer registries. European Journal of Cancer, 33(11), 1829-1834. Retrieved 
 from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Buiatti+E%2C+Crocetti+E%2C+Ac
 ciai+S%2C+Gafa+L%2C+Falcini+F%2C+Milandri+C%2C+et+al.+Incidence+of
 +second+primary+cancers+in+three+Italian+population-
 based+cancer+registries.+Eur+J+Cancer+1997%3B33%3A1829-34. 
Burke, W., Daly, M., Garber, J., Botkin, J., Kahn, M. J., Lynch, P… McTiernan, A.
 (1997). Recommendations for follow-up care of individuals with an 
 inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics 
 Studies Consortium. In National Cancer Institute. (2014). BRCA1 and BRCA2: 
180 
 
 
 
 Cancer Risk and Genetic Testing. Retrieved from 
 http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA#r17 
Campeau, P. M., Foulkes, W. D., & Tischkowitz, M. D. (2008). Hereditary breast  cancer: 
 New genetic developments, new therapeutic avenues. Human Genetics, 
 124(1):31–42.  Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18575892 
Cancer Facts and Figures (2012). American Cancer Society. Retrieved from 
 http://www.cancer.org/Research/CancerFactsFigures/index. 
Cancer Research UK. (2014). What is secondary breast cancer? Retrieved from  
http://www.cancerresearchuk.org/cancer-help/type/breast-
 cancer/secondary/about/what-is-secondary-breast-cancer  
 Candido-dos-Reis, F. J., Song, H., Goode, E. L., Cunningham, J. M., Fridley, B. L., 
 Larson, M. C. (2015). Germline mutation in BRCA1 or BRCA2 and ten-year 
 survival for women diagnosed with epithelial ovarian cancer. Clinical Cancer 
 Research, 21(3), 652-7. Retrieved from.
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Candido-dos-
 Reis%2C+Song%2C+Goode%2C+Cunningham%2C+Fridley%2C+Larson%2C+
 2015. 
Cappell, M. S. (2008). Pathophysiology, clinical presentation, and management of colon 
 cancer. Gastroenterology Clinics, 37, 1. Retrieved from 
 http://www.mdconsult.com/das/article/body/456440233-
 779/jorg=journal&source=&sp=20501653&sid=0/N/632275/1.html?issn=088985
181 
 
 
 
 53&_returnURL=http%3A//linkinghub.elsevier.com/retrieve/pii/S088985530700
 1264%3Fshowall%3Dtrue#h0700126402 
Cardoso, F., Di, L. A., Lohrisch, C., Bernard, C., Ferreira, F., Piccart, M. J. (2002). 
 Second and subsequent lines of chemotherapy for metastatic breast cancer: what 
 did we learn in the last two decades? Annal of Oncology, 13, 197-207. Retrieved 
 from http://www.ncbi.nlm.nih.gov/pubmed/11885995?dopt=Abstract 
Centers for Disease Control and Prevention. (2014). Gynecologic Cancers: What are the 
 risk factors? Retrieved from 
 http://www.cdc.gov/cancer/uterine/basic_info/risk_factors 
Centers for Disease Control and Prevention. (2003). National Breast and Cervical Cancer 
 Early Detection Program: Summarizing the first 12 years of partnerships and 
 progress against breast and cervical cancer. Retrieved from 
 http://www.cdc.gov/cancer/nbccedp/pdf/national_report.pdf 
Checkoway, H., Pearce, N., Crawford-Brown D. (1989). Research methods in 
 occupational epidemiology. New York: Oxford University Press. 
Chen, W. Y., Colditz, G. A., Rosner, B., Hankinson, S. E., Hunter, D. J., Manson, J. 
 E…Stamfer, M. J. (2002). Use of postmenopausal hormones, alcohol, and risk for 
 invasive breast cancer. 137(10), 798-804. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/12435216 
Chua, T. C., Saxena, A., Chu, F., Zhao, J.,Morris, D. L. (2011). Predictors of cure  after 
 hepatic resection of colorectal liver metastases: an analysis of actual 5- and 
182 
 
 
 
 10-year survivors. In T. Dragovich. (2014). Pancreatic Cancer. Medscape. 
 Retrieved from http://emedicine.medscape.com/article/280605-overview 
Chang-Claude, J., Andrieu, N., Rookus, M., Brolet, R., Antoniou, A. C., Peock, 
 S…Davidson, R. (2007). Age at Menarche and Menopause and Breast Cancer 
 Risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology 
 Biomarkers and Prevention, 16(4), 740-746. Retrieved from 
 http://cebp.aacrjournals.org/content/16/4/740.full.pdf 
Chow, W., Lester, L., Ainsworth, P., Nisker, K., & Brackstone, M. (2012). 
 Recognizing  BRCA gene mutation risk subsequent to breast cancer diagnosis in 
 southwestern Ontario. Canadian Family Physician, 58(5):e258-e266. Retrieved 
 from http://www.cfp.ca/content/58/5/e258.abstract 
Collaborative Group on Hormonal Factors in Breast Cancer and Hormonal 
Contraceptive. (1996). Breast cancer and hormonal contraceptives: collaborative 
analysis of individual data on 53, 297 women with breast cancer and 100, 239 
without breast cancer from 54 epidemiological studies. Lancet, 347:1713-27. . In 
S. E. Singletary, G. L. Robb,, & G. N. Hortobagyi (2004). Advanced therapy of 
breast cancer (2nd ed.). Hamilton, England: BC Decker Inc. 
Collins, N., McManus, R., Wooster, R., Mangion, J., Seal, S., Lakhani, S. R., 
 Ormiston, W…Daly, P. A. (1995). Consistent loss of the wild type allele in breast 
 cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. 
 Oncogen, 10(8):1673-1675. Retrieved from 
183 
 
 
 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Collins%2C+McManus%2C+Woost
 er%2C+1995 
Contractor, K. B., Kaur, K., Rodrigues, G. S., Kulkarni, D. M., & Singhal, H. (2008). 
 Male breast cancer: is the scenario changing. World Journal of Surgical 
 Oncology, 6:58. Retrieved from http://www.wjso.com/content/6/1/58#B4 
Colombo, N.,Preti, E., Landoni, F., Carinelli; S., Colombo, A., Marini, C… Sessa, 
 C. (2013). Endometrial cancer: ESMO clinical practice guidelines for 
 diagnosis, treatment and follow-up. Annals of Oncology, 24(6), 33-38. Retrieved 
 from http://annonc.oxfordjournals.org/content/24/suppl_6/vi33.full.pdf 
Csoka, B., Udvarhelyi, N., Sulyok, Z., Besznyak, I., Ramus, S., Ponder, B…Olah, E. 
 (1999). High frequency of germ-line BRCA2 mutations among Hungarian male 
 breast cancer patients without family history. Cancer Research, 59 (5), 995-8. 
 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10070953 
Cullinane, C. A; Lubinski, J; Neuhausen, S. L; Ghadirian, Lynch, Isaac, C…Weber, B. 
 (2005). Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 
 mutation carriers. International Journal Cancer, 117(6):988-91. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/15986445 
DeShantis, C., Ma, J., Bryan, L., & Jemal, L. (2014). Breast cancer statistics, 2013. 54(1), 
 52-62. Retrieved from 
 http://onlinelibrary.wiley.com/doi/10.3322/caac.21203/abstract 
184 
 
 
 
Dite, G. S; Whittemore, A. S., Knight, J. A., John, E. M., Milne, R. L., Andrulis, I. 
 L…Southey, M. C. (2010). Increased cancer risks for relatives of very early-onset 
 breast cancer cases with and without BRCA1 and BRCA2 mutations. British 
 Journal of Cancer, 103(7), 1103-1108. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2965877/ 
Dorum, A., Hovig, E., Trope, C., Inganas, M., Moller, P. (1999). Three per cent of 
 Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA. 
 European Journal of Cancer, 35, 779-81.Retrieved from http://serials.unibo.it/cgi-
 ser/start/it/spogli/df-
 s.tcl?prog_art=6232744&language=ITALIANO&view=articoli 
Dragovich, T. (2014). Pancreatic Cancer. Medscape. Retrieved from 
 http://emedicine.medscape.com/article/280605-overview 
Drost, R., & Jonkers, J. (2014). Opportunities and hurdles in the treatment of BRCA1-
 related breast cancer. Oncogene, 33, 3753-3763. Retrieved from 
 http://www.nature.com/onc/journal/v33/n29/full/onc2013329a 
Drucker, L., Stackievitz, R., Shpitz, B., &Yarkoni, S. (2000). Incidence of BRCA1 and 
 BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study. 
 Anticancer Research, 20(1B), 559-561. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/10769725 
Egan, K. M., Stampfer, M. J., Hunter, D., Hankinson, S., Rosner, B. A., Holmes, 
 M…Willett, W. C. (2002). Active and passive smoking in breast cancer: 
185 
 
 
 
 prospective results from the Nurses' Health Study. Epidemiology; 13(2):138-45. 
 Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Egan%2C+Stampfer%2C+Hunter+( 
 2002) 
Elwood, J. M., Cole, P., Rothman, K. J., & Kaplan, S. D. (1997). Epidemiology of 
 endometrial cancer. Journal of National Cancer Institute, 59(4), 1055-1060. 
 Retrieved from http://jnci.oxfordjournals.org/content/59/4/1055.short 
Evans, D. G., Gaarenstroom, K. N., Stirling, D., Shenton, A., Maehle; L., Dørum, A., 
 Steel, M., & Lalloo, F. (2009). Screening for familial ovarian cancer: Poor 
 survival of BRCA1/2 related cancers. Journal of Medical Genetics, 46(9), 593–  
 597. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18413372 
Evans, J. S., Wennberg, J. E., & Mcneil, B. J. (1986). The influence of diagnostic 
 radiography on the incidence of breast cancer and leukemia. New England 
 Journal of Medicine; 315(13), 810-5. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Evans%2C+Wennberg%2C+Mcneil
 %2C+(1986). 
Ewertz M., Holmberg L., Karjalainen S., Tretti, S., Adami, H. O. (1989). Incidence of 
 male breast cancer in Scandinavia, 1943–1982. International Journal of Cancer,
 43, 27–31. Retrieved from 
 http://onlinelibrary.wiley.com/doi/10.1002/ijc.2910430107/abstract 
186 
 
 
 
Facing our risk of cancer empowered.org. (2014). Other cancers. Retrieved from 
 http://www.facingourrisk.org/info_research/risk-factors/other-cancer-
 risks/index.php 
Fedier, A., Steiner, R. A., Schwarz, V. A., Lenherr, L., Haller, U., & Fink, D. (2003). 
 The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-
 deficient cells. In? In Moskwa, P; Buffa, F. M; Pan, Y; Panchakshari, R; 
 Gottipati, P; Muschei, R. J…Beech, J. (2012). MiR-182-mediated down-
 regulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. 
 Molecular Cell 41(2), 210-220. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249932/#R44 
Ferreira-Gonzalez, I., Permanyer-Miralda, G., Busse, J. W., Bryant, D. M., Montori, 
 V. M., Alonso-Coello, P…Walter, S. D. (2007). Methodologic discussions for 
 using and interpreting composite endpoints are limited, but still identify major 
 concerns. Journal of Clinical Epidemiology, 60(7), 658-662. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/17573977?access_num=17573977&link_ty
 pe=MED&dopt=Abstract 
Ferrone, C. R., Levine, D. A., Tang, L. H., Allen, P. J., Jarnagin, W., Brennan, M. E., 
 Offit, K., & Robson, M. E. (2009). BRCA germline mutations in Jewish patients 
 with pancreatic adenocarcinoma. Journal of Clinical Oncology, 27(3), 433-438. 
 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19064968 
187 
 
 
 
Fidler, I. J. (1991). Orthotopic implantation of human colon carcinomas into nude mice 
 provides a valuable model for the biology and therapy of metastasis. Cancer 
 metastasis review, 10(3), 229-243. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/1764766 
Fidler, I.J., Hart, I. R. (1982). Biological diversity in metastatic neoplasms: origins and 
 implications. Science, 217(4564), 998-1003. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/7112116 
Fidler, J. Radisky, R. (1986). Search for genes that suppress cancer metastasis. Journal of 
 National Cancer Institute, 88(23), 1700-1703. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/2167000 
Fisher, B., Constantino, J., Redmond, C., Poisson, R., Bowman, D., Counture, 
 J…Dimitrov, N. V. (1989). A randomized clinical trial evaluating tamoxifen in 
 the treatment of patients with node-negative breast cancer who have 
 estrogen-receptor-positive tumors. New England Journal of Medicine, 320(8), 
 479-84. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2644532 
Fisher, E. R., Fisher, B., Saas, R., & Wickerham, L. (1984). Pathologic findings from 
 the National Surgical Adjuvant Breast Project (Protocol No. 4). XI. Bilateral 
 breast cancer. Cancer; 54 (12), 3002-11. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/6498774 
Fokas, E., Engenhart-Cabillic, R., Danillidis, K., Rose, F., An, H. X. (2007). 
 Metastasis: The seed and soil theory gains identity. Cancer metastasis review, 
188 
 
 
 
 26(3), 705-715. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Frank%2C+Engenhart-
 Cabillic%2C+Danillidis%2C+An%2C+2007 
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999). Clinical 
 score for predicting recurrence after hepatic resection for metastatic colorectal 
 cancer: analysis of 1001 consecutive cases. In Dragovich, T. (2014). Pancreatic 
 Cancer. Medscape. Retrieved from 
 http://emedicine.medscape.com/article/280605-overview 
Ford, D., Easton, D. F., Bishop, D. T.,Narod, S. A., & Goldgar, D. E. (1994). Risks of 
 cancer in BRCA1-mutation carriers. Lancet 343692-695. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/7907678 
Fox, J. (2002). Cox Proportional-Hazards Regression for Survival Data. Appendix to an 
 R and S-Plus Companion to Applied Regression. Retrieved from http://cran.r-
 project.org/doc/contrib/Fox-Companion/appendix-cox-regression.pdf 
Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hulick, M., Ward, B. E., Lingenfelter, 
 B…Gumpper, K. L. (2002). Clinical characteristics of individuals with germline 
 mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. 20(6), 1480-
 1490. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Frank%2C+Deffenbaugh%2C+Reid
 %2C+2002)%3B 
  
189 
 
 
 
Fred Hutch.org. (2016). Cancer in our communities: American Indians/Alaska Natives 
 and Cancer. Retrieved from https://www.fredhutch.org/en/events/cancer-in-our-
 communities/american-indians-alaska-natives-and-cancer 
Friedman, L. S.,Ostermeyer, E. A., Szabo, C. I.,Dowd, P., Lynch, E. D., Rowell, S. 
 E., King, M. C. (1994). Confirmation of BRCA1 by analysis of germline 
 mutations linked to breast and ovarian cancer in ten families. Nature Genetics, 
 8(4), 399-404. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7894493 
Fu, L., Wang, D., Shah, W., Wang, Y., Zhang, G., & He, J. (2015). Association of 
 human papillomavirus type 58 with breast cancer in shaanxi province of China. 
 Journal of Medical Virology, 87(6), 1034-1040. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/25676062 
Garcia-Patino, E., Gomendio, B., Proventio, M., Silva, J. M., Garcia, J. M., Espana, P. 
 (1998). Germ-line BRCA1 mutations in women with sporadic breast cancer: 
 clinical correlations. Journal of Clinical Oncology, 16:1, 115-120. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/9440731 
Gaudet, M. M., Kirchhoff, T., Green, T., Viljai, J., Korn, J. M., Guiducci, C…Segrel, 
 A. V. (2010). Common genetic variants and modification of penetrance of 
 BRCA2-associated breast cancer. PLoS Genetics; 6(10), e1001183. Retrieved 
 from http://www.ncbi.nlm.nih.gov/pubmed/21060860 
Gehrig, P. A Bae-Jump, V. L., Boggess, Groben, J. F., Fowler P. A., & Van Le, L. 
 (2004). Association between uterine serous carcinoma and breast cancer. 
190 
 
 
 
 Gynecologic Oncology, 94(1), 208-211. Retrieved from 
 http://www.sciencedirect.com/science/article/pii/S0090825804002628 
Ginsburg, D., Ghadirian, P., Lubinski, J.,Cysbulski, C., Lynch, H., Neuhausen, 
 S…Kim Sing, C. (2009). Smoking and the risk of breast cancer in BRCA1 and 
 BRCA2 carriers: an update. Breast cancer research treatment, 114(1), 127-135. 
 Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033012/ 
Giordano, S. H., Cohen, D. S., Buzdar, A. U., Perkins, G., & Hortobagyi, G. N. (2004). 
 Breast  carcinoma in men: a population-based study. Cancer, 101(1), 51-57. 
 Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/15221988?dopt=Abstract&holding=f1000,f
 1000m ,isrctn 
Goldberg, J. I., & Borgen, P. I. (2006). Breast cancer susceptibility testing: past present 
 and future. Expert review anticancer theory, 6(8), 1205-14. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Goldberg+%26+Borgen%2C+2006 
Goggins, M., Schutte, M., Lu, J., Muskaluk, C. A., Weinstein, C. L., Peterson, G. 
 M…Yeo, C. J. (1996). Germ-line BRCA2 gene mutations in patients with 
 apparently sporadic pancreatic carcinoma. Cancer Research; 56, 5360-364. 
 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8968085 
Golafshani, N. (2003). Understanding reliability and validity in qualitative research. The 
 Qualitative report, 8(4), 597-607. Retrieved from 
 http://www.nova.edu/ssss/QR/QR8- 4/golafshani.pdf  
191 
 
 
 
Greer, J. B., & Whitcomb, D. C. (2007). Role of BRCA1 and BRCA2 mutations   
 in pancreatic cancer. GUT; 56(5), 601–605. Retrieved from    
 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942153/ 
Groot, M. T., Baltussen, R., Uyl-de Groot, C. A., Anderson, B. O., Hortobágyi, G. N. 
 (2006). Costs and health effects of breast cancer interventions in 
 epidemiologically different regions of Africa, North America, and Asia. The 
 Breast Journal, 12 (1), S81–S90. Retrieved from   
 http://screening.iarc.fr/doc/Costs%20and%20Health%20Effects%20of%20Breast 
 %20Cancer%20Interventions%20in%20Epidemiologically%20Different%20Regi 
 ons%20of%20Africa,%20North%20America,%20and%20Asia.pdf 
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Hue, B…King, 
 M. C. (1990). Linkage of early-onset familial breast cancer to chromosome 
 17q21. Science; 250(4988), 1684-1689. Retrieved from 
 http://www.sciencemag.org/content/250/4988/1684 
Hampl, M., Hampl, J. A., Reisss, G., Schackert, G.,Seager, H. D., Schackert, H. K. 
 (1999). Loss of heterozygosity accumulation in primary breast carcinomas and 
 additionally in corresponding distant metastases is associated with poor outcome. 
 Clin Cancer Research, 5:6, 1417-1425. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/10389927 
192 
 
 
 
Harris, R. E; Lynch, H. T; & GuirgisH. A. (1978). Familial breast cancer: risk to the 
 contralateral breast. Journal of National Cancer Institute; 60(5),955-60. 
 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/642037 
Harvard University. (2014). Bayes and Mendel Lab. Predicting who may carry inherited 
 susceptibility to cancer. Retrieved from 
 http://bcb.dfci.harvard.edu/bayesmendel/index.php 
Harvey, E. B., & Brinton, L. A. (1985). Second cancer following cancer of the breast in 
 Connecticut, 1935-82. National Cancer Institute Monograph, 12(68), 99-112. 
 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/4088315 
Hemminki, K., Scelo, G., Boffetta, P., Mellemkjaer, L., Tracey, E., Andersen, 
 A…Brewster, D. H. (2005). Second primary malignancies in patients with male 
 breast cancer. British Journal of Cancer, 92, 1288-1292. Retrieved from 
 http://www.nature.com/bjc/journal/v92/n7/full/6602505a. 
Hill, D. A., Preston-Martin, S., Ross, R. K., Bernstein, L. (2002). Medical radiation, 
 family history of cancer, and benign breast disease in relation to breast cancer risk 
 in young women, USA. Cancer Causes Control, 13(8), 711-8. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Hill%2C+Preston-
 Martin%2C+Ross%2C+(2002) 
Hiripi, E., Lorenzo Bermejo, J., Li, X., Sunquist, J., & Hemminki, K. (2009). Familial 
 association of pancreatic cancer with other malignancies in Swedish families. 
193 
 
 
 
 British Journal of Cancer, 101, 1792-1797. Retrieved from 
 http://www.nature.com/bjc/journal/v101/n10/full/6605363a. 
Ibrahim, E. M., Aboelkhair, K. M., Kazkaz, G. A., Elmasiri, O. A., Al-Foheidi, M. 
 (2012). Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a 
 meta-analysis. BMC Cancer, 12,197. Retrieved from 
 http://www.biomedcentral.com/content/pdf/1471-2407-12-197.pdf 
Ihekwaba, F. N. (1994). Breast cancer in men in black Africa: a report of 73 cases. 
 Journal of the Royal College of Surgeons of Edinburgh, 39(6), 344-7. Retrieved 
 from 
 http://www.ncbi.nlm.nih.gov/pubmed/7869287?dopt=Abstract&holding=f1000,f1
 000m,isrctn 
Jardines, L., Goyal, S., Fisher, P., Weitzel, J., Royce, M., Goldfarb, S. B. (2015).  Breast 
 cancer overview: Risk factors, screening, genetic testing, and prevention. Cancer 
 Management, (13th edn). Retrieved from
 http://www.mims.co.id/resources/module/customcontent/OTHERS/cancer%20ma
 nagement%20articles/%E7%AC%AC05%E7%AB%A0%20%20%E4%B9%B3%
 E8%85%BA%E7%99%8C%E6%A6%82%E8%BF%B0%20Breast%20cancer%2
 0overview.pdf 
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., Thun, M. I. (2003). Cancer 
 Statistics. CA Cancer Journal for Clinicians, 53(1), 5-26. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/12568441 
194 
 
 
 
Johannesdottir, G., Gudmundsson, J., Bergthorsson, J. T., Arason, A., Agnasson, B. 
 A., Eriksdottir, G. (1996). High prevalence of the 999del5 mutation in Icelandic 
 breast and ovarian cancer patients. Cancer Research, 56(16), 3663-3665. 
 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8706004 
Johannsson, O., Ostermeyer, E. A., Hakansson, S., Friedman, L. S., Johansson, U., 
 Sellberg, G…Brondum-Nielsen, K. (1999). Founding BRCA1 mutations in 
 hereditary breast and ovarian cancer in southern Sweden. American Journal of 
 Human Genetics, 58(3), 441-50. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/8644702 
John, E. M., Miron, A., Gong, G., Phipps, A. L., Felberg, A., Li, F. P… West, D. W. 
 (2007). Prevalence of  pathogenic BRCA1 mutation carriers in 5 US racial/ethnic 
 groups. JAMA, 298(24):2869-76.Retieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Prevalence+of+pathogenic+BRCA1
 +mutation+carriers+in+5+US+racial%2Fethnic+groups. 
Haenszel, W., & Kurihara, M. (1968). Studies of Japanese migrants I. Mortality from 
 cancer and other diseases among Japanese in the United States. Journal of 
 National Cancer Institute, 40, 43–68. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/5635018?dopt=Abstract 
Hancock, S. L., Tucker, M. A., & Hoppe, R. T. (1993). Breast cancer after treatment of 
 Hodgkin's disease. Journal of National Cancer Institute, 85(1), 25-31. Retrieved 
 from http://www.ncbi.nlm.nih.gov/pubmed/8416252 
195 
 
 
 
Haynes, R., Sackett, D., Guyatt, G., & Tugwell, P. (2006). Clinical epidemiology: How 
 to do clinical practice research. In Houser, J. (2012). Nursing research: Reading, 
 using and creating evidence (2nd ed.). Sudbury, MA: Jones and Bartlett. 
Hernandez-Rey, A. E. (2014). Anovulation. Medscape. Retrieved from 
 http://emedicine.medscape.com/article/253190-overview 
Houser, J. (2012). Nursing research: Reading, using and creating evidence (2nd 
 ed.).Sudbury, MA: Jones and Bartlett. 
Ibrahim, E. M., Aboelkhair, K. M., Kazkaz, G. A., Elmasiri, O. A., & Al-Foheidi, M. 
 (2012). Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a 
 meta-analysis. BMC Cancer, 12, 197. Retrieved from 
 http://www.biomedcentral.com/content/pdf/1471-2407-12-197.pdf 
Ingvarsson. S. (1999). The Brca1 and Brca2 proteins and tumor pathogenesis. Anticancer 
 Research, 19 (4B), 2853-61. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/10652564 
 
Kadouri, L., Hubert, A., Rotenberg, Y., Hamburger, T., Sagi, T., Nechushtan, C., 
 Abeliovich, C; and Peretz, T… (2007). Cancer risks in carriers of the BRCA1/2 
 Ashkenazi founder mutations. Journal of Medical Genetics, 44(7), 467–471. 
 Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2598014/ 
Kelsell, D. P., Spurr, N. K., Barnes, D. M., Gusterson, B., Bishop, D. T. (1996). 
 Combined loss of BRCA1/BRCA2 in grade 3 breast carcinomas. Lancet, 
196 
 
 
 
 347(9014), 1554-1555. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Kelsell%2C+Spurr%2C+Barnes%2
 C+Gusterson%2C+Bishop%2C+1996 
Kerbel, R. S. (1990). Growth dominance of the metastatic cancer cell: cellular and 
 molecular aspects. Advanced Cancer Research, 55, 87-132. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/2167000 
Kinsey, D. L. (1960). An experimental study of preferential metastasis. Cancer, 13, 674-
 676. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14409241 
King, M. C., Wieand, S., Hale, K., Lee, M., Walsh, T., Owens, K…Tait, J. (2001). 
 Tamoxifen and breast cancer incidence among women with inherited mutations in 
 BRCA1 and BRCA2:  National Surgical Adjuvant Breast and Bowel Project 
 (NSABP-P1) Breast Cancer  Prevention Trial. In National Cancer Institute. 
 (2014). BRCA1 and BRCA2: Cancer Risk and Genetic Testing. Retrieved from 
 http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA#r17 
Kleinerman, R. A. (2006). Cancer risks following diagnostic and therapeutic radiation 
 exposure in children. Pediatric Radiology, 36(2), 121-125. Retrieved from 
 http://link.springer.com/article/10.1007/s00247-006-0191-5 
Kmet, L. M., Cook, L. M., Weiss, N. S., Schwartz, S. M., & White, E. (2003). Risk 
 factors for colorectal cancer following breast cancer. Breast Cancer Research 
 Treatment, 79(2), 143-147. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/12825849 
197 
 
 
 
Knudson, A. G. (1971). Mutation and cancer: statistical study of retinoblastoma. 
 Proceedings of National Academic of Science, 68(4), 820-823. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/5279523 
Kriege, M., Brekelmans, C. T., Boetes, C., Besnard, P. E., Zonderland, H. M., 
 Obdein…Manollu, R. A. (2004). Efficacy of MRI and mammography for breast-
 cancer screening in women with a familial or genetic predisposition. In National 
 Cancer Institute. (2014). BRCA1 and BRCA2: Cancer Risk and Genetic Testing. 
 Retrieved from http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA#r17 
Lakhani, S. R., Manek, S., Llorca, F. P., Flanagan, A., Arnout, L., Merrett, 
 S…McGuffog, L. (2004). Pathology of ovarian cancers in BRCA1 and 
 BRCA2 carriers. Clinical Cancer Research, 10, 2473. Retrieved from 
 http://clincancerres.aacrjournals.org/content/10/7/2473.abstract 
Lancaster, J. M; Wooster, R; Mangion, J; Phelan, C. M; Cochrane, C; Gums, C…Futreal, 
 P. A. (1996). BRCA2 mutations in primary breast and ovarian cancers. Nat 
 Genetics, 13:2, 238-240. Retrieved from   
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Lancaster%2C+Wooster%2C+Mang
 ion%2C+1996 
La Vecchia, C., Levi, F., & Lucchini, F. (1992). Descriptive epidemiology of male 
 breast cancer in Europe. International Journal of Cancer, 51 (1), 62-66. 
 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1563846 
198 
 
 
 
La Vecchia, C., Franceshi, S., Decarli, A.,Gallus, G., Tognoni, G. (1984). Risk factors for 
 endometrial cancer at different ages. Journal of National Cancer Institute, 73(3), 
 667-671. Retrieved from http://jnci.oxfordjournals.org/content/73/3/667.abstract 
Le, T., Bhushan, V., & Tolles, J. (2011). First Aid for the USMLE STEP 1 (20th 
 Anniversary).  New York: McGraw Hill. 
Le, T.,Bhushan, V., & Skapik, J. (2006). First Aid for the USMLE step 2 Clinical 
 Knowledge (6th edn.) McGrawHill Medical. New York. 
Lee, K., Chen, S., Hubert, C., Lu, C., Chen, C., Lin, J., Chen, M… Huang, S (2008). 
 Increased risk for second primary malignancies in women with breast cancer  
 diagnosed at young age: A population-based study in Taiwan. Cancer 
 Epidemiology Biomakers Prevention, 17(10), 2647-2655. Retrieved from 
 http://cebp.aacrjournals.org/content/17/10/2647.full 
Lee, J. S., John, E. M., McGueri, V., Felberg, A., Ostrow, K. L., & DiCiccio, R. A… 
 Whittemore, A. S. (2006). Breast and ovarian cancer in relatives of cancer 
 patients, with and without BRCA mutations. Cancer Epidemiology Biomakers 
 Prevention, 15 (2),359-63. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/16492929 
Levine, D. A., Lin, O., Barakat, R. R.,Robson, M. E., McDermott, D., Cohen, 
 L…Satagopan, J. (2001). Risk of endometrial carcinoma associated 
 with BRCA mutation. Gynecology Oncology, 80(3), 395-398. Retrieved from 
199 
 
 
 
 http://www.gynecologiconcology-online.net/article/S0090-8258(00)96082-
 7/abstract 
Levy-Lahad, E., & Friedman, E. (2007). Cancer risks among BRCA1 and BRCA2 
 mutation carriers. British Journal of Cancer, 96, 11-15. Retrieved from 
 http://www.nature.com/bjc/journal/v96/n1/full/6603535a. 
Lewis, Z. K., Frost, C. J., Venne, V. L. (2009). Pancreatic cancer surveillance among 
 high-risk populations: knowledge and intent. Journal of Genetic Counseling, 
 18(3), 229-38. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/19263198 
Liede, A., Karlan, B. Y., Narod, S. A (2004). Cancer risks for male carriers of germline 
 mutations in BRCA1 or BRCA2: a review of the literature, 22 (4), 735-
 42.Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14966099 
Lindor, N. M. (2004). Recognition of genetic syndromes in families with suspected 
 hereditary colon cancer syndromes. Clinical Gastroenterology and Hepatology, 
 2(5), 336-375. Retrieved from http://www.cghjournal.org/article/S1542-
 3565(04)00120-X/fulltext# Hereditary breast and colorectal cancer. 
Lowery, M. I., Shah, M. A., Smyth, E., Epstein, A., Segal, A., Rosengarten, O. (2011). 
 A 67-year old woman with BRCA1 mutation associated with pancreatic 
 adenocarcinoma. Journal of Gastrointestinal Cancer, 42(3), 160-164. Retrieved 
 from http://www.ncbi.nlm.nih.gov/pubmed/20711688 
200 
 
 
 
Lubezky, N., Ben-Haim, M., Lahat, G., Marmor, S., Solar, I., Brazowski,  E…Nackache, 
 R. (2012). Intraductal papillary mucinous neoplasm of the pancreas: associated 
 cancers, family history, genetic predisposition? Surgery, 151 (1), 70-75. 
 Retrieved from Malone, K. E; Daling, J. R; Doody, D. R; Hsu, L; Bernstein, L; 
 Coates, R. L… Marchbanks, P. A. (2006). Prevalence and predictors of BRCA1 
 and BRCA2 mutations in a population-based study of breast cancer in white and 
 black American women ages 35 to 64 years. Cancer Research 2006; 66(16):8297–
 8308. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16912212 
Mayor Clinic. (2014). The future of colorectal cancer screening. Retrieved from 
 http://www.mayoclinic.org/medical-professionals/clinical-updates/digestive-
 diseases/future-colorectal-cancer-screening 
McGuire, V; John, E. M; Felberg, A; Haile, R. W; Boyd, N. F., Thomas, D. C…Jenkins, 
 M. A. (2006). No Increased Risk of  Breast  Cancer Associated with Alcohol 
 Consumption among Carriers of BRCA1 and BRCA2 Mutations Ages <50 Years. 
 Cancer Biomarkers and Prevention, 15; 1565. Retrieved from 
 http://cebp.aacrjournals.org/content/15/8/1565.full 
Mclure, L. A; Glaser, S. L; Shema, S. J; Allen, L; Quesenberry, C; John, E. M…Gomez, 
 S. L. (2010). Availability and accuracy of medical record information on language 
 usage of cancer patients from a multi-ethnic population. J. Immigration Health; 
 12(4):480-8. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19685187 
201 
 
 
 
MedlinePlus. (2015). Cervical Cancer. Retrieved from 
 http://www.nlm.nih.gov/medlineplus/cervicalcancer. 
Meindl, A. (2002). Comprehensive analysis of 989 patients with breast or ovarian cancer 
 provides BRCA1 and BRCA2 mutation profiles and frequencies for the German 
 population,” International Journal of Cancer, 97(4), pp. 472–480. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/11802209 
Meijer-Heijboer, H; Wijnen, J. Vasen, H; Wasielewski, M; Wagner, A; Hollestelle, 
 A…Estrodt, F. (2003). The CHEK2 1100delC mutation identifies families with 
 hereditary breast and colorectal cancer phenotype. In Lindor, N. M. (2004). 
 Recognition of genetic syndromes in families with suspected hereditary colon 
 cancer syndromes. Clinical Gastroenterology and Hepatology, 2 (5), 336-375. 
 Retrieved from http://www.cghjournal.org/article/S1542-3565(04)00120-
 X/fulltext#Hereditary breast and colorectal cancer. 
Menard, S; Pupa, S. M; Camiglio, M; Tagliabue, E. (2003). Biologic and therapeutic role 
 of HER2 in cancer. Oncogenes, 22, 6570-6578. Retrieved from 
 http://www.nature.com/onc/journal/v22/n42/full/1206779a. 
Menes, T. S; Terry, M. B; Goldgar, D; Andrulis, I. L; Knight, J. A; John, E. M… (2015). 
 Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year 
 cumulative incidence in the Breast Cancer Family Registry. Breast Cancer Res 
 Treat; 151(3):653-60. Retrieved from 
202 
 
 
 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Menes%2C+Terry%2C+Goldgar%2
 C+Andrulis%2C+Knight%2C+John%2C+2015. 
Mitchell, R; Kumar, V; Abbas, A; Fausto, N; & Aster, J. (2012). Pocket companion to 
 Robbins and Cotran pathologic basis of diseases (8th edn). Philadelphia, 
 Pennsylvania; Elsevier. 
Montori, V. M; Permanyer-Miralda, G; Ferreira-Gonzalez, I; Bryant, D; Alonso, J; Akl, 
 E. A…Domingo-Salvany. (2005). Validity of composite end points in clinical 
 trials. BMG, 330(491):594-6. 
 http://www.ncbi.nlm.nih.gov/pubmed/15761002/ 
Mocci, E; Milne, R. L; Mendez-Villamil, E. Y; Hopper, J. L; John, E. M; Andrullis, I. 
 L…Chung, W. K. (2013). Risk of pancreatic cancer in breast cancer families from 
 the breast cancer family registry. Cancer Epidemiology Biomarkers Prevention. 
 22(5), 803-11. doi: 10.1158/1055-9965. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/23456555 
Mohammed, S. N., Smith, P., Hodgson, S. V., Fentiman, I. S., Miles, D. W., Barnes, 
 D. M…Rubens, R. D. (1998). Family history and survival in premenopausal 
 breast cancer. Br. J Cancer, 77(12):2252-6. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/9649141?systemMessage=Wiley+Online+
 Library+will+be+disrupted+on+the+18th+October+from+10%3A00+BST+%280
 5%3A00+EDT%29+for+essential+maintenance+for+approximately+two+hours+
 as+we+make+upgrades+to+improve+our+services+to+you 
203 
 
 
 
Molina-Montes, E., Perez-Nevot, B., Polan, M., Sanchez-Cantalejo, E., Epin, J., & 
 Sanchez, M. (2014). Cumulative risk of second primary contralateral breast 
 cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A 
 systematic review and meta-analysis. Breast, 23(6), 721-742. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/25467311 
Moslehi, R; Chu, W; Karlan, B; Fishman, D; Risch, H; Fields, A;  Smotkin, D; Ben-
 David, Y…(2000). BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi 
 Jewish women with ovarian cancer. Am J Hum. Genet 66 (4): 1259-72. Retrieved 
 from http://www.ncbi.nlm.nih.gov/pubmed/10739756 
Mullan, P. B; Gorski, J. J; & Harkin, D. P. (2006). BRCA1--a good predictive marker of 
 drug sensitivity in breast cancer treatment? In Moskwa, P; Buffa, F. M; Pan, Y; 
 Panchakshari, R; Gottipati, P; Muschei, R. J…Beech, J. (2012). MiR-182-
 mediated own-regulation of BRCA1 impacts DNA repair and sensitivity to PARP 
 inhibitors. Molecular Cell 41(2):210-220). Retrieved from 
 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249932/#R44 
Murphy, K. M., Brune, K. A., Griffin, C., Sollenberger, J. E., Petersen, G. M., Bansal, 
 R… Hruban, R. H. (2002). Evaluation of Candidate Genes MAP2K4, MADH4, 
 ACVR1B, and BRCA2 in Familial Pancreatic Cancer Deleterious BRCA2 
 Mutations in 17%. Cancer Research, 62, 3789. Retrieved from 
 http://cancerres.aacrjournals.org/content/62/13/3789.full 
204 
 
 
 
National Cancer Institute. (2015). Endometrial Cancer Treatment (PDQ). Retrieved from 
 http://www.cancer.gov/types/uterine/patient/endometrial-treatment-pdq 
National Cancer Institute. (2014). A snapshot of cervical cancer: Incidence and mortality. 
 Retrieved from http://www.cancer.gov/research/progress/snapshots/cervical 
National Cancer Institute. (2014). A snapshot of endometrial cancer: Incidence and 
 mortality. Retrieved from 
 http://www.cancer.gov/research/progress/snapshots/endometrial 
National Cancer Institute (2013). Breast cancer. Retrieved from 
 http://www.cancer.gov/cancertopics/types/breast 
National Cancer Institute. (2014). High-penetrance breast and/or ovarian cancer 
 susceptibility genes. Retrieved from  
 http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-
 ovarian/HealthProfessional/page2#Section_95 
National Vital Statistics System. (2013). Mortality public use data files. Retrieved from 
 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6402a4. 
Narod, S. A., Dube, M. P., Klijn, J., Lubinski, J., Lynch, H. T., Ghadirian, 
 P…Provencher, P. (2002). Oral contraceptives and the risk of breast cancer in 
 BRCA1 and BRCA2 mutation carriers. Journal of National Cancer Institute, 
 94(23): 1773-1779. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Narod%2C+Dube%2C+Klijn+(2002 
 ) 
205 
 
 
 
Narod, S. A. (2001). Hormonal prevention of hereditary breast cancer. Annal of New York 
 Academic Science, 952,36-43. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/11795442 
Neuhaussen, S. L., Godwin, A. K., Gershoni-Baruch, R., Shubert, E., Garber, J., 
 Stoppa-Lyonnet, D…Olah, E. (1998). Haplotype and phenotype analysis of nine 
 recurrent BRCA2 mutations in 111 families: results of an international study. 
 American Journal of Human Genetics, 62(6), 1381-8. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Neuhaussen%2C+Godwin%2C+Ger
 shoni-Baruch%2C+1998 
Neveling, K., Kalb, R., Florl, A. R., Herterich, S., Friedl, R., Hoehn, H…Hader, C. 
 (2007). Disruption of the FA/BRCA pathway in bladder cancer. Cytogenetics 
 Genome Research, 118(2-4), 166-76. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/18000367 
Niell, B. L; Rennert, G; Bonner, J. D; Almog, R; Tomsho, L, P; Gruber, S. B. (2004). 
 BRCA1 and BRCA2 Founder Mutations and the Risk of Colorectal Cancer. 
 Journal of National Cancer Institute. 96(1), 15-21.. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/14709734 
Nowell, P. C. (1976). The clonal evolution of tumor cell populations. Science, 194:4260, 
 23-28. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/959840 
Nussbaum, R. L., McInnes, R. R., Willard, H. F. (2007). Thompson & Thompson 
 Genetics in Medicine (7th ed.). Philadelphia, PA; W. B. Saunders Company. 
206 
 
 
 
Obedian, E., Fisher, D. B., & Haffty, B. G. (2000). Second malignancies after treatment 
 of early-stage breast cancer: lumpectomy and radiation therapy versus 
 mastectomy. Journal of Clinical Oncolology, 18(12), 2406-12. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/10856100 
Obdeijn, I. M., Loo, C. E., Rijnsburger, A. L., Wasser, M. N., Bergers, E., Kok, 
 T…Klijn, J. G. (2010). Assessment of false-negative cases of breast MR 
 imaging in women with a familial or genetic predisposition. In National Cancer 
Institute. (2014). BRCA1 and BRCA2: Cancer Risk and Genetic Testing. Retrieved from 
 http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA#r17 
Offer, L., Gila, H., Alon Ben, A., Paul, R., Ephrat, L…Uziel, B. (2000). BRCA1 
 Germline Mutations in Women with Uterine Serous Papillary Carcinoma. 
 Obstetrics and Gynecology, 96(1), 28-32. Retrieved from 
 http://journals.lww.com/greenjournal/Abstract/2000/07000/BRCA1_Germline_M
 utations_in_Women_With_Uterine.7.aspx 
Oh, S. E., Kim, S. H., Kim, M. S., & Kim, M. K. (2015). Endometrial cancer 
 occurrence five years after breast cancer in BRCA2 mutation patient. Obstetric 
 Gynecology Science, 58(2), 175-178. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366872/ 
Ohgaki, H., & Kleihues, P. (2007). Genetic pathways to primary and secondary 
 glioblastoma. American Journal of Pathology, 170(5), 1445-1453. Retrieved 
 from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1854940/ 
207 
 
 
 
Oliver, K. E., Enewold, L. R., Zhu, K., Conrads, T. P., Rose, G. S., Maxwell, G. 
 L…Farley, J. H. (2011). Racial disparities in histopathologic characteristics of 
 uterine cancer are present in older, not younger blacks in an equal-access 
 environment. Gynecology Oncology, 123(1), 76–81. Retrieved from 
 http://digitalcommons.unl.edu/cgi/viewcontent.cgi?article=1047&context=usuhs 
Oncolink. (2015). Endometrial cancer: The basics. Retrieved from 
 http://www.oncolink.org/types/article.cfm?c=191&id=8227 
Ormiston, W. (1995). Hereditary breast cancer. European Journal of Cancer Care, 5, 
 13-20. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8715465 
Ottini, L., Masala, G., D’Amico, C., Mancin, B., Saieva, C., Aceto, G… Gestri, D. 
 (2003). BRCA1 and BRCA2 mutation status and tumor characteristics in male 
 breast cancer: a population-based study in Italy. Cancer Research, 63 (2), 
 16(2):342-247. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Ottini%2C+Masala%2C+D%E2%8
 0%99Amico%2C+2003%3B 
O’Shaughnessy, J. (2002). Clinical experience of capectabine in metastatic breast cancer. 
 European Journal of Cancer, 38(2), 10-14. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=O%E2%80%99Shaughnessy%2C+J.
 +(2002).+Clinical+experience+of+capectabine+in+metastatic+breast+cancer 
Osorio, A., Barroso, A., Martinez, B., Cebrian, A., San Roman Lobo, F…Robiedo, M. 
 (2000). Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or 
208 
 
 
 
 ovarian cancer Spanish families. British, Journal of Cancer, 2(7), 1266-70. 
 Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Osorio%2C+Barroso%2C+Martinez
 %2C+2000). 
Paget, S. (1889). The distribution of secondary growths in cancer of the breast. Lancet, 1, 
 571–73. Retrieved from 
 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)49915-
 0/fulltext 
Papelard, H., de Bock, G. H., van Eijk, R., Viet Vlieland, T. P., Cornelisse, C. J., 
 Deville, P…Tolenaar. R. A. (2000). Prevalence of BRCA1 in a hospital-based 
 population of Dutch breast cancer patients. British Journal of Cancer; 83(6), 
 719-24. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10952774 
 
Petrucelli, N., Daly, M. B., & Feldman, G. L. (2011). BRCA1 and BRCA2 Hereditary 
 Breast and Ovarian Cancer. Gene Reviews, Retrieved from 
 http://www.ncbi.nlm.nih.gov/books/NBK1247/ 
Petrij-Bosch, A., Peelan, T., van Vliet, M., van Eijk, R., Olmer, R., Drusedan, 
 M…Hogervorst, F. B. L. (1997). BRCA1 genomic deletions are major founder 
 mutations in Dutch breast cancer patients. Nature Genetics, 17, 341-345. 
 Retrieved from http://www.nature.com/ng/journal/v17/n3/pdf/ng1197-341.pdf 
209 
 
 
 
Phelan, C. M., Igbal, J., Lynch, H. T., Lubinski, J., Gronwald, J., Moller,  P…Ghadirian, 
 P. (2014). Incidence of colorectal cancer in BRCA1 and BRCA2  mutation 
 carriers: results from a follow-up study. British Journal of Cancer;  110(2):530-4. 
 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24292448 
Phelan, C. M., Lancaster, J. M., Tonin, P., Gumbs, C., Cochrane, C., Carter, R. (1996). 
 Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer 
 families. Nature Genetics, 13(1), 120-122. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Phelan%2C+Lancaster%2C+Tonin
 %2C+1996 
Phillips, K. A., Milne, R. L., Roocus, M. A., Daly, M. B., Antoniou, A. C., Peock, 
 S…Frost, D. (2013). Tamoxifen and risk of contralateral breast cancer for 
 BRCA1 and BRCA2 mutation carriers. In National Cancer Institute. (2014). 
 BRCA1 and BRCA2: Cancer Risk and Genetic Testing. Retrieved from 
 http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA#r17 
Phillips, K. (2000). Immunophenotypic and Pathologic Differences between 
 BRCA1 and BRCA2 Hereditary Breast Cancers. Journal of Clinical Oncology, 
 18,(21), 107s-112s. Retrieved from 
 http://jco.ascopubs.org/content/18/suppl_1/107.full.pdf 
Pijpe, A., Andrieu, N., Easton, D. F., Kesminiene, A., Cardis, E., Nogue,  C…Gauther-
 Villars, M. (2012). Exposure to diagnostic radiation and risk of breast cancer 
 among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-
210 
 
 
 
 RISK). 345 doi: http://dx.doi.org/10.1136/bmj.e5660. Retrieved from 
 http://www.bmj.com/content/345/bmj.e5660 
Psaila, B., Kaplan, R. N., Port, E. R., Lyden, D. (2007). Priming the 'soil' for breast 
 cancer  metastasis: the pre-metastatic niche. Breast Disease, 26, 65-74. Retrieved 
 from http://www.ncbi.nlm.nih.gov/pubmed/17473366 
Ren, J., Jin, F., Yu, Z., Zhao, L., Wang, L.,Bai, X., Zhao, H., Yao, W… (2013). MYC 
 overexpression and poor prognosis in sporadic breast cancer with BRCA1 
 deficiency, Tumor Biology; 34(6), 3945-3958 Retrieved from 
 http://link.springer.com/article/10.1007/s13277-013-0983-9 
Rheim, K., Fisher, C., Bosse, K., Wappenschmidt, B., & Schmutzler R. K. (2007). 
 Increased risk of cervical cancer in high-risk families with and without mutations 
 in the BRCA1 and BRCA2 genes. Journal of Clinical Oncology, ASCO Annual 
 Meeting Proceedings (Post-Meeting Edition), 25(18), 5588. Retrieved from 
 http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/5588 
Riveras-Varas, V. (1998). Breast cancer genes and inheritance. North Dakota State 
 University. Retrieved from   
 http://www.ndsu.edu/pubweb/~mcclean/plsc431/students98/rivera. 
Roa, B. B., Boyd, A. A., Volcik, K., Richards, C. S. (1996). Ashkenazi Jewish 
 population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet, 
 14:2, 185-187.Retrieved from 
211 
 
 
 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Roa%2C+Boyd%2C+Volcik%2C+
 Richards+(1996 
Rosen, E. M., Fan, S., Pestell, R. G., Goldberg, I. D. (2003). BRCA1 in hormone-
 responsive cancers. Trends in endocrinology metabolism, 14(8), 378-385. 
 Retrieved from 
 http://www.sciencedirect.com/science/article/pii/S1043276003001607 
Ross, S. (2007). Composite outcomes in randomized clinical trials: arguments for and 
 against. American Journal of Obstetrics Gynecology, 196:119e1-6. Retrieved 
 from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Ross+S.+Composite+outcomes+in+
 randomized+clinical+trials%3A+arguments+for+and+against 
Russo, I. H. (2002). Cigarette smoking and risk of breast cancer in women. Lancet, 360 
 (9339), 1044-9. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Russo+(2002)+Cigarette+smoking+
 and+risk+of+breast+cancer 
Sasco, A. J., Lowenfels, A. B., Pasker-de Jong, P. (1993). Review article: epidemiology 
 of male breast cancer. A meta-analysis of published case-control studies and 
 discussion of selected aetiological factors. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/8436428 
Satagopan, J. M., Offit, K., Foulkes, W., Robson, M. E., Wacholder, S., Eng, C. M., 
 Karp, S. E., & Begg, C. B… (2001). The lifetime risks of breast cancer in 
212 
 
 
 
 Aschenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer 
 Epidemiology Biomarkers Prevention, 10 (5) 467-73. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/11352856?dopt=Abstract&holding=npg 
Setiawan, V. W., Pike, M. C., Kolonel, L. N., Nomura, A. M., Goodman, M. T., & 
 Henderson, B.E. (2006). Racial/Ethnic Differences in Endometrial Cancer Risk:  
 The Multiethnic Cohort Study. American Journal of Epidemiology, 165(3), 262-
 270. Retrieved from http://aje.oxfordjournals.org/content/165/3/262.short. 
Schwartz, A. G., Ragheb, N. E., Swanson, G. M., & Satariano. (1989). Racial and age 
 differences in multiple primary cancers after breast cancer: a population-based 
 analysis. Breast Cancer Research Treatment. 14 (2), 245-254. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/2605351 
Shih, H. A Nathanson, K. L Seal, S. N., Collins, N., Stratton, M. R., Rebbeck, T. 
 R…Weber, B. L. (2000). BRCA1 and BRCA2 Mutations in Breast Cancer 
 Families with Multiple Primary Cancers. Clinical Cancer Research, 6, 4259. 
 Retrieved from http://clincancerres.aacrjournals.org/content/6/11/4259.abstract 
Shu, C. A., Pike, M., Jotwani, A. R., Soslow, R. A., Levine, D. A., Konner, 
 J…Aghajanian, C. (2014). Risk of developing uterine corpus cancer (Ut Ca) 
 following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA 
 mutations: Late-Breaking Abstract. Society of Gynecology 2014 Annual Meeting. 
 Retrieved https://www.sgo.org/wp-content/uploads/2014/05/LATE-BREAKING-
 ABSTRACTS-FINAL-03-15-14.pdf 
213 
 
 
 
Skare, T. L., & da Rocha, B. V. (2014). Breast and cervical cancer in patients with 
 systemic lupus erythematosus. Review of Brasil Ginecology Obstetrics, 36(8), 
 367-367. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25184350 
Smigal, C., Jemal, A., Ward, E., Cokkinides, V., Smith, R., Howe, H. L.. Thun, M. 
 (2006). Trends in breast cancer by race and ethnicity: update 2006. CA Cancer 
 Journal of Clinical, 56, 7168-183. Retrieved from  
 http://www.ncbi.nlm.nih.gov/pubmed/16737949?dopt=Abstract&holding=f1000,f
 1000m,isrctn 
Sing, J. H Chang, J Feroze, F Rahman, N Tan, W Lim, S…Lenhert, M. (2000). The 
 prevalence of BRCA1 mutations in Chinese patients with early onset breast 
 cancer and affected relatives. British Journal of Cancer, 82(3), 538-42. Retrieved 
 from http://www.ncbi.nlm.nih.gov/pubmed/10682662 
Singh, H Shu, E & Fraddeth, K. (2012). Trends in time to diagnosis of colon cancer and 
 impact on clinical outcomes. Canadian journal of gastroenerology, 26(12), 877-
 880. Retrieved  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551560/ 
Singletary, S. E Robb, G. L Hortobagyi, G. N. (2004). Advanced Therapy of Breast 
 Cancer (2nd ed.). Hamilton, London; BC Decker Inc. 
Singletary, K. W., Gapstur, S. M. (2001). Alcohol and Breast Cancer Review of 
 Epidemiologic and Experimental Evidence and Potential Mechanisms. Journal of 
 American Medical Association, 286(17):2143-2151. Retrieved from 
 http://jama.jamanetwork.com/article.aspx?articleid=194343 
214 
 
 
 
Spruance, S. L., Reid, J. E., & Samore, M. (2004). Hazard ratio in clinical trials. 
 Antimicrobial  Agents and Chemotherapy, American Society of Microbiology, 
 48(8), 2787-2792. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC478551/?report=reader 
Suchy, J Cybuski, C., Gorski, B., Huzarski, T., Bryski, T., Debriak, T., Gronwald, J; 
 Jakubowska, A … (2010). BRCA1 mutations and colorectal cancer in Poland. 
 Family Cancer, 9(4), 541-545. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/20862552 
Suchy, J., Cybuski, C., Gorski, B., Huzarski, T., Bryski, T., Debriak, T., Gronwald, J., 
 Jakubowska, A … (2010). CHEK2 mutations and HNPCC-related colorectal 
 cancer. International Journal of Cancer, 126(12), 3005-3009. Retrieved from 
 http://onlinelibrary.wiley.com/doi/10.1002/ijc.25003/full 
Sugarbaker, E. D. (1952). The organ selectivity of experimentally induced metastases in 
 rats. Cancer, 5(3), 606-612. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Sugarbakeer+(1952) 
Surveillance, Epidemiology, and End Results Program. (SEER, 2015). SEER stat fact 
 sheets: Endometrial cancer. Retrieved from 
 http://seer.cancer.gov/statfacts/html/corp. 
http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/5588 
215 
 
 
 
Surveillance Epidemiology and End Results Program. (SEER, 2014). SEER Stat Fact 
 Sheets: Colon and Rectum Cancer, Retrieved from 
 http://seer.cancer.gov/statfacts/html/colorect. 
Szklo, M., Nieto, J. (2014). Epidemiology: Beyond the basis. Burlington, MA, Jones and 
 Bartlett Learning. 
The Breast Cancer Linkage Consortium. (1999). Cancer risks in BRCA mutation carriers. 
 Journal National Cancer Institute, 91 (15), 1310-1316. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/10433620 
The University of Texas Health Science Center (2016). Courses: Statistical methodology 
 in clinical trials fall 2015. Retrieved from 
 https://sph.uth.edu/courses/biometry/lmoye/Webs/PH1835/ClinTrialWebMats/PH
 1835%20Downloads/Chapter%207%20Introduction%20to%20Composite%20En
 dpoints.pdf 
Thomas, D. B., Jimernez, L. M., McTiernan, A., Rosenblatt, K., Stalsberg, H., 
 Stemhagen, A …Thompson, W. D. (1992).  Breast cancer in men: risk factors 
 with hormonal implications. American Journal of Epidemiology, 135(7), 734-48. 
 Retrieved from  
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Thomas%2C+Jimernez%2C+McTie
 rnan%2C+(1992) 
Thompson, D., & Easton, D. (2004). The genetic epidemiology of breast cancer 
 genes. Journal of Mammary Gland Biology and Neoplasia,  9,(3), 221–
216 
 
 
 
 236. Retrieved from 
 http://link.springer.com/article/10.1023/B:JOMG.0000048770.90334.3b 
Thompson, D., Easton, D. F., & the Breast Cancer Consortium. (2002). Cancer 
 incidence in BRCA1 mutation carriers. Journal National Cancer Institute, 94 
 (18), 1358-1365. Retrieved from 
 http://jnci.oxfordjournals.org/content/94/18/1358.short 
U.S. Preventive Services Task Force. (2013). Risk assessment, genetic counseling, 
 and genetic testing for BRCA-related cancer in Women: Clinical summary of 
 USPSTF recommendation. In National Cancer Institute. (2014). BRCA1 and 
 BRCA2: Cancer Risk and Genetic Testing. Retrieved from 
 http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA 
Van Asperen, C. J., Brochet, R. M., Meijers-Heijboer, E. J., Hoogerbrugge, N., 
 Verhoef, S., Vasen, H. F. A…Ausems, M. G. E. M. (2005). Cancer risks in 
 BRCA2 families: estimates for sites other than breast and ovary. Jorrnal of 
 Medical Genetics, 42(9), 711-719. Retrieved from 
 http://jmg.bmj.com/content/42/9/711.abstract 
Venkitaraman, A. R. (2002). Cancer susceptibility and the functions of BRCA1 and 
 BRCA2. Cell, 108 (2), 171-82. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/11832208?dopt=Abstract 
Verhoog, L. C., Brekelmans, C. T., Seynaeve, C., van de Bosch, L. M., Dahman, G., 
 van Geel, A. N… (1998). Survival and tumour characteristics of breast-cancer 
217 
 
 
 
 patients with germline mutations of BRCA1. Lancet, 351(9099), 316-321. 
 Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/?term=Verhoog%2C+Brekelmans+Seynae
 ve%2C+(1998) 
Warner, E., Plewes, D. B., Hill, K. A., Causer, P. A., Zubovits, J. T., Jong, R. 
 A…Cutara, M. R. (2004). Surveillance of BRCA1 and BRCA2 mutation carriers 
 with magnetic resonance imaging, ultrasound, mammography, and clinical breast 
 examination.  In National Cancer Institute. (2014). BRCA1 and BRCA2: Cancer 
 Risk and Genetic Testing. Retrieved from 
 http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA#r17 
Wei, Q., Xu, J., Shen, L., Fu, X., Zhang, B., Zhou, X., & Carlsson, J. (2014). HER2 
 expression in primary gastric cancers and paired synchronous lymph node and 
 liver metastases. A possible road to target HER2 with radionuclides. Tumour 
 Biology, 35(7), 6319-6326. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/24643685 
Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N…Nguyen, 
 K. (1994). Localization of a breast cancer susceptibility gene, BRCA2, to 
 chromosome 13q12-13. Science, 265(5181), 2088-90. Retrieved from 
 http://www.ncbi.nlm.nih.gov/pubmed/8091231 
Youlden, D. R., & Baade, P. D. (2011). The relative risk of second primary cancers in 
 Queensland, Australia: a retrospective cohort study. BMC Cancer, 11(83), 1-12. 
218 
 
 
 
 Retrieved from 
 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3052198/pdf/1471-2407-11-
 83.pdf 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
219 
 
 
 
Appendix A: Summary of the Results 
Summary of Findings of Research Questions 1 and 2, Confounder, and Covariates 
 
Research question 
1 
Statistical results Conclusions  
RQ1a: Is there a 
relationship 
between BRCA1 
and time to 
diagnosis of 
second primary 
cancers, 
colorectal, 
endometrial, 
cervical, kidney, 
thyroid, or 
bladder, among 
women with breast 
cancer? 
RQ1b: Is there a 
relationship 
between BRCA2 
and time to 
diagnosis of 
second primary 
cancers, 
pancreatic, 
colorectal, 
endometrial, 
cervical, kidney, 
thyroid, or 
bladder, among 
women with breast 
cancer? 
 
 
RQ1c: Is there a 
relationship 
between BRCA 
both 1 and 2 
mutation status 
and time to 
diagnosis of 
second primary 
cancers, 
pancreatic, 
colorectal, 
endometrial, 
Kaplan-Meier overall median  
time to event = 14.000 years 
Log-rank test p-value = 0.797 
Based on the CPH  
model, I will fail to  
reject the null  
hypothesis of no 
relationship between 
BRCA1 and time to  
diagnosis of second  
primary cancers,  
colorectal, endometrial, 
cervical, kidney, thyroid 
or bladder, among 
women with breast 
cancer. 
 
Based on the CPH model 
I am able to reject the  
null hypothesis of no 
relationship between 
BRCA2 and time to  
diagnosis of second  
primary cancers,  
colorectal, endometrial, 
cervical, kidney, thyroid, 
or bladder, among  
women with breast  
cancer. 
 
 
 
 
 
Based on the CPH model, 
I will fail to reject the 
null hypothesis of no 
relationship between 
BRCA both 1 and 2 and 
time to diagnosis of 
second primary cancers, 
colorectal, endometrial, 
cervical, kidney, thyroid, 
or bladder, among 
women with breast 
cancer. 
Cox Proportional Hazard (CPH) 
analysis 
Hazard ratio =0.781 
95% Confidence Interval 
[0.53 – 1.74] 
 
 
 
 
 
 
Kaplan-Meier overall median  
time to event = 14.000 years 
Log-rank test p-value = 0.179 
Cox Proportional Hazard analysis 
Hazard ratio =1.471 
95% Confidence Interval 
[1.03 – 1.50] 
 
 
 
 
 
 
 
 
 
 
Kaplan-Meier overall median 
 time to event = 14.000 years 
Log-rank test p-value = 0.972 
Cox Proportional Hazard analysis 
Hazard ratio = 0.981 
95% Confidence Interval 
[0.53 – 1.50] 
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cervical, kidney, 
thyroid, or 
bladder, among 
women with breast 
cancer? 
 
 
 
 
 
 
Stratification of 
breast cancer by 
BRCA both 1 and 
2 
 
 
 
 
Research  
Question 2                                               
                                                                                                                                            
 
 
RQ2a: Is there a 
relationship 
between ethnicity 
and time to 
diagnosis of 
second primary 
cancers, 
colorectal, 
endometrial, 
cervical, renal, 
thyroid, or 
bladder, among 
women with breast 
cancer? 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kaplan-Meier overall median 
time to event = 14.000 years 
Log-rank test p-value = 0.003 
 
 
 
 
Statistical Results 
 
 
Kaplan-Meier overall median                         
time to event = 14.000 years 
White = 14.000 years 
Black = 11.000 years 
American I/H = 15.000 years 
Asian = 12.000 years 
Log-rank test for race/ethnicity 
p-value = 0.000 
 
 
 
 
 
Cox Proportional Hazard analysis 
White Hazard ratio = 1.511 
95% Confidence Interval 
[1.18 – 1.94] 
Black Hazard ratio = 0.647 
95% Confidence Interval 
[0.23 – 167] 
American I/H Hazard ratio  = 1.424 
95% Confidence Interval 
[1.12 – 1.81] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on the Log-rank 
test of equality, after the 
stratification, the 
result is statistically 
significant. 
 
continue 
Conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on the CPH 
 model, I will reject the 
null hypothesis of no 
relationship between 
ethnicity (White and 
American I/H) and time to  
diagnosis of second 
primary cancers, 
colorectal, endometrial, 
cervical, kidney, thyroid, 
or bladder, among 
women with breast 
cancer. I will fail to 
reject the null hypothesis 
of no relationship 
between ethnicity (Black 
) and time to diagnosis 
Of second primary 
Cancers, colorectal,  
endometrial, 
cervical, kidney, thyroid, 
or bladder, among 
women with breast 
cancer. 
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RQ2b: Is there a 
relationship 
between age status 
and time to 
diagnosis of 
second primary 
cancers, 
pancreatic, 
colorectal, 
endometrial, 
cervical, kidney, 
thyroid, or 
bladder, among 
women breast 
cancer? 
 
 
 
 
 
 
 
Adjusting for 
confounder and 
Covariates 
 
 
Confounder 
 
 
 
 
 
In RQ2a, I 
presented that 
race/ethnicity was 
a confounder. In 
order to further 
examine this, I 
evaluated BRCA 
status using the 
confounder in the 
analysis. I 
reevaluated the 
relationship 
between BRCA 
gene mutations 
(BRCA1, BRCA2, 
and BRCA both 1 
 
Kaplan-Meier overall median  
time to event = 14 years 
Spearman Correlation test 
p- value = 0.487 
Cox Proportional Hazard analysis 
< 46 years Hazard ratio = 0.942 
95% Confidence Interval 
[0.53 – 1.50] 
47-56 years Hazard ratio = 0.925 
95% Confidence Interval 
[0.76 – 1.13 
 
 
 
 
 
 
 
 
Statistical results 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cox Proportional Hazard analysis 
White Hazard ratio = 1.559 
95% CI = [1.21 -2.01] 
Black Hazard ratio = 0.673 
95% CI = [0.25 -1.80] 
American I/H Hazard ratio =1.476  
95% CI = [1.16 – 1.87] 
BRCA1 Hazard ratio = 0.867 
95% CI = [0.73 – 1.04] 
 
 
 
 
 
 
 
 
Based on the CPH  
model, I will fail to  
reject the null  
hypothesis of no 
relationship between 
age and time to 
diagnosis of second 
primary cancers, 
colorectal, endometrial, 
cervical, kidney, thyroid, 
or bladder, among  
women with breast  
cancer. 
 
 
 
continue 
 
 
Conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on the CPH 
Models observed, 
race/ethnicity as 
 a confounder may 
 have a relationship with diagnosis of 
second primary cancers, 
colorectal, endometrial, cervical, kidney, 
thyroid, or bladder  
in the population of  
women with BRCA 
related breast cancer 
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and 2) and White 
to American I/H 
race by 
conducting 
multivariate test 
(CPH) to see if 
there could be a 
difference 
 
Race/ethnicity and 
BRCA2 
 
 
 
 
 
 
 
 
Race/ethnicity and 
BRCA both 1 and 
2 
 
 
 
 
 
 
 
 
Covariates 
 
 
 
 
 
Smoking 
 
 
 
 
 
 
 
 
 
 
 
White Hazard ratio = 1.895 
95% CI = [1.16 -1.92] 
Black Hazard ratio = 0.642 
95% CI = [0.24 -1.72] 
American I/H Hazard ratio =1.414  
95% CI = [1.12 – 1.81] 
BRCA2 Hazard ratio = 1.025 
95% CI = [0.86 – 1.23] 
 
 
White Hazard ratio = 1.537 
95% CI = [1.19 -1.98] 
Black Hazard ratio = 0.664 
95% CI = [0.25 -1.78] 
American I/H Hazard ratio =1.459  
95% CI = [1.14 – 1.87] 
BRCA2 Hazard ratio = 0.925 
95% CI = [0.78 – 1.10] 
 
 
 
 
 
 
 
 
Kaplan-Meier overall median  
time to event = 14.000 years 
Log-rank test p- value = 0.174 
Cox Proportional Hazard analysis 
Hazard Ratio = 1.086 
95% CI = [0.94 -1.26] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on the CPH 
model observed, 
the result is not  
statistically significant. 
  
BRCA1 family 
status 
 
  
 
 
 
Kaplan-Meier overall median  
time to event = 14.000 years 
Log-rank test p- value = 0.000 
Cox Proportional Hazard analysis 
Hazard Ratio = 1.193 
95% CI = [0.95 -1.51] 
 
Based on the CPH 
model observed, 
the result is not  
statistically significant. 
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BRCA 2 family 
status 
 
 
 
 
 
 
 
Kaplan-Meier overall median  
time to event = 14.000 years 
Log-rank test p- value = 0.001 
Cox Proportional Hazard analysis 
Hazard Ratio = 1.086 
95% CI = [0.86 -1.38] 
 
 
Based on the CPH 
model observed,  
the result is not  
statistically significant. 
 
 
 
 
 
 
